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ABSTRACT
UTILIZING CONSUMER HEALTH POSTS FOR PHARMACOVIGILANCE:
IDENTIFYING UNDERLYING FACTORS ASSOCIATED WITH PATIENTS’
ATTITUDES TOWARDS ANTIDEPRESSANTS
by
Maryam Zolnoori

The University of Wisconsin-Milwaukee, 2017
Under the Supervision of Professor Timothy Patrick
Non-adherence to antidepressants is a major obstacle to antidepressants therapeutic
benefits, resulting in increased risk of relapse, emergency visits, and significant burden on
individuals and the healthcare system. Several studies showed that non-adherence is weakly
associated with personal and clinical variables, but strongly associated with patients’ beliefs and
attitudes towards medications. The traditional methods for identifying the key dimensions of
patients’ attitudes towards antidepressants are associated with some methodological limitations,
such as concern about confidentiality of personal information. In this study, attempts have been
made to address the limitations by utilizing patients’ self report experiences in online healthcare
forums to identify underlying factors affecting patients attitudes towards antidepressants. The
data source of the study was a healthcare forum called “askapatients.com”. 892 patients’ reviews
were randomly collected from the forum for the four most commonly prescribed antidepressants
including Sertraline (Zoloft) and Escitalopram (Lexapro) from SSRI class, and Venlafaxine
(Effexor) and duloxetine (Cymbalta) from SNRI class. Methodology of this study is composed of
two main phases: I) generating structured data from unstructured patients’ drug reviews and
ii

testing hypotheses concerning attitude, II) identification and normalization of Adverse Drug
Reactions (ADRs), Withdrawal Symptoms (WDs) and Drug Indications (DIs) from the posts,
and mapping them to both The UMLS and SNOMED CT concepts. Phase II also includes testing
the association between ADRs and attitude. The result of the first phase of this study showed that
“experience of adverse drug reactions”, “perceived distress received from ADRs”, “lack of
knowledge about medication’s mechanism”, “withdrawal experience”, “duration of usage”, and
“drug effectiveness” are strongly associated with patients attitudes. However, demographic
variables including “age” and “gender” are not associated with attitude. Analysis of the data in
second phase of the study showed that from 6,534 identified entities, 73% are ADRs, 12% are
WDs, and 15 % are drug indications. In addition, psychological and cognitive expressions have
higher variability than physiological expressions. All three types of entities were mapped to 811
UMLS and SNOMED CT concepts. Testing the association between ADRs and attitude showed
that from twenty-one physiological ADRs specified in the ASEC questionnaire, “dry mouth”,
“increased appetite”, “disorientation”, “yawning”, “weight gain”, and “problem with sexual
dysfunction” are associated with attitude. A set of psychological and cognitive ADRs, such as
“emotional indifference” and “memory problem" were also tested that showed significance
association between these types of ADRs and attitude. The findings of this study have important
implications for designing clinical interventions aiming to improve patients' adherence towards
antidepressants. In addition, the dataset generated in this study has significant implications for
improving performance of text-mining algorithms aiming to identify health related information from
consumer health posts. Moreover, the dataset can be used for generating and testing hypotheses
related to ADRs associated with psychiatric mediations, and identifying factors associated with
discontinuation of antidepressants. The dataset and guidelines of this study are available at
https://sites.google.com/view/pharmacovigilanceinpsychiatry/home
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Chapter 1: Introduction

1

1.1 Statement of the Problem
Depression is a major public health concern due to the high prevalence and it is a
substantial burden on families, society, and healthcare system (De las Cuevas, Peñate, & Sanz,
2014). It is estimated that 150 million people suffer from depression at a certain point in their life
(World Health Organization, 2003) and by 2020, depression will be the most common cause of
disability in the world (Murray & Lopez, 1997), mainly because of cognitive and emotional
impairment, such as memory recall and low motivation.
In the United States, according to The Centers for Disease Control and Prevention
(CDC), about 9 percent of Americans show symptoms of desperation, regret, and sadness that
result in depression (CDC 2014) and approximately six percent of adults annually are affected by
depression, which is the major cause of suicide (NCCMH, 2010). The financial burden of
depression in the United States increased from $173.2 billion to $210.5 billion (21.5 percent)
from 2005 to 2010 (Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015). Forty-five percent of
this cost was related to depression treatment, fifty percent of the cost was indirect cost related to
patients’ dysfunction and low productivity in the workplace, and five percent of this cost was
related to suicide-related behavior.
Antidepressants from SSRI (Selective Serotonin Reuptake Inhibitor) and SNRI
(Serotonin and Norepinephrine Reuptake Inhibitors) classes have proliferated pharmacological
interventions for depression in both psychiatric and primary care settings. This level of
popularity may be related to efficacy of these drugs and their relatively mild adverse effects
(Sansone & Sansone, 2010). Therapeutic benefits of antidepressant treatment depend on
maintaining an appropriate drug regimen for a certain period of time and a proper method of
discontinuation. Many patients recognize the necessity of the treatment (Murata, Kanbayashi,
2

Shimizu, & Miura, 2012), but non-adherence to the treatment is a major obstacle to its clinical
effectiveness (López-Torres, Párraga, Del Campo, & Villena, 2013). Non-adherence to
antidepressants is associated with the increased rate of emergency visits, longer hospital
admission, low quality of life, and significant cost at individual, family, and health care system
levels (Vives et al., 2014).
Research showed that across chronic medical illness in general, non-adherence is loosely
associated with demographic information and clinical variables, such as severity of the
symptoms or types of drug adverse effects. However, it is more strongly associated with patients’
beliefs and attitudes toward medication, low perceived necessity, and high perceived medication
risks (Aikens & Klinkman, 2012), (Acosta, Rodríguez, & Cabrera, 2013; Aikens, Nease, &
Klinkman, 2008; Brown et al., 2005; Chakraborty, Avasthi, Kumar, & Grover, 2009; De las
Cuevas et al., 2014; López-Torres et al., 2013; Richardson, McCabe, & Priebe, 2013; Verdoux et
al., 2000) . It is more likely that patients with positive attitudes show better adherence behavior
than patients with negative or indifferent attitudes(Aikens, Nease, Nau, Klinkman, & Schwenk,
2005; De las Cuevas et al., 2014; Richardson et al., 2013). Ultimately, It is patient perception of
beneficial aspects of the medication versus the harmful aspects that will determine the
acceptance or rejection of the medication (Acosta et al., 2013; Christensen, 2004).
Identifying the key dimensions of patients’ attitudes towards antidepressants is
challenging work that is often neglected (Demyttenaere et al., 2004). This partly due to the lack
of reliable and comprehensive methods to capture underlying factors affecting patients’ attitudes.
It has been evident that identifying potential predictive factors for attitude may have significant
implications for understanding the complexity of this phenomenon and for designing effective
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interventions to improve drug therapy adherence (Kessing, Hansen, Demyttenaere, & Bech,
2005).
Some studies have attempted to develop structured self-report measures to operationalize
the concept of attitude towards psychiatric drugs in various scales. The Drug Attitude Inventory
(DAI) (Hogan, Awad, & Eastwood, 1983) and the Antidepressants Compliance Questionnaire
(ADCQ) (Demyttenaere, Adelin, Patrick, Walthère, & Michèle, 2008) are examples of selfreport scales employed by studies focused on measuring patient attitudes toward antidepressants.
Although, the self-report scales are well validated, they are associated with some limitations.
Firstly, the ADCQ is the only self-report scale that is primarily designed for measuring attitude
to antidepressants. However, other scales, such as the DAI, which are primary designed for
patients with psychotic disorders, have been widely used in the studies addressing attitudes to
antidepressants. Secondly, the scales do not include a comprehensive set of potential factors
influencing attitudes, such as antidepressants’ adverse effects or patients’ knowledge. Therefore,
studies interested in determining association of the factors with attitude need to employ relevant
self-report scales such as the Self-report Antidepressant Side-Effect (ASEC), which may increase
complexity and cost of a study. Third, to reduce complexity of data analysis, most of the studies
represented outputs of the self-report scales as dichotomous variables (positive vs. negative
attitude) that may not capture meaningful variance in data. Finally, stigma associated with
mental disorders (Griffiths, Calear, & Banfield, 2009), sample bias and inherent limitations with
such data collection, concern about confidentiality of personal information, and patients’
reluctance to reveal personal information may reduce the reliability of the studies’ findings.
Detecting Adverse Drug Reactions (ADRs) for antidepressants is also associated with
several challenges. First of all, clinical trial studies, as the pre-marketing phase of
4

pharmacovigilance systems, suffer from limitations, such as specific inclusion and exclusion
criteria for recruiting patients and limited duration and size of the trials. These limitations may
hinder the discovery of long-term effects of antidepressants’ usage, such as antidepressantsinduced weight gain or rare adverse effects, such as “eye pain”, which may occur in less than
5000 patients (Ferguson, 2001). In addition, the post-marketing phase of pharmacovigilance
systems, such as Food and Drug Administration (FDA)’s Adverse Event Reporting System
(FAERS), are voluntary in nature for clinicians and the general public, leading to detection that
may not be timely and is incomplete (Sarker et al., 2015). To facilitate the process of assessing
adverse effects of medications, some studies designed instruments to measure the adverse effects
in clinicians’ offices, including Systematic Assessment for Treatment Emergent Side Effects
(SAFTEE) (Levine & Schooler, 1986) and the UKU Side Effect Rating (Lingjaerde, Ahlfors,
Bech, Dencker, & Elgen, 1987). However, these instruments are not widely in use because of
their length, complexity, and demand on clinicians’ time.
1.2 Significance of the Study
A fundamental assumption of this project is that social media technologies may be used as a
much needed and important source of data for determining attitudes leading to non-adherence
with antidepressant medications. Social media sites show promise as a much needed and
important source of data for determining attitudes leading to non-adherence with antidepressant
medications. Novel social media technologies have provided patients with a unique platform to
freely report their experiences and express their attitudes about healthcare services and
treatments. Social media applications with a focus on healthcare topics have been constantly
growing in recent years (Metke-Jimenez & Karimi, 2015).The findings of a public opinion
survey conducted in 2009 by Pew Research Center’s Global Attitudes Project showed that 61
5

percent of Americans looked online for general health information, 41 percent read others
experience and 30 percent were actively participating in creating new knowledge (Fox & Jones,
2012).
Facebook, Twitter, YouTube, and patient forums such as “patientslikeme.com”, and
“Online Messaging Boards” (OMB) such as “webmd.com” are popular online platforms used by
patients or caregivers for creating online healthcare communities. Patients and caregivers discuss
various health concerns and treatment experiences in the communities (Metke-Jimenez &
Karimi, 2015). Such communication can happen in various forms, such as sharing videos or
images, questions/answers, posts/comments, and expressing emotional reactions using emoticons
and “like” buttons (Mao et al., 2013).
Currently, patients’ self-reports about their experience with pharmacological therapy in
online communities has received growing attention in the area of psychiatric disorders,
indicating that individual’s cognitive representations may be associated with therapeutic
outcomes in this group of patients (Richardson et al., 2013). The International Society of Drug
Bulletins emphasized in 2005 that “patient reporting systems should periodically sample the
scattered drug experiences that patients reported on the internet” (Leaman et al., 2010).The selfreports captured in OMB may provide practical information useful for identifying patient
concerns and the root determinants of patients’ specific attitudes or behaviors that might not be
traditional self-report tools, such as questionnaire or interview, and in a physician’s office
(Benton, Ungar, et al., 2011; Harpaz et al., 2014; Sarker et al., 2015). This is particularly the case
with antidepressants.
Regarding the growing emphasis on individuals’ cognitive representations about
treatment in the format of self-report evaluation, the ability to measure individuals’ attitudes
6

toward medications directly from their reviews in social media may increase early detection of
factors that contribute to negative outcomes by highlighting aspects of treatment that prompt
negative attitudes towards pharmacological treatment (Kane, Kishimoto, & Correll, 2013). In
general, signals detected from social media, and in particular from OBMs could be used by
pharmaceutical companies and the healthcare system to supplement existing pharmacovigilance
systems. Patients in drugs’ review may disclose adverse effects associated with a particular drug,
such as antidepressants that may not be captured by pharmacovigilance systems (Benton, Ungar,
et al., 2011; Harpaz et al., 2014; Sarker et al., 2015).
The premise of this study is that patients’ self-reports on OMBs of their experiences with
antidepressants therapy may constitute a reliable source to uncover various dimensions of
attitude towards these medications. To date, there are no reports in the medical or social sciences
literature that focused on identifying underlying factors influencing attitude towards
antidepressant treatment as reported by patients in social media, particularly in OMBs.
1.3 Statement of Aims
This study is composed of two main phases. The aim of the first phase is to determine
usability of drug reviews in social media in providing insight into medication tolerability,
adherence, and perception (attitude) towards antidepressants treatment. We aim to
Aim (1): Explore reliability of drug reviews in social media to identify underlying factors
for patients’ attitudes and adherence towards antidepressants.
Aim (2): Evaluate usability of drug reviews in social media compare to self-report scales
in measuring patients’ attitudes towards antidepressants.
The aim of the second phase of this study is to determine usability of drug reviews in
social media in detecting ADRs associated antidepressants. We aimed to:
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Aim (3): Evaluate reliability of drug review posts in social media for detecting
pharmacological aspects of antidepressants, including adverse drug reactions (ADRs),
withdrawal symptoms (WD), and drug effectiveness (EF).
Aim (4): Explore the usability of Drug reviews in social media in addressing limitations
of self-repot scales, such as the Antidepressants Side-Effect Checklist (ASEC)
1.4 Data Source and Methodology of the Study
“Askapatient.com”, a particular OMB, constitutes the source of data for this study. It
enables respondents to post reviews about prescribed medications and rate the medications on a
scale from 1 to 5 where 1 represents the least satisfaction with the medication and 5 represents
the highest satisfaction. In addition, for each review, respondents may disclose clinical and
demographic attributes including age, gender, duration of use, and dosages of medication usage.
We considered the rating number associated with each review as the respondent’s overall attitude
towards the medication. Although, the rating originally indicates respondents’ satisfaction with
the medications in “Askapatient.com”, patient’s satisfaction with a medical therapy in several
studies was characterized by the patient’s attitude and belief (Taylor & Cronin Jr, 1994;
Williams, 1994). Satisfied patients have positive attitude to the therapy, while dissatisfied
patients have negative attitude. Therefore, we considered the respondents’ rate for a medication
as their overall attitudes, which is equivalent to the ordinal discrete values (Likert scale) that
used to represent output of structured self-report scales, such as the the Antidepressant
Compliance Questionnaire (ADCQ) and the the Drug Attitude Inventory (DAI).
892 patients’ reviews collected randomly from “askapatient.com” for the four most
commonly prescribed antidepressants including Sertraline (Zoloft) and Escitalopram (Lexapro)
from SSRI class, and Venlafaxine (Effexor) and duloxetine (Cymbalta) from SNRI class.
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A mixed-method approach was used to provide structured data from the unstructured
drug reviews and to test the hypotheses. In qualitative analysis, the framework method with
hybrid approach of inductive and deductive analysis was used to provide the analytical
framework for data analysis. The drug reviews at level of sentences were coded against the
analytical framework. In quantitative analysis, the identified adverse drug reactions (ADRs),
withdrawal symptoms (WD), and Drug Indications (DIs) were identified and normalized by
mapping to both UMLS and SNOMED CT concepts. In addition, statistical methods have been
used for developing a predictive model and testing the association between ADRs and patients
attitude toward antidepressants.
1.5 Contributions
Major contributions of this study are as follows:
① Developing an analytical framework for analyzing patients’ self-report experiences of
pharmacological treatment in the social media.
② Generating structured data from unstructured patients’ self-report experiences of
psychiatric medications using the Framework Method.
③ Using a systematic approach to develop a corpus consisted of three main components: (1)
Sentence classification, (2) Entity identification (ADRs, WD, and DIs), and (3) entities
normalization: mapping the entities to equivalent medical concepts in both UMLS and
SNOMED CT.
④ Filling the gap between layperson and professional terminologies of psychiatric
medications by identifying semantic links among the expressions of medical terms.
⑤ Identifying ADRs and WDs associated with two classes of antidepressants (SSRI and
SNRI) using real-world patients.
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⑥ Identifying underlying factors associated with patients’ attitudes towards antidepressants
using consumer health posts.
⑦ Developing a predictive model of factors affecting patients’ attitudes toward
antidepressants using data provided by real-world patients.
⑧ Measuring association between physiological, psychological, and cognitive ADRs and
levels of attitude.
The dataset and guidelines of this study are available at:
https://sites.google.com/view/pharmacovigilanceinpsychiatry/home
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Chapter 2: Background
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2.1 Treatment of Depression
Treatment of depression disorder in patients with depression may include psychotherapy
treatment or psychopharmacology treatment. Psychological treatment is characterized by three
essential factors: (1) it is designed with the purpose of reducing anxiety and depression
symptoms, 2) it is based on psychological theory, such as learning theory, and 3) it involves a
structured interaction between a facilitator and a patient (Orgeta, Qazi, Spector, & Orrell, 2015).
Eligible interventions for psychological treatment include cognitive behavioral therapies,
relaxation training therapies, psychodynamic therapies, interpersonal therapies, and supportive or
counseling therapies. McHugh, Whitton, Peckham, Welge, and Otto (2013) using a meta-analytic
review showed that patient preferences across diverse settings yielded a significant three-fold
preference for psychological treatment relative to pharmacology treatment. Therefore, improving
access to psychotherapy treatment is needed to connect more patients to their preferred
treatment. However, the focus of this study is on pharmacological treatment.
Over the years, antidepressants as psychopharmacology treatment of depression have
become the major source for treatment of depression, particularly for moderate to severe
depression. Chisholm (2015) has introduced antidepressants as a cost-effective choice for
depression treatment that is quite affordable and feasible to be prescribed in primary care
settings. From 1999 to 2012, the percentage of Americans used antidepressants increased from
6.8 percent to 13 percent (Karter, 2015). In 2010, antidepressants were the second most
commonly prescribed medication after cholesterol medications, and about 254 million
prescriptions were written, resulting in nearly $ ten billion (B. L. Smith, 2012).
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2.2 Psychopharmacology Treatment VS. Psychological Treatment
There is a wide range of pharmacological and psychological treatment that healthcare
professionals use to treat patients with depression. The lay public’s preference is psychotherapy,
and psychopharmacology treatment is rejected by most participants in studies conducted in the
United States (US), United Kingdom (UK), Germany, and Australia. Although the preference of
patients with depression is psychological treatment, financial factors such as low reimbursement
by insurance companies and high out of pocket costs have led to increasing rate of
pharmacological treatment for depression (Olfson & Marcus, 2009).
Because this study aimed to identify the underlying factors affecting attitudes towards
antidepressants, the focus of the rest of this study is on psychopharmacology treatment of
depression.
2.3 Types of Antidepressants
Antidepressants for forty years were the core pharmacological treatment for depression.
Tricyclic antidepressants (TCAs) were the first antidepressants introduced to market in the 1950s
(Ferguson, 2001). The efficacy of this drug was linked to mood-elevating properties. Although
TCAs were in practice for several years, anticholinergic and cardiac side-effects, the risk of
morbidity and mortality in overdose cases, and the lack of specific treatments led to development
of new classes of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs) and
Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs).
2.3.1 Selective serotonin reuptake inhibitors (SSRIs)
SSRI class is currently the most common antidepressants recommended to be prescribed
for patients suffering from different phases of depression (Sayyah, Eslami, AlaiShehni, & Kouti,
2016). This class encompasses five agents: sertraline (brand name: Zoloft), Escitalopram (brand
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name: Lexapro), paroxetine (brand name: Paxil), citalopram (brand name: Celexa), and
fluoxetine (brand name: Prozac). SSRIs in comparison with TCAs use the same property
(serotonin reuptake inhibitors) for mood elevation. However, the mechanism in SSRIs is
selective, which causes fewer adverse reactions and therefore enhances the safety of the drugs.
Since SSRIs treatment has reduced the risk of pharmacotherapy, antidepressants now can be
prescribed for patients with mild or moderate phases of depression, possibly even subsyndromal
symptomatic depression (SSD) (Santarsieri & Schwartz, 2015). Some SSRI agents, in addition to
approval for treating major depression, received approval for treating other mental disorders such
as obsessive-compulsive disorder and social anxiety disorder. Sertraline and paroxetine have the
highest approval by the FDA to treat a wide range of mental disorders.
SSRI agents have subtle yet notable differences in adverse effects and effectiveness. For
example, Fluoxetine’s efficacious aspect takes longer to emerge in comparison with other SSRIs,
and Escitalopram has better effectiveness in comparison with Citalopram (Gorman, Korotzer, &
Su, 2002). All SSRIs may cause physiological and psychiatric adverse effects, such as
gastrointestinal side effects, insomnia, weight gain, and fatigue. Sertraline may lead to more
gastrointestinal disturbance than others, while Citalopram and Paroxetine are accompanied with
more sedative side effects. In terms of withdrawal symptoms, Sertraline and Paroxetine, in the
case of sudden discontinuation, can cause more severe effects. SSRIs plus the use of other
medications may also lead to different drug-drug interactions. Lower adverse effects and the
effectiveness of SSRIs, as well as diagnostic factors such as phase of depression and patient
conditions, cause healthcare providers to prescribe a SSRI.
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2.3.2 Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)
The mechanism of Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) is by
inhibiting reuptake of serotonin and norepinephrine, which is similar to the mechanism of TCA
class, but like the SSRI class, SNRIs have less adverse effects. Therefore, SNRIs are prescribed
for a wide range of psychotic disorders. SNRIs include mainly Venlafaxine (brand name:
Effexor), Desvenlafaxine (brand name: Pristiq), Duloxetine (brand name: Cymbalta) and
Levomilnacipran (brand name: Fetzima). Like the SSRI class, SNRIs may cause physiological
and psychiatric adverse effects, but they tend to induce more nausea, insomnia, dry mouth, and,
in rare cases, elevated blood pressure(Santarsieri & Schwartz, 2015).
In terms of efficacy, SNRI agents may show higher effectiveness than SSRI agents. For
example, results of three studies have shown that a greater number of patients treated with
Venlafaxine showed depression symptom remission compared with patients on SSRIs and on
placebos (Nemeroff et al., 2003; D. Smith, Dempster, Glanville, Freemantle, & Anderson, 2002;
Thase, Entsuah, & Rudolph, 2001). On the other hand, one study did not find any significant
statistical difference between the efficacy of Duloxetine and SSRI agents (Goldstein et al., 2004).
According to the dataset from Symphony Health Solutions with one year of prescriptionfilling data (from July 1, 2011 to June 30, 2012) for patients from Washington DC, Maryland,
Virginia and West Virginia, Sertraline (Zoloft), Escitalopram (Lexapro), Venlafaxine (Effexor),
and duloxetine (Cymbalta) are the four most common antidepressants prescribed for depression.
2.4 Experience of Patients With Antidepressants
The experiences of people using antidepressants vary considerably. It has been accepted
that 10%-30% of people with mental disorders do not respond to medications (Al-Harbi, 2012).
Some patients found the medications very helpful in treating symptoms of the disorders and they
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could tolerate troublesome adverse effects. Others found the drugs ineffective and believed the
risks associated with adverse effects outweighed the beneficial aspects of antidepressants and
therefore had a low level of acceptance of the drugs (De las Cuevas & Sanz, 2007).
2.5 Duration of Antidepressants Usage
According to NCCMH (2010), antidepressant treatment should be continued at least for
six months to reduce risk of relapse, even if the therapy goal was achieved and the full remission
of depression symptoms was observed. More importantly, the relapse rate would be lower if the
acute treatment dosage was maintained rather than reducing the dosage over the six months
(NCCMH, 2010).
2.6 Adherence to Antidepressant Treatment
Despite the clinical trials’ proof of antidepressants efficacy, non-adherence to treatment is
a major barrier to their effectiveness in clinical practice (López-Torres et al., 2013). Overall,
therapeutic benefits of antidepressant treatment depend on maintaining an appropriate drug
regimen for a certain period time and a proper method of discontinuation. Many patients
recognize the necessity of treatment due to warnings by their healthcare providers about the
importance of adherence (Murata et al., 2012). Unfortunately, a significant number of individuals
diagnosed with depression do not follow the prescription and they may discontinue
antidepressant use abruptly, which may lead to severe withdrawal symptoms, increasing
emergency room visits, and even hospitalization (Grenard et al., 2011). Research showed that
about 50 percent of patients with depression discontinue their medication during the first month
of treatment, and nearly 68 percent of patients, discontinue their medication in the first 3 months
of treatment (De las Cuevas et al., 2014). Results of other studies indicate that between 30
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percent and 68 percent of patients with depression did not complete their prescribed course of
antidepressant treatment (Aikens et al., 2005).
2.6.1 Importance of adherence to antidepressant treatment
Adherence to antidepressant regimes is important to achieve expected clinical outcomes.
According to one meta-analysis, efficacy of antidepressants cannot be achieved with poor
adherence in patients with depression (Grenard et al., 2011). That underlies the need for
innovations to assist patients in following their prescription. Non-adherence can also increase the
risk of relapse (Alekhya et al., 2015; NCCMH, 2010). The ratio of mental illness relapse is about
five times greater in non-adherent patients compared to adherent patients (Masand, Roca, Turner,
& Kane, 2009). Relapse of depression, in turn, may affect long-term prognosis, severity of
depression recurrence, and difficulty of treatment. Moreover, non-adherence to antidepressants is
associated with increased rate of emergency visits, longer hospital admission, low quality of life,
and significant cost at individual, family, and health care system levels (Vives et al., 2014).
2.6.2 Factors Affecting on non-Adherence behavior
In response to the substantial negative impact of non-adherence behavior, identifying
high risk factors associated with non-adherent patients is important from the view of both clinical
practice and interventions targeting these patients (Rivero-Santana, Perestelo-Perez, PérezRamos, Serrano-Aguilar, & De las Cuevas, 2013). Several studies identified predictive factors
associated with non-adherence behavior in pharmacological treatment. Jin, Sklar, Oh, and Li
(2008) in a literature review categorized potential predictive factors for non-adherence in five
categories:
! Patient-centered factors, such as demographic factors and patient-physician
relationship;
! Therapy-related factors, such as treatment complexity and medication adverse
effects;
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!
!
!

Healthcare system factors, such as lack of accessibility;
Social and economic factors, such as social support and treatment affordability;
and
Disease factors, such as severity and duration of a disease.

Research focused on antidepressant non-adherence found a broad range of factors
associated with premature discontinuation of these drugs. Likewise, in the categorical system
provided by Jin et al. (2008), the potential predictive factors for antidepressants non-adherence
can also be summarized in the same five groups (Table 2-1). Examples of factors that can be
included in the categories of patient-centered factors are patient forgetfulness (Bulloch & Patten,
2010), patient’s specific personality type or issue such as being extroverted or having a
personality disorder (Akerblad, Bengtsson, Holgersson, von Knorring, & Ekselius, 2008; Holma,
Holma, Melartin, & Isometsä, 2010; Woolley, Fredman, Goethe, Lincoln, & Heeren, 2010),
substance abuse (Holma et al., 2010), and low motivation to continue treatment (Masand, 2003).
The group of therapy-related factors can include antidepressants’ adverse effects (Fortney et al.,
2011) such as sexual dysfunction, (Cohen, Kühn, Sträter, Scherbaum, & Weig, 2010), concern
about adverse effects, such as possibility of addiction (Brown et al., 2005) , impact on
personality (Chakraborty et al., 2009), and being doubtful about drug effectiveness (Hoencamp,
Stevens, & Haffmans, 2002). The group of socioeconomic factors contains issues such as cost of
antidepressants and lack of coverage by insurance companies. This may lead to the erroneous
views in patients that antidepressants are not necessary (Kennedy, Tuleu, & Mackay, 2008). The
group of healthcare system factors includes poor instruction of intake (Woolley et al., 2010), and
lack of follow-up care by clinicians (Masand, 2003). Finally, the group of disease factors include
patient’s perceived severity of depression and duration of symptoms (Demyttenaere et al., 2008).
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Table 0-1 Potential Predictive Factors Affecting Non-adherence towards Antidepressants
Category
Patient-centered factors
Therapy-related factors
Socioeconomic factors
Healthcare system factors
Disease factors

Example of potential Factors in each category
Patient forgetfulness, specific personality type
Antidepressants’ adverse effects, drug ineffectiveness
Cost of antidepressants
Lack of follow-up care by clinicians, instruction of intake
Perceived severity of depression and duration of symptoms

There are several inconsistencies in the literature regarding the significant factors
affecting drugs adherence in patients with depression. For example, from ten studies that tested
the impact of depression severity on non-adherence, only two of them concluded that depression
severity was a significant predictive factor (Rivero-Santana et al., 2013). Among studies that
evaluated the relationship between basic demographic factors and non-adherence, there is no
consistency on the findings related to gender, educational level, living situation, income, marital
status, or employment status (Rivero-Santana et al., 2013).
One of the major reasons for this inconsistency is the complexity of non-adherence and
the underlying factors. For example, education level might not directly be related to nonadherence behavior (Rivero-Santana et al., 2013). In fact, other confounding variables such as
attitude towards medication may drive any observed association between education and nonadherence.
2.6.2.1 Attitude as a significant predicative factor for non-adherence to antidepressants
Patients’ self-reports about medication effectiveness have received growing attention in
the area of psychopharmacology. Cognitive representations, that is, the person’s thoughts about
their medication, may be associated with therapeutic outcomes (Richardson et al., 2013). This
perspective is supported by cognitive representation models such as the Health Belief Model
(HBM) (Green & Murphy, 2014) and the Population and Theory of Planned Behavior (TPB)
(Ajzen, 1985). According to these models, the intention and motivation of patients to present a
19

specific health behavior, such as taking medication, is a function of three factors: 1) individual
attitude towards the behavior, 2) perception of social norms regarding the behavior, and 3)
intention to perform the behavior.
Attitude is a tendency or disposition of an individual to a particular act (Bergman, 1998),
representing the overall evaluation of that act. In other words, attitude is a function of an
individual’s belief, which is the base of comparing and contrasting potential harms and benefits
of a specific behavior (Richardson et al., 2013). For example, a patient who believes that taking
antidepressants causes more harm than good has a negative attitude towards taking
antidepressants.
There is well established that understanding patients views about their problems and their
treatments can significantly improve process of treatment (Moncrieff, Cohen, & Mason, 2009).
Aikens et al. (2005) emphasized the importance of association between patients’ perceptions
about medication and the clinical outcome, such as adherence. Aikens et al. (2005) showed that
outcomes of the interventions targeting non-adherence behaviors (such as intensified follow up
plan) ultimately depend on the patients’ willingness to take the drugs.
Research showed that across chronic medical illness in general, non-adherence is loosely
associated with demographic information and clinical variables, such as severity of the
symptoms or type of drug adverse effects, but more strongly it is associated with patients’ beliefs
and attitudes, perceived necessity, and perceived medication risks (Aikens & Klinkman, 2012),
(Acosta et al., 2013; Aikens et al., 2008; Brown et al., 2005; Chakraborty et al., 2009; De las
Cuevas et al., 2014; López-Torres et al., 2013; Richardson et al., 2013; Verdoux et al., 2000). It
is more likely that patients with positive attitudes show better adherence behavior than patients
with negative or indifferent attitudes(Aikens et al., 2005; De las Cuevas et al., 2014; Richardson
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et al., 2013). It is ultimately patient perception of beneficial aspects of the medication versus the
harmful aspects that will determine the acceptance or rejection of a medication (Christensen,
2004) (Acosta et al., 2013). For example, recent studies found that a majority of patients on
antidepressants have erroneous views towards these drugs, which in turn influence adherence
behavior (Chakraborty et al., 2009) (Jacob, Ab Fatah Ab Rahman, & Hassali, 2015). A study
with a sample of 573 primary care patients indicated that the only identifiable baseline predictive
factor of early discontinuation was belief about the appropriateness of taking antidepressants
(Aikens & Klinkman, 2012). Moreover, a significant negative correlation has been found
between patients’ attitudes and beliefs toward antidepressants and the percentage of days of
missed dosages (Jacob et al., 2015). On the other hand, Hung, YIaCHAO, and JAUa (2014)
found that the main reason for patients continued acceptance of depression treatment was a
positive view toward antidepressants effectiveness.
“Patients’ perspective towards antidepressants treatment is complex, neglected and
ambivalent” (Demyttenaere et al., 2004). It has been evident that identifying potential predictive
factors for attitude may have significant implications for understanding the complexity of this
phenomenon and therefore, designing effective interventions to improve drug therapy adherence
(Kessing et al., 2005). Patients with depression may have some specific beliefs and perceptions
that may lead to failure to follow antidepressant instructions. For example, concerns about
addictive possibilities and perceived distress received from adverse effects are significant factors
leading to negative attitude toward antidepressants and consequently non-adherence behavior
(Fawzi et al., 2012).
According to Horne’s theoretical model (Lin et al., 1995), beliefs about medication in
general seem to be most relevant for adherence at the start of treatment (Vergouwen, Burger,
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Verheij, & Koerselman, 2009). For example, believing that antidepressants are associated with
harmful aspects increase the patients’ sensitivity and decrease the patients’ tolerability for antidepressants.
Aikens and Klinkman (2012) suggested that there are different factors affecting
medication adherence in the acute and maintenance phase of antidepressant treatment. In the
acute phase of treatment, a change in functional health predicts change in medication beliefs.
Patients’ perceptions become more positive as medication becomes effective. On the other hand,
occurrence of side effects reinforces the belief that there is harmful aspect of the drug. In the
maintenance phase, patients' beliefs about antidepressant necessity versus harmfulness were the
only identifiable predictor of adherence. Perceived necessity for antidepressant treatment is
directly connected to the antidepressants perceived effectiveness. The perceptions of potential
harm is connected to adverse effects and withdrawal symptoms in the case of missing a dosage
or dose reduction (Aikens et al., 2005).
2.7 Potential Predicative Factors Associated With Attitude Towards Antidepressants
Attitudes of patients and caregivers toward chronic psychiatric disorders appeared to be
shaped by pharmacological treatment factors, healthcare system factors, social-cognitive and
psychological factors, patient-related factors, and depression factors.
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Table 0-2 Factors Affecting Patients Attitude Towards Antidepressants (Suggested by Literature)
Category
Pharmacological treatment factors

Healthcare system factors

Social-cognitive and psychological
factors
Patient-related factors

Depression factors

Factors in each category
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Perceived effectiveness
Perceived necessity
Perceived concerns
Adverse drug reaction
Perceived distress from adverse effects
Patient-provider relationship
Healthcare settings
Affordability
Stigma and cultural related factors
Partner supports
General concern and necessity
Knowledge about pharmacological aspects of medication
Socio-demographic factors
Educational level
Depression severity, type, and duration
Patient insight about depression

Table 2-2 shows the categories and factors in each category affecting patient attitudes
towards antidepressants. The following sections explain the factors and their association with
attitudes.
2.7.1 Pharmacological treatment factors
Identified factors in the pharmacological treatment category include medication perceived
effectiveness, adverse effect reaction (side-effects), perceived distress from side effects,
perceived necessity, and perceived concern of treatment.
2.7.1.1 Perceived effectiveness
Drug effectiveness is a strong predictive factor for shaping patients’ attitudes in both the
acute and the maintenance phase of treatment. Patients with depression generally express the
effectiveness of antidepressants as subjective experiences that mostly indicate the impact on their
quality of life. The patients commonly suffer from emotional problems and cognitive
impairments, such as “stress” and “slow information processing speed” (Culang-Reinlieb, Sneed,
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Keilp, & Roose, 2012) that restrict their capabilities in daily functioning and social
participations. Therefore, from patients’ viewpoints, antidepressant effectiveness is the extent to
which they help patients reduce emotional problems (Demyttenaere et al., 2004; Ferguson,
2001), improve cognitive functionality, such as psychomotor speed and ability to plan and
initiate a behavior (Demyttenaere et al., 2004; Reilly JL, 2011), and enhance their coping
mechanisms, such as dealing with stress or difficult relationships (Demyttenaere et al., 2004;
Prins, Verhaak, Bensing, & van der Meer, 2008).
2.7.1.2 Perceived necessity
From the layperson’s viewpoint, the necessity of antidepressants as the main source of
treatment is much lower than other methods of treatment, such as psychotherapy. People usually
view counseling as the best solution for depression treatment (Demyttenaere et al., 2004).
Therefore, it is not surprising that the perspective of patients with mental disorders regarding the
perceived necessity of pharmacological treatment is in line with this viewpoint. From 49% to
84% of patients with mental disorders who are looking for treatment feel that pharmacological
treatment is not a desirable solution (Prins et al., 2008). A plausible implication of these findings
is that patients with depression may discontinue taking medication in the acute phase of
treatment if they find perceived effectiveness less than expectations. Surprisingly, they may also
discontinue the treatment prematurely if they feel better, assuming they no longer need
medication to feel better.
2.7.1.3 Perceived concerns
Patients’ perceived concerns about antidepressants mechanism and its long-term effects
on patients’ quality of life are strongly associated with patients’ negative attitudes towards
antidepressants (Aikens et al., 2005; Benton, Hill, et al., 2011; Demyttenaere et al., 2004; Horne,
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Weinman, & Hankins, 1999; Hunot, Horne, Leese, & Churchill, 2007). The main concerns of
patients on antidepressants are related to addictive possibilities (Chakraborty et al., 2009; Jacob
et al., 2015; Prins et al., 2008) and immunity to antidepressants (Kessing et al., 2005).
Demyttenaere et al. (2004) in a self-report scale, the Antidepressant Compliance Questionnaire
(ADCQ), designed for assessing patients attitudes toward antidepressants introduced four
dimensions to measure patients’ concerns including addictive possibility of antidepressants,
control over feelings and thoughts, altering personality, and immunity to antidepressants. In
another self-report scale, the Beliefs about Medicine Questionnaire (BMQ) (Horne et al. (1999),
perceived concern is measured based on three dimensions: 1) long-term effects and its impact on
quality of life; 2) concern about the mechanism and addictive possibilities of antidepressants;
and 3) concern about losing autonomy because of the effects of the medication.
2.7.1.4 Adverse drug reaction
Adverse effects of antidepressant treatment correlate with the perceived harmfulness of
antidepressants (Aikens et al., 2005). This provokes negative attitudes towards the drugs
(Dougherty, Klein, Olino, Dyson, & Rose, 2009; Murata et al., 2012; Ng, Smith, King, Ong, &
Schweitzer, 2012), and in turn leads to patients’ non-adherence (De las Cuevas et al., 2014;
Dougherty et al., 2009). Cash and Brown (2000) reported that related adverse-effects of weight
gain influence patient attitude toward antidepressants and therefore lowers patients’ acceptability
of the drugs. Bradley, McGrath, Brannen, and Bagnell (2010) also found that among adolescents,
the most adverse effects that made adherence to antidepressant treatment difficult were the
increase of weight among girls and the sexual side effects among boys.
Patients may express adverse effects of antidepressants as physiological symptoms that
are directly correlated with pharmacological aspects of the medications. But there is still a large
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number of patients who express adverse effects in terms of subjective complaints (Hogan et al.,
1983) such as “not feeling like themselves”, “ unable to sit”, or “ alcohol craving”. These
adverse effects are recognized as behavior toxicity of pharmacological treatment and may reflect
extrapyramidal or autonomic side-effects, or subtle and frequently syndromes of akathisia
(Hogan et al., 1983). Further, patients may report side effects as emotional problems (Kikuchi,
Uchida, Suzuki, Watanabe, & Kashima, 2011; Price, Cole, & Goodwin, 2009; Sansone &
Sansone, 2010) or cognitive dysfunction (Sayyah et al., 2016) such as “aggressiveness” or “brain
fog”. In addition, impacts of adverse effects on daily functioning and social participation
(Giannangelo, Bowman, Dougherty, & Fenton, 2005) and in overall impact on quality of life,
such as job loss are determinant factors that influence patients’ attitudes towards antidepressants
(Hofer et al., 2004). Self report scales for measuring ADRs associated with antidepressents are
reported in Appendix A.
2.7.1.5 Perceived distress from adverse effects
“There is preliminary evidence that pharmacogenetic variations may affect the efficacy
and tolerability of antidepressant drugs” (NCCMH, 2010). It is also convincible that patients
self-attention to internal bodily sensation can vary from patient to patient and this can lead to
their expressing a range of intensity for identical physiological and emotional pain (Hogan et al.,
1983). The perceived pain (distress) from medication can influence patient attitude toward
medication and in turn can determine patient drug intake behavior. For example, patient may
frequently forget to follow a prescription. This information implies that in addition to a specific
ADR and the level severity associated with it, perceived stress received from adverse reaction is
another treatment factor affecting on patient attitude toward medication. For example, a young
female patient experiencing a small weight gain may receive high perceived distress that may
26

result in antidepressant discontinuation. While for another patient who experienced the same
amount of weight gain, the level of perceived distress from this adverse effect may be low.
Overall, patient distress from antidepressants adverse effects is not only a function of
patient tolerability, but also a function of perceived stress received from depression symptoms
and also concern about the long term effect of adverse effects on mental and physical
functioning.
Regarding the importance of perceived distress in shaping attitudes toward
antidepressants, educational strategies designed merely to inform patients the type of side-effects
may be relatively ineffective in patients whose interceptive cues provide less than favorable
information about the medication in their body system.
2.7.2 Healthcare system factors
Patient-provider relationship and healthcare setting are factors that are associated with
medication attitude. Few studies discussed medications affordability as factors that may
influence attitudes towards medications.
2.7.2.1 Patient-provider relationship
Several studies emphasized patient positive experience as a strong predictive factor of
patients’ positive attitudes toward medications and adherence behavior (Chakraborty et al., 2009;
Day et al., 2005; Demyttenaere et al., 2004; Hunot et al., 2007; Prins et al., 2008; Vives et al.,
2014). The importance of this interaction is not limited to the prescriber-patient relationship. Day
et al. (2005) suggested that patients’ admission experiences and relationship with healthcare
staffs also influence patients’ attitudes toward medication. Studies have found that in a patientcentered approach where providers actively seek to understand patients’ perspectives to
treatment and respect patients’ preferences by involving them in the process of treatment
27

decision making and providing supportive continued management, providers are most likely to
enhance and maintain patients positive attitude toward therapy (Day et al., 2005; Hunot et al.,
2007).
The Antidepressants Compliance Questionnaire (ADCQ) (Demyttenaere et al., 2004),
incorporated patient-physician interaction as one of the main components for assessing patient
attitude toward antidepressants. Patients’ perceptions of physicians’ knowledge, patients’
perceptions of the sufficiency of knowledge provided by physicians about disorder and treatment
process, and patients’ perceptions of communication effectiveness such as the perception of
clinicians interest to a patient’s problem and the level of support received from clinicians are
three dimensions that ADCQ addressed in assessing patient physician interaction Demyttenaere
et al. (2004).
2.7.2.2 Healthcare settings
Few studies evaluated the relationship between patients’ attitudes toward psychotic
medications and healthcare settings, i.e. primary care sites vs. psychiatric sites. Aikens et al.
(2005) suggested that patients with depression treated in primary care settings are more likely to
discontinue antidepressants at initial stages. A plausible explanation is that patients have more
uncertainty about diagnosis results and prescribed treatment in primary care settings compared
with psychiatric settings. This uncertainty can lower patients’ perceived necessity for
antidepressants, which may result in a negative attitude toward medications.
2.7.2.3 Affordability
Affordability is a significant factor for predicting patient adherence behavior (Jin et al.,
2008). Nevertheless, studies related to attitude did not consider this factor as a potential
predictive factor for attitude toward antidepressants, but Weiden et al. (1994) suggested lack of
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insurance coverage and unaffordability of a drug may reduce the necessity of medication from a
patient’s view point.
2.7.3 Psycho-social factors
Psycho-social factors that are significantly associated with attitude towards medication
are stigma and cultural related factors, and perceived support from partners ass well as family
and friends.
2.7.3.1 Stigma and cultural related factors
Stigma against depression and antidepressants are significant factors for negative attitude
and premature discontinuation in patients with depression (Acosta et al., 2013; Jacob et al., 2015;
Malpass et al., 2009). Stigma about the use of antidepressants is similar to the stigma against
depression, such as perceived emotional and mental weakness and inability to cope with daily
problems. However, lack of belief in the therapeutic efficacy of antidepressants and showing
non-adherence behavior are indicators of avoiding to being labeled as mentally ill (Acosta et al.,
2013; Castaldelli-Maia et al., 2011).
2.7.3.2 Partner support
Patients perceived support from partners, family, and friends is associated with patients
positive attitude towards antidepressants (Demyttenaere et al., 2004). This factor is incorporated
as one of the components in the Antidepressants Compliance Questionnaire (ADCQ). Items in
this component measure patient’s perceived support from partners regarding their views about
being diagnosed with depression and treated with antidepressants (Demyttenaere et al., 2004).

29

2.7.4 Patient related factors
Patients related factors that may influence patients’ attitudes about antidepressants are
general concern and necessity of medications, knowledge about antidepressants’ mechanisms
and adverse effects, socio-demographic information, and patient’s education.
2.7.4.1 General concern and necessity
Horne et al. (1999) in the Concern-Necessity Framework discussed that patients’ general beliefs
about the necessity and harmfulness of medications are significant factors affecting patients’
attitudes toward prescribed medications and adherence behavior. Patients who have concerns
about pharmacological treatment and believe that natural remedies or changing their life style
will have better healthcare outcomes than pharmacological treatment are more likely to reject a
prescribed medication or show non-adherence behavior, particularly at initial phase of treatment.
2.7.4.2 Knowledge about medication
Clarifying the purpose of a medication, possible physiological adverse effects, the nature
of regimen, and the proper time for discontinuation are a set of pharmacology knowledge that
healthcare providers need to share with patients with depression.
A qualitative study (Haslam, Atkinson, Brown, & Haslam, 2005) showed that many
patients taking antidepressants suffer from side-effects that they felt they were not sufficiently
informed about them and mechanisms of their management. Gabriel and Violato (2010)
discussed that patients with more knowledge about their illness and their treatment are likely to
be have positive perception about treatment and, in tern, to be more adherent.
2.7.4.3 Socio-demographic factors
Gender, age, ethnicity, and education level are important predisposing characteristics
influencing attitude and perceived needs in people with depression.
30

Women are two times more likely to seek treatment for depression as they believe less in
the addictiveness of antidepressants (Prins et al., 2008). Young, senior, and minority-group
patients are more vulnerable having a low perceived need and a negative attitude towards
treatment. Young people prefer to cope with depression symptoms without seeking for help,
because they view depression as a sign of weakness and feel embarrassed to express their
feelings. On the other hand in the elderly, diagnosis is usually missed, particularly in patients
with a stressful life and retirement (Prins et al., 2008). Minority groups tend to have less access
to healthcare services, and they also have a different perceived need and attitude toward
pharmacological treatment (Scheppers, Van Dongen, Dekker, Geertzen, & Dekker, 2006).
Contrary with Prins et al. (2008) findings pertinent to age and gender, some studies found that
age and gender are not significant predictive factors for attitude towards antidepressant (Jacob et
al., 2015; Murata et al., 2012; Ng et al., 2012).
2.7.4.4 Educational level
Education level is loosely associated with attitude toward medication and belief toward
antidepressants(Murata et al., 2012; Ng et al., 2012). Intuitively, it may be expected that
individuals with a higher education are more motivated to follow prescriptions. However,
patients with a higher education may be more skeptical about the mechanism of antidepressants
or the accuracy of diagnosis. In addition, they may have more access to alternative sources of
treatment, thereby they will show less positive attitudes toward antidepressants compared to
patients with low education. On the other hand, patients with a low education level may have
more trust in a physicians’ diagnosis and treatment plan (Jin et al., 2008).
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2.7.5 Depression disorder characteristics
Depression disorder characteristics including type, severity, and duration and patient
insight about depression characteristics may influence patients attitude toward antidepressants.
2.7.5.1 Depression severity, type, and duration
“Patients with major depressive disorder appeared to have a more negative view of
antidepressants than those with bipolar disorder” (Acosta et al., 2013). Murata et al. (2012) also
found that there is no correlation between types of depression including melancholic,
nonmelancholic, and bipolar depression and attitude toward antidepressants. In terms of duration,
Ng et al. (2012)) did not find a significant correlation between the duration or severity of
depression and the patients attitude was found.
2.7.5.2 Patient insight about depression
A majority of patients believe that depression is a psychological problem rather than a biological
problem (Hansson, Chotai, & Bodlund, 2010; Jacob et al., 2015; Jorm, Christensen, & Griffiths,
2005). This erroneous view causes patients to reject biological interventions, i.e., antidepressants
in moderate- to-severe cases, as they feel they can heal themselves by simply changing their
behavior or personality(Prins et al., 2008)
The factors (explained in this section) identified by literature as important factors affecting
attitude will be used for developing initial themes for data analysis. The the detail of data
analysis procedure is explained in the methodology section.
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2.8 Self-Report Scales Used in Antidepressants Studies for Measuring Attitude
Identifying dimensions of patients attitude towards psychotic medications, particularly
antidepressants is a challenging work, partly due to the lack of reliable and comprehensive
methods to capture predictive factors affecting patients’ attitudes. Few studies have attempted to
develop structured methods, such as self-report measures, to operationalize the concept of
attitude towards psychiatric drugs in various scales (Demyttenaere et al., 2004; Hogan et al.,
1983; Horne et al., 1999; López-Torres et al., 2013). The well-validated self-report scales for
assessment of attitude among patients with psychotic disorders include the Drug Attitude
Inventory (DAI) (Hogan et al., 1983), The Rating of Medication Influence Scale (ROMI)
(Weiden et al., 1994), the Antidepressants Compliance Questionnaire (ADCQ) (Demyttenaere et
al., 2008), and the Beliefs about Medicines Questionnaire (BMQ) (Hogan et al., 1983). The
detail of the self-report scales is presented in Appendix B.
2.8.1 Methodological Limitations of self-report scales
Self report scales, including the ADI (Drug Attitude Inventory), the ADCQ
(Antidepressant Compliance Questionnaire), the BMQ (Beliefs about Medications
Questionnaire), and the ROMI (Rating of Medication Influence Scale), are non-intrusive and
efficient to capture information about patients’ attitudes and beliefs toward psychiatric
medications (Nunkoosing, 2005). However, they are associated with some limitations.
First, these tools are different in dimensions used for measuring attitude and the impact of
medications on patients’ quality of life (Richardson et al., 2013) Wolters, Knegtering, van den
Bosch, and Wiersma (2009). While ADI, ADCQ, and BMQ assigned some items for assessing
patient’s perceived necessity and concern directly or indirectly, ROMI did not include factors for
measuring patient concern about medications. In terms of healthcare settings, ADCQ and ROMI
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included items expressing quality of patient-physician relationship and also psychosocial
support, but ADI and BMQ did not. BMQ is unique in terms of assessing patient belief in
general towards medications. This factor has a significant role in adherence behavior at initial
stage of treatment. In addition, ROMI is unique in suggesting items assessing patient perception
of illness.
Second, the focus of the questionnaires is on extrapyramidal side effects and patients’
subjective experiences with medications, whereas physiological side effects such as muscle
spasm may have a strong impact on forming patients’ attitudes toward medications. Studies
interested in finding association between side effects and attitude, need to administer other
questionnaires, such as self-report antidepressant Side-Effect Checklist (ASEC) or Liverpool
University Neuroleptic Side Effect Rating Scale (LUNSERS) Ng et al. (2012).
Third, the DAI, the ROMI, the BMQ, and the ANT questionnaire are primarily developed
to assess attitudes toward antipsychotics. They have thus been mainly used among patients with
psychosis or schizophrenia, and few studies used them in patients with depression (Grover,
Chakrabarti, Sharma, & Tyagi, 2014).
Fourth, studies employing the scales represented the scales’ output score in
a continuous range, in a set of ordinal discrete values (such as a Likert scale) or in a binary
construct (positive attitude vs. negative attitude). Although, representing data in an ordinal
discrete values may capture meaningful variance in data to some extent, a binary construct
discards the variance. To simplify process of data analysis, most of the studies represented output
in a binary construct.
Fifth, self-report questionnaires depend on individuals’ ability to understand items and
their willingness to reveal personal information. Patients tends to report minimally with a
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reluctance to be critical (Nunkoosing, 2005). Participant answers may be biased because of
“social desirability despite its anonymity and confidentiality and distance from the researchers or
those responsible for clinical care” De las Cuevas and Sanz (2007). Furthermore, reliability of
questionnaires may be affected by patients’ memory recall, specifically for questions that need
long term recall period or are not specified by time period. These limitations can affect response
accuracy and consequently the validity and reliability of the questionnaire.
Sixth, there is always this risk that patients with most the positive or most negative
attitude may have a high tendency to participate in studies focused on measuring attitude or
adherence, while patients with indifferent attitudes may be less willing to participate in these
studies. This problem can lead to sample bias and thereby limit generalizability of studies’
findings to the population.
The premise of this study is that patients’ self-reports experience in online healthcare
forums may constitute a reliable source to uncover various dimensions of attitude towards the
medications, and in turn, addresses the limitations of self-report scales (questionnaires) in
measuring patients attitudes toward antidepressants.
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2.9 Social Media and its Application in Healthcare
Novel social media technologies have provided patients with a unique platform to freely
report their experiences and express their attitudes about healthcare services and treatments. The
number of social media applications with a focus on healthcare topics has been constantly
growing in recent years (Metke-Jimenez & Karimi, 2015).The findings of a public opinion
survey conducted in 2009 by Pew Research Center’s Global Attitudes Project showed that 61
percent of Americans looked online for general health information, 41 percent read others
experience and 30 percent were actively participating in creating new knowledge (Fox & Jones,
2012).
Patients with mental disorders usually prefer to share health experiences and concerns
with each other rather than in clinical research studies or with their healthcare providers
(Blenkinsopp, Wilkie, Wang, & Routledge, 2007; Leaman et al., 2010). This may be stigma
associated with mental disorders and help seeking for the conditions (Griffiths et al., 2009).
Currently, many patients’ self-reports about their experience with pharmacological
therapy in online communities are specifically in the area of adverse drug reactions. The
International Society of Drug Bulletins emphasized in 2005 that “patient reporting systems
should periodically sample the scattered drug experiences that patients reported on the internet”
(Leaman et al., 2010).
Previous studies showed that clinical trials and post-marketing surveillance systems
established by regulatory agencies, such as the Adverse Event Reporting System (AERS) of
Food and Drug Administration (FDA), are not able to detect potential risks of drugs pre and post
marketing. It is estimated that such surveillance systems capture less than 10 % of the Adverse
Drug Reaction (ADR) occurrence, due to the voluntary nature of the systems in data collection
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and perhaps patients’ negative perceptions of the systems (Yang, Yang, Jiang, & Zhang,
2012). These limitations have led to major concerns in public health; thousands of incidents of
hospitalizations and deaths have occurred due to undetected and uncontrolled risks (Karimi,
Metke-Jimenez, Kemp, & Wang, 2015).
According to recent studies showed, patients’-self reports of ADRs and drug efficacy to
surveillance systems have the same quality as reports by healthcare professionals (Uher et al.,
2009). As such, patients’ self-reports are used as a reliable source for risk discovery through
programs such as FDA’s MedWatch program or the UK MHRA’s Yellow Card Scheme.
However, many patients do not report to these systems, perhaps due to negative attitude towards
providers, ignorance of the availability of these systems, or their severity of illness (Yang et al.,
2012). Instead, they prefer to report and discuss their detailed experience with prescribed
medications in various social media platforms, such as online support groups and message
boards. Accordingly, these social media platforms have turned out to be reliable sources for
discovering various aspects of medications benefits and risks, such as drugs’ adverse effects,
drug effectiveness, and drug impacts on patients' quality of life.
2.10 Challenges in Health Information Extraction from Consumer Health Posts
Social media health-related content is typically found in the form of unstructured, natural
language text. Regarding the relatively large size of this type of data in social media, methods
for automatic extraction and analysis of the data received considerable attention (Sarker et al.,
2015). However, performance of the methods is affected by the inherent complexity of the posts.
This complexity is the result of:
1) Colloquial phrase and sentence structure,
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2) Deviation of lay person language from professional medical language in expressing the
pharmaceutical effects of drugs, and
3) Ambiguity in presentation of a specific term; a given term may be used variously as a
side-effect, a withdrawal symptom, or a drug indication.
Due to the first challenge, the conventional methods for named entity recognition for
detecting boundaries of terms and phrases are subject to bias inherent in the data (Liu & Chen,
2013).Therefore, a dictionary-based approach to named entity recognition has been used as an
alternative. Nevertheless, because of the second and third challenges, the systems face low recall,
leading to high frequency of undetected desirable terms, such as side-effects and withdrawal
symptoms.
The lexicon-based approach for name entity recognition in the area of
pharmacovigilance currently dominates other methods of data extraction in consumer health
posts. The lexicons have been mostly developed by combining standard medical vocabularies
including COSTART (that was developed by the FDA for coding post-marketing ADR reports
and was later replaced by MedDRA), the FDA Adverse Event Reporting System (FAERS)
(Edwards et al., 2013), MedEffect (Canadian Adverse Reaction and Medical Device Problem
Reporting database) ("Medeffect Canada. MedEffect Canada [Internet],"), SIDER (which has
been developed based on resources published by public sources, mainly the FDA such as
structured product labeling (SPL)) (Kuhn, Letunic, Jensen, & Bork, 2015) , the Drug Bank
Database (Wishart et al., 2006), and the European agency for the Evaluation of Medical Product
(EMEA) (Gardner, 1996). The lexicons were mainly built on clinical trial findings and
clinicians' reports, which often have low coverage of colloquial expressions available
in consumer health posts. To address this problem, pharmacovigilance studies used few
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approaches that mostly focused on augmenting the standard medical lexicons by embedding
Consumer Health Vocabularies (CHV). CHV was developed mainly with the purpose of
covering colloquial expression of health professional vocabularies (Zeng & Tse, 2006).
2.10.1 Automatic extractions of ADRs from consumer health posts
Leaman et al. (2010) constructed a lexicon of SIDER, MedEffect, and COSTART,
which were augmented with CHV and a small set of colloquial expression of ADRs to identify
adverse drug reaction in consumer drug reviews in the "Daily Strength" forum. In addition, the
search algorithm was set on window-based search with size five to capture syntactic variation in
ADR expressions composed of two or more parts, such as “gained huge weight” for “weight
gain”. To address the ambiguity and distinguish ADRs from drug indications and beneficial
aspects of drugs, they used a rule-based approach built on the closest verb to the
ADR expressions. The study had 78.3% precision and 69.9% recall, and F-measure 73.9%. (see
Table 1 for a summary of these studies.)
Benton, Ungar, et al. (2011) complied a lexicon of dietary supplements, pharmaceutical
terms mentioned in the Cerner Multum’s Drug Lexicon, list of signs and symptoms in the
Medicinenet database, FAERS, and CHV to identify ADRs of hormonal drugs used for breast
cancer treatment in breast cancer healthcare forums. Since the authors could not filter reviews for
the desirable drugs, they used co-occurrence techniques to determine the association between
mentions of the drugs and ADRs. The authors did not provide any information about employing
specific methods to address colloquial phrases or ambiguity in the health posts. The reported
recall was 35.1%, precision 77%, and F-measure 73.9%.
Liu and Chen (2013) designed AZDDrugMinor, a general application for detecting ADRs
in health post forums. MetaMap (A. R. Aronson, 2006), a tool that mainly developed for
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identifying in unstructured texts medical concepts expressed by standard medical
vocabularies, was configured to recognize all terms belonging to ‘Chemicals and Drugs’ and
‘Disorder’ semantic groups. Then the identified terms were compared against the list of ADRs in
FAERS. To identify negated side-effects, NegEX (Chapman, Bridewell, Hanbury, Cooper, &
Buchanan, 2001) was used. To distinguish ADRs from drugs indications, they used
the drugs indications list specified in FAERS database. The application was tested by 200
sentences collected from a forum and showed 56.5% recall, 82% precision, and F-measure
66.9%.
Nikfarjam, Sarker, O’Connor, Ginn, and Gonzalez (2015) designed the ADRMine, a
feature-based machine learning system, to identify adverse effects from health posts' sentences
in Daily Strength and Twitter. First, to address the challenge of colloquial expression of ADRs in
the posts, they trained a supervised sequence labeling CRF classifier on a set of corpora from
Daily Strength (4720 reviews) and Tweeters (1340). In these two corpora, the drug
reviews were annotated for the presence of ADRs, the span (boundary) of the ADRs, and the
beneficial effects of drugs. To address the ambiguity (distinguishing ADRs from instances of
other semantic types), they used a list of features, including a binary feature indicating
presence/absence of ADRs that construed, based on the same ADRs lexicon developed by
Leaman et al. (2010), part of speech of the token, context features, and negation. Moreover, to
extend the semantic variability of the ADRs annotated in the corpus (Daily Strength
and Tweets), they used the word embedding technique (word2vec) (Ganguly, Roy, Mitra, &
Jones, 2015) trained on unseen drug review posts. The result for daily strength was 78%
recall, 86% precision, and 82% F-measure, and for Twitter 76% recall, 68% precision, and F-
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measure 72%. The authors attributed the errors to the colloquial expressions of ADRs,
spelling errors, and informal sentence structure.
(Sarker & Gonzalez, 2015) designed a feature-based machine learning system to classify
text segments from drug review posts into the ADR or non-ADR categories. First, they trained
three supervised classification approaches, including Naïve Bayes (NB), Support Vector
Machines (SVM) and Maximum Entropy (ME) trained on the two corpuses of daily strength and
Twitter introduced by (Nikfarjam et al., 2015). To improve performance of the system, they
created a binary feature using the same ADRs lexicon developed by Leaman et al. (2010). The
binary feature indicating presence/absence of ADRs mentions. They also created a numeric
feature, which was calculated by counting the number of ADR mentions divided by the number
of words in the text segment. The authors also used other features for representing semantic
properties, including n-grams, UMLS semantic types and CUIs, synonyms extracted from
WordNet, and sentiword scores. Among the tree feature-based classifiers, SVM
significantly outperformed NB and ME in both Daily Strength and Twitter corpora with FScore 67% and 54% respectively. Authors attributed the relatively low F-scores to
misspelling, short posts, ambiguous statements, and colloquial expression of ADRs, such as
descriptive phrases of adverse effects, non-standard terms and high variability of semantic
representation of specific ADRs in health posts.
Huynh, He, Willis, and Rüger (2016) trained and tested four different structures of Neural
Network for classifying ADRs assertive text segments on a social media source (the same
Twitter corpus introduced by (Nikfarjam et al., 2015)) and a non-social
media source, the Adverse Drug Effects (ADEs) (Gurulingappa, Mateen-Rajput, & Toldo, 2012),
which was constructed by sampling from MEDLINE case reports. Among Convolutional Neural
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Network (CNN), Recurrent Convolutional Neural Network (RCNN), Convolutional Recurrent
Neural Network (CRNN), and Convolutional Neural Network with Attention (CNNA), CNN and
CRNN had 51% F-measure on Twitter data and 87% F-measure on the ADEs corpus. The low
performance of Neural Network classifiers on the Twitter corpus compared with the non-social
media corpus occurred due to high structural variability in text segments including ADRs and
high syntactic and semantic variability of ADR expressions in social media posts.
(Nguyen et al., 2017) attempted to calculate the frequency of the top 10 ADRs of the
top10 psychiatric medications in LiveJournal, Reddit posts, Reddit comments, and Twitter. The
data for top 10 ADRs was collected from the SIDER database. To improve performance of their
system in capturing semantic and syntactic variability of the 10 ADRs (mentioned by SIDER),
they employed the word embedding technique (word2vec framework). For example, for
instances of “diarrhea”, the word2vec included the alternative spelling or misspelling in the final
tally. The authors did not provide any information about the accuracy of their system in finding
semantic and syntactic variations of the ADR terms, but they concluded that the frequency of
ADRs calculated in social media by extending the list of ADRs has better agreement with the
frequency of the ADRs in the SIDER database.
As the low recall of the ADRs extraction systems and low F-measure of ADRs assertive
text segment classifiers show, informal sentence structure, low coverage of standard medical
lexicons for colloquial expression of ADRs, and ambiguity in semantic types of medical terms
are three main obstacles in enhancing performance of the systems. Even the use of advanced
machine learning methods, such as deep learning and the word2vec framework did not upgrade
performance of the systems significantly. Moreover, augmenting the standard lexicons with
CHV did not improve results of the systems significantly, indicating that the CHV is not rich in
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colloquial expression of ADRs. Therefore, there is clearly a need for an annotated corpus that not
only clarifies the text segments of health posts for presence of specific information, such as drug
effectiveness and ADRs and detecting desirable medical terms, but also filling the gap between
patients’ and clinicians’ terminologies by mapping the colloquial expressions to standard
medical terminologies.
Table 0-3 Specifications of Studies Used Lexicon-based Approach and Machine Learning Methods for
Automatic Extraction of Health-Related Information from Consumer Health Posts.
Study

Purpose

Leaman, Identifying
Wojtulewi ADRS from
cz et al.
Daily Strength
(2010)

Benton,
ADRs of
Ungar et hormonal breast
al. (2011) cancer drugs
from breast
cancer forums

Liu and
Chen
(2013)

A general
application for
detecting ADRs
in health post
forums

Nikfarjam Identifying
, Sarker et ADRS in Daily
al. (2015) Strength and
Twitter

Professional lexicon
used

Methods for
extending
standard medical
lexicon
COSTART, SIDER, CHV, a small set
MedEffect,
of colloquial
language mapped
to UMLS,
Window based
search
Dietary supplements, CHV
Pharmaceuticals
terms mentioned in
Cerner Multum’s
Drug Lexicon, sign
and symptoms in
Medicine website,
FAERS database
UMLS, MetaMap the CHV
findings compared
with by FAERS
database.

The lexicon generated
by Leaman,
Wojtulewicz et al.
(2010) used for
constructing binary
feature indicating
presence/absence
of ADRs

Training a
supervised CRF
classifier
on corpuses from
Daily Strength
and Tweeters,
Word2Vec to
extend the
semantic
variability of of
the ADRs
annotated in
the corpus
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Identifying
performance
semantic type of
expressions
Rule-based
approach that
uses cures from
nearby terms

78.3%
precision,
69.9% recall,
73.9% Fmeasure

—-

77 precision,
35.1 %
recall, 73.9%
F-measure

NexEX (for
negation
detection),
FAERS
Database to
distinguish drug
indication from
ADRs
Applying
Features
including art of
speech of the
token, context
features, and
Negation
detection.

82%
precision,
56.5% recall,
66.9% Fmeasure.

86% precisio
n
78% recall,
82% Fmeasure

Sarker and Binary
Gonzalez classification of
(2015)
ADR assertive
text

lexicon developed by
Leaman, Wojtulewicz
et al. (2010) used for
generating a binary
and numeric features

Training
Classifier
Methods on two
corpuses: twitter
and Daily
Strength

Huynh,
He et al.
(2016)

No lexicon

Four different
structure of
Neural Network
based Classifiers
were trained on a
Twitter corpus

10 top side effects of
psychiatric
medications in the
SIDER.

The word2vec
—
framework for
generating the
alternative
spelling or
misspelling in the
final tally

Binary
classification of
ADRs assertive
text

Nguyen,
Frequency
Larsen et estimation f top
al. (2017) 10 ADRs of the
top10 psychiatric
medications.
Sources:
LiveJournal,
Reddit posts,
Reddit
comments, and
Twitter.

Generating a set
of features,
representing
semantic
properties of a
text (e.g., ngrams,
sentiment,
polarity, topic,
synonyms
extracted from
WordNet)
—

Twitter
Corpus: 53%
F-measure
Daily
Strength
Corpus: 67%
F-measure

Convolutiona
l Recurrent
Neural
Network:
51% Fmeasure

No computed
recall/specifi
city/Fmeasure.
Conclusion:
The
word2vec
increase the
estimation
frequency to
the point of
agreement
with SIDER.

2.10.2 Corpora Developed Using Consumer Health posts
Currently, there are two open-source corpora based on health-related social media: (1) a
Twitter corpus that was built on 10,822 instances of randomly selected tweets (each instance of
tweet is a maximum of 140 characters) for 71 drugs prescribed for chronic illness, and (2) the
CADEC corpus, constructed based on drug review posts on the online message board
“askapatients.com". These corpora are summarized in Table 2.
The tweets in the Twitter corpus were double coded by two annotators for presence of
ADRs, spans of ADR indications, and beneficial effects. For this data set, the Inter Annotator
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Agreement (IAA) calculated using Cohen’s Kappa was 71%. The authors normalize the
identified medical terms by mapping layperson expressions to the UMLS (Ginn et al., 2014)
The CADEC corpus consists of 1,231 comments for two sets of drugs, Diclofenac and
Lipitor. The drug reviews were annotated for span of ADRs (6,318), symptoms (275), and
disease (283), and drug names (1,800). The pair-wise agreement between annotators was
calculated using Metke-Jimenez, Karimi, and Paris (2014) method, which was 86.5% , when
span and annotation settings were both relaxed and 60.4 % , when span and annotation settings
were both strict. All the entities other than drug names were mapped to SNOMED CT. All the
drugs were mapped to AMT (the Australian Medicines Terminology). In addition, all the ADRs
also mapped to MedDRA (Karimi et al., 2015).
2.1.3 Corpora developed using biomedical literature.
There are also other corpora for identifying ADRs that developed based on biomedical
literature, mainly from Medline case reports and abstracts. These are summarized in Table 2.
Gurulingappa, Klinger, Hofmann-Apitius, and Fluck (2010) developed a corpus of
ADRs and diseases using randomly selected MEDLINE abstracts. It consists of 813 mentions of
adverse effects and 1,428 mentions of disease. Further, Gurulingappa, Mateen-Rajput, et al.
(2012) developed a corpus using 2,972 medical case reports randomly selected from MEDLINE.
The corpus was annotated for mentions of drugs (5,063), adverse effects (5,776), dosage (231),
as well as the relationships between drug-adverse effect (6,821) and drug-dosage (279). In
addition, Gurulingappa, Rajput, et al. (2012) created Adverse Drug Effects (ADEs), a corpus of
annotated sentences, indicating the presence/absence of ADRs, which were obtained from 2,094
MEDLINE medical case reports. The corpus contains annotations of 5,063 drugs, 5,776
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conditions (e.g. diseases, signs, symptoms), and 6,821 relations between drugs and conditions
representing clear adverse events.
Table 0-4 Specifications of Existing Corpus Relevant to the Corpus Specified in this Study
Study
Gurulingappa,
Klinger et al.
(2010)
Gurulingappa,
Rajput et al.
(2012)

Gurulingappa,
MateenRajput et al.
(2012)
Ginn,
Pimpalkhute
et al. (2014).
(Karimi,
MetkeJimenez et al.
2015)
Our corpus

Source
Medicine
abstract

Type
Biomedical
literature

Entity and Size
813 ADRs
1,428 mentions of disease

Normalized
…

2,972 medical
case reports
randomly
selected from
MEDLINE
2,094
MEDLINE
medical case
reports.
10,822
instances of
randomly
selected tweets
1,231 comments
for two sets of
drugs

Biomedical
literature

Drugs (5,063), Adverse
effects (5,776), dosage (231)
Relationships between drugadverse effect (6,821) and
drug-dosage (279)
5,063 drugs, 5,776 conditions
(e.g. diseases, signs,
symptoms), 6,821 relations
between drugs and conditions
Presence of ADRs, spans of
ADR indications, and
beneficial effects

….

Social Media
(askapatient.co
m)

ADRs (6,318), symptoms
(275), and disease (283), and
drug names (1,800)

896 comments
for two classes
of psychiatric
medications:
SSRI and SNRI

Social Media
(askapatient.co
m)

Sentence classification:
presence of Side-effects,
Withdrawal symptoms, Drug
indicators, Effectiveness, and
Ineffectiveness.
Entity identification: sideeffects, withdrawal
symptoms, and drug
indicators.

Identified entities
mapped to
SNOMED-CT,
AMT, and
MEDRA.
Identified entities
mapped to both
UMLS and
SNOMED-CT

Biomedical
literature
Social MediaTwitter

…

Mapped to UMLS
concepts

Although the corpora annotated for mentions of ADRs using biomedical literature and
clinical notes in Electronic Health Records (EHRs) have important implications for automatic
extractions of ADRs from these resources, they may not provide significant performance
improvement for ADRs identification in consumer health posts in social media. As Sarker and
Gonzalez (2015) showed, incorporation of ADEs corpus (Gurulingappa, Mateen-Rajput, et al.,
2012) with corpus obtained from social media data does not provide significant improvement in
the accuracy of ADRs of an assertive sentences-classifier system, because the corpus structure is
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not compatible with the social media corpora. In addition, corpora developed with biomedical
literature follow grammatical rules and are not rich in colloquial expression of medical entities.
Therefore, they do not address the challenges of ADR medical entity extractions from consumer
health posts in social media.
In response to these challenges, we developed a corpus in this study that addresses
pharmacological effects of psychiatric medications including ADRs, drugs indications, and drug
effectiveness. We followed a systematic approach to develop this corpus consisted of two main
components: entity identification, and entity normalization. The identified entities were mapped
to the equivalent medical concepts in both the UMLS and SNOMED CT. ADRs and WDs were
further classified as physiological, psychological, cognitive, and functional problems (e.g.,
limitation in daily functioning, social activities or inter-personal relationships) that did not
receive any attention in previous studies. The methodology for developing this corpus is
explained in the methodology section of this study.
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Chapter 3: Methodology
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This study involves a mixed-method approach for providing structured data from
unstructured drug reviews for testing hypotheses concerning attitudes and adverse drug reactions
associated with antidepressants. Methodology for developing the structured data and testing the
hypotheses consisted of seven major phases:
! Phase 1: identification of data source and drug source
• Drug sources of this study are Sertraline (brand name: Zoloft), Escitalopram
(brand name: Lexapro), venlafaxine (brand name: Effexor XR), duloxetine (brand
name: Cymbalta).
• Data source of this study is a healthcare forum called “askapatient.com”.
! Phase 2: Data collection
This phase includes the following steps:
• Developing an Application Program Interface (API) for data collection
• Calculating the sample size: 892 reviews were collected for four drugs specified
in this study.
! Phase 3: Developing an Analytical Framework fro generating structured data from
unstructured text
This phase includes the following steps:
• Developing the initial analytical Framework using deductive approach (reviewing
the literature)
• Annotating the drug reviews using the initial analytical framework
• Generating themes using inductive approach (open coding)
• Developing the final analytical framework by refining themes obtained from
inductive and deductive approaches.
! Phase 4: Applying the final analytical framework to the drug reviews
This phase includes the following steps:
• Data preprocessing: This step includes using regular expression codes to remove
personal information and noisy pattern from sentences structure.
• Splitting drug reviews to sentences.
• Annotating sentence using analytical framework: This step includes developing
guideline for annotators, developing annotation environment, calculating interannotator agreement and resolving disagreement between annotators.
! Phase 5: Entity identification
This phase includes the following steps:
• Developing guidelines for identifying Adverse Drug Reactions (ADRs),
Withdrawal Symptoms (WDs), and Drug Indications (DIs)
• Annotation process
• Calculating inter-annotator agreement
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! Phase 6: Terminology association (entities normalization)
• Developing guidelines for mapping the identified entities (ADRs, WDS, and DIs)
to UMLS and SNOMED-CT. The guidelines include requirements for selective
proper/preferred concepts, procedure of mapping, and instruction for selecting
proper standard concept for colloquial expressions of ADRs/WDs/DIs.
• Reviewing the mapping for consistency
! Phase 7: Usability of the data set
The structured dataset provided through phase 1 to phase 6 used for generating and
testing hypotheses related to association between variables and ADRs identified in
this study. This phase includes the following steps:
• Summarizing the dataset
• Using imputation methods for handling missing values
• Testing hypotheses
• Developing a predictive model
Figure 1-3 shows the summary of the research methodology and the outcome of each phase,
which is specified in the result section.
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Figure 0-1 Summary of the research methodology
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Phase 1
3.1 Data Source Information
3.1.1 Data sources
We examined data from a healthcare forum "askapatient.com" that compiles uncensored
user comments on the effects of taking different sorts of medication from people with a range of
diagnoses. In this forum, patients can record their experience with a medication by filling out a
form for a medication brand name. This form is composed of eight fields including rating, reason
for prescription, side-effects, comments, gender, age, duration/dosage, and date of posting the
review. Patients can rate their satisfaction with drugs ranging from 1 to 5, where 1 presents the
least satisfaction and 5 presents the highest satisfaction. Patients are supposed to report drugs’
ADRs in the side-effects field and the detail of their experience in the comment field. However,
patients reported various aspects of their experiences, such as drugs’ effectiveness or perceived
distress received from ADRs, in both fields. Table 3-1 shows an example of posts for Cymbalta
in "askapatient.com".
Table 0-1 An Example of a Post for Cymbalta in "askapatient.com”
Ratin
g
3

Reason

Side-effect

Comment

Gender

Age

Duration

Date

fibromyalgia
/depression

Nausea, diarrhea,
upset stomach,
dry mouth,
sleepiness

I have only been on 30mg for 4
days and have the extreme runs.
Upset stomach and no appetite.
Pain in minimal though and I feel
less anxious and depressed.

F

38

4 days

2009-10-05

3.1.2 Drug Source
We used drug review posts in "askapatients.com" to collect information for four
psychiatric medications, including Sertraline (brand name: Zoloft) and Escitalopram (brand
name: Lexapro) from Selective Serotonin Reuptake Inhibitor (SSRI) Class and venlafaxine
(brand name: Effexor XR) and duloxetine (brand name: Cymbalta) from Serotonin
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Norepinephrine Reuptake Inhibitor (SNRI) Class. These four drugs have been primarily
prescribed for depression and mood disorders, and according to a dataset from Symphony Health
Solutions*, they had the highest prescription rate in 2012. Although the medications have shown
substantial evidence of effectiveness in promoting mood elevating properties, they are associated
with a significant number of ADRs causing debilitating impacts on patients’ daily activities and
social participation.

Phase 2
3.2 Data collection
3.2.1 Website policy
All the data in the healthcare forum “askapatient.com” are anonymous and publicly
available, however some respondents may disclose their email address or their phone number in
the field of comment. We sought IRB approval through University of Wisconsin-Milwaukee
(UWM) and we received the following response:
“Based on the activities described in the Determination of UWM IRB Submission form, your study does
NOT involve research with human subjects and IRB review and approval is NOT required for your
project. By analyzing publicly available posts, you will not be obtaining data through intervention or
interaction with the individual and you will not be obtaining private information.”

We also attempted to contact the website administrators, but we did not receive any
replies despite repeated requests. Regarding the anonymous data recording process, website
privacy policy, and response of UWM to our IRB request, we decided it is ethically acceptable to
conduct a passive data collection from the healthcare forum. Thus we did not seek IRB approval
for data collection phase. To further protect respondents’ identities, we removed all the emails
and phone numbers from dataset.
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3.2.2 Designing application program interface (API)
The website does not have API (application program interface) access. We developed a
web-crawler system to collect all the respondents comments available in this website for the four
antidepressant drugs. Because data in this website are classified based on the type of drugs, it is
possible to easily filter other drugs that are not purpose of this study. For each respondent’s
comment, type of disorder, side effects, comments, dosage, duration of the drug intake, age, and
gender were collected, if they were available. The information was collected in August 2016.
3.2.3 Calculating the sample size
Since the focus of this study is on patients ‘attitudes towards antidepressants, we first
filtered review posts in which patients reported depression with or without comorbid with other
mental/physical illness as the reason for drug prescription. Table 3.2 provides information about
the total number of reviews available in the forum for the four drugs focused on in this study and
the number of reviews after filtering the dataset for depression.
In order to select a subset of data that sufficiently represents the whole dataset in the
healthcare forum, we used the following sample size formula (Charan & Biswas, 2013):
𝑧 ! × 𝑝(1 − 𝑝)
𝑒!
𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 =
𝑧 ! × 𝑝 (1 − 𝑝)
1+(
)
𝑒! 𝑁

Where z is the confidence interval, e is the margin of error, p is the standard deviation,
and N is the population size. For this study, z is 90%, e is 5%, p is 0.5 to ensure the sample is
large enough, and N is the number of post reviews for each drug in the healthcare forum. The
calculated sample for Zoloft, Lexapro, Cymbalta, and Effexor XR were 213, 219, 231, 229
respectively. We used Python Random Module (Python, 2017) to select the calculated sample
from the healthcare from randomly.
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Table 0-2 Total Number of Review Posts and the Calculated Sample Size
Drugs
Zoloft
Lexapro
Cymbalta
Effexor XR

Number of reviews
available in the forum
1528
1913
2481
2129

Number of reviews include depression
as the reason for drug prescription
980
1145
1573
1447

Sample Size
213
219
231
229

Phase 3
3.3 Developing the Analytical Framework for Generating Structured Data
Management and summarization of unstructured data in qualitative research is a critical
aspect in data analysis. The Framework method is a flexible tool that provides researchers with
the approaches of developing themes to generate highly structured data from qualitative data.
The Framework method was developed at the qualitative research unit at the National
Center for Social Research in the United Kingdom for large-scale policy research. However, it is
becoming an increasingly popular approach in medical and health research data (Gale, Heath,
Cameron, Rashid, & Redwood, 2013). Like other qualitative approaches, the Framework method
helps to identify similarity and discrepancy in qualitative data before determining the
relationship between different parts of the data. This identification involves developing a
descriptive summary of the data clustered around themes.
Depending on the research question, the Framework method uses an inductive, a
deductive, or a combination of inductive and deductive approaches on the inductive-deductive
continuum. The difference between these three approaches is the way in which the themes for
developing structured data are generated. In the deductive approach, themes are developed based
on literature, pervious theories, or specifics of a research question. In the inductive approach,
generates themes from data by open coding and refining themes. In a combined approach, a
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study starts with predefined themes to explore, but also it leaves space to discover the
unexpected aspect of respondents experiences with the subject of the study.
To provide structured data from the review posts, we adopted the Framework method by
focusing on a combined approach (inductive-deductive). A deductive approach was used that
involved reviewing the literature the set of important variables affecting attitudes towards
antidepressants, which construct the initial that provided a framework for data analysis.
Conducting the inductive approach generated the list of themes for data analysis that were not
discussed by the literature. The following steps were followed for constructing the final set of
codes for qualitative analysis of reviews.
3.3.1 Developing the initial analytical framework using deductive approach
We conducted a review of literature to identify important clinical and personal factors
affecting patients attitude to antidepressants. Table 3.3 provides the identified factors (codes)
from literature with their description. The factors were categorized into five categories, including
pharmaceutical treatment factors, healthcare system factors, psycho-social factors, patient related
factors, and disorder related factors. The identified factors were used as the initial codes for
constructing the initial Analytical Framework. Each identified code may include sub-codes
indicating the spectrum of the levels of patient experience for that variable.
3.3.2 Coding (annotating) the drug reviews using the initial analytical framework
The purpose of this step is to understand to what extent the pre-defined themes could be
applied to the comments. In addition, it helped us to identify passages of comments that could
not be mapped to the predefined codes.
For the purpose of initial analysis, 310 reviews from the combined drug samples were
randomly selected. Because, reviewers entered their experiences with antidepressants in two
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fields, including side-effects and comments, we first combined the two fields and generated one
segment of text for each review that was identified by drug id.
Table 0-3 Description of Predefined Themes Developed Deductively from Literature Review
Categories

Factors (predefined
codes)
Perceived
effectiveness
Perceived necessity

Pharmacologi
cal treatment Perceived concern
factors
Side-effects

Perceived distress
from side-effects

Healthcare
system
factors

Patient-provider
relationship
Healthcare settings
Affordability
Stigma and cultural
related factors

Psycho-social
factors
Partner support
Patientrelated
factors

General concern and
necessity
Knowledge about
medication
Education level

Disorder
related
factors

Patient insight about
source of depression
Severity of
depression
/symptoms
Type of depression

Description
Patient’s subjective assessment of antidepressant helpfulness in reduction of depression
symptoms, enhancing emotional and cognitive functionalities, and in overall, enhancing
life quality.
Patient subjective assessment of antidepressant necessity in improving and maintaining
current and future health conditions. For example, patient may find an antidepressant
vital in reducing the risk of relapse.
Patient subjective assessment of antidepressant harmful aspects in long-term. Patient
may view antidepressant as an agent, which is addictive, take control over feelings and
thought, and altering personality in long-term.
Any adverse reactions that patient report as side effects of antidepressants intake.
Antidepressants’ adverse reaction may include physiological side-effects, emotional
syndromes, cognitive impairment, and limitations on daily functioning, and in overall
reducing quality of life
Patient’s perceived distress from antidepressants side effects depends on patient’s selfattention to internal bodily sensation that may have an influence on patient tolerability
of side effects. Patient may show the distress by using adjective showing severity of a
side effect, negative impact on work or daily activities, or visiting emergency
department. A severe side-effect including self-harm and suicidal ideation or attempt
reflects distress received from antidepressants.
Patient expresses their satisfaction or dissatisfaction with healthcare providers from
various aspects, such as perceived support from providers or perception of healthcare
providers knowledge about illness and treatment.
Patients may demonstrate a higher level of trust and satisfaction towards diagnosis and
treatment offered in a psychiatric setting compared with a primary care setting.
Patient may complain about the high cost of antidepressants and lack of insurance
coverage.
Patient may express their concern about stigma and cultural-related factors that may
make prolonged pharmacological treatment notoriously difficult for patients. For
example, the public may view antidepressants intake as a sign of weakness or
incapacity to deal with daily emotional distress that may influence on patient
acceptance of antidepressants.
Patients may express their perceived support from partners (family and friends) about
having depression as a proper diagnosis and having an antidepressant as a proper
treatment.
Patient may express their general view toward medications. For example, they may
view all the medications harmful and believe natural remedies and changing life style
will have a better healthcare outcome than pharmacological treatment.
Patient may complain about lack of knowledge of side effects or complexity of
treatment, proper time of discontinuation, and withdrawal adverse effects.
Patient may disclose their level of education in the comments or in the section of
demographic information.
Patient may express their insight towards the source of depression, and severity of
symptoms. For example, patient may attribute source of depression to psychological
problem rather than biological factors.
Patient with major depression disorder may have a higher tolerability of adverse effects.
In addition, patient’s perceived effectiveness of antidepressant may be higher in the
patients.
Type of depression may be an important factor in shaping patient’s attitude toward
antidepressants.
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Selected reviews with drug ids were arranged in rows and predefined codes were arranged in
columns, developing the initial framework of analysis. Microsoft Excel was used for developing
the initial framework of analysis.
Figure 3-1 provides an excerpt of the initial framework of analysis that was generated
using pre-defined codes. As illustrated in the figure, we highlighted each meaningful passage of
text and attached it to a cell corresponding to the appropriate code in the initial framework. For
passages of text that did not fit into the existing themes in the framework, we determined and
documented the theme of the passage and recorded it in a new column named “Not-Matched”.
We also created a column named “Not-applicable” that contains passages without any
meaningful information about respondents’ experiences with antidepressants. For example:
•
•

“Feel free to email me, I have been through it all with Effexor.”
Thank God I was pregnant or I may NEVER have forced myself through to the
other side!!!”

Patients in the review posts did not provide any information about the pre-defined themes
of “type of healthcare setting” where they received treatment for depression, “stigma and cultural
related factors”, or “educational level”. In addition, the initial analysis showed that there is little
information available in the reviews for some of the predefined themes, including
“affordability”, “general concern and necessity”, “partner support”, and “patient insight about
depression”. Table 3.4 provides the identified codes and related sub-codes with examples from
patients’ reviews for each code.
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Figure 0-2 an expert of initial comment analysis generated using predefined themes
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Table 0-4 Predefined Themes Developed Inductively with Examples from Drug Reviews
Predefined codes

Sub-codes

Examples from patients’ reviews

Perceived
effectiveness

Positive

“Anyway, my life is on track, I have nothing to be depressed or sad about.”

Negative

But I still havnt noticed any change in my energy or anxiety.

Positive

“All in all, I love it. I have not have a depressed moment since I've been on it,
approx. 8 month. I do not think I cannot live without it.”

Negative

“There's no doubt that Effexor XR saved my life, however long-term use is not
the best.”
“Pure poison!”
“I was so scared to take it that I delayed it because I read all the comments on
this site.”
“I am worried about trying to cut down gradually as I read so much scary stuff
about going off it.”
“The withdrawal is hell. You would think you were going through heroin
withdrawals.”
“Typical with effexor XR- Dizzy, jaw tight, teeth grinding.”
“I had tolerable, minimal side effects.”
“I didn't really experience any side effects...”
“The side effects are far less hassle than being in my dark depression.”
“The side effects are hell.”
“No wonder I suffered so many side effects.”
“My pharmacist convinced me that it was safe for me to use along with my
topamax, and encouraged me to try it. I'm really glad I did.”

Perceived
Necessity
Perceived concern

ADRs
Perceived Distress
from side-effects

Physician patient interaction

Concern
about sideeffects
Concern
about
withdrawal
symptoms
Tolerable
(low)
Intolerable
(high)
Positive
Negative

Healthcare setting
*
Affordability *
Stigma and cultural
related Factors
Partner support*

Positive
Negative

General concern
and necessity*
Demographic
information
Knowledge about
medication
Education level*
Patient insight
about depression *

Severity of
depression/sympto
m
Type of depression
Duration of
depression

Positive
insight
Negative
insight

“I am suffering and should of not trusted the NP who prescribed the pills without
first checking it out.”
“Respondents did not explicitly mention in which healthcare setting they
received treatment for depression.”
“If the depression doesn't eventually cripple you, the costs will.
It is too expensive if you don’t have insurance!”
Non of the respondents did not explicitly complain about stigma or did not
present any information indicating cultural factors affecting on patients attitudes
antidepressants.
No example
“My husband has no compassion to my withdrawal symptoms.”
“Do NOT believe the MDs and pharm corp. hype and lies! FLEE!”
“Basic demographic information including age and gender was reported by
respondents.”
“No one ever told me even as I was seeing my psych and psychologists weekly,
and my physician, that what I was experiencing could be from the drug.”
Patient did not disclose their education level in their comments. The website also
did not provided a field to request responded educational level.
Mental illness (i.e. lack of serotonin) is just like any other defect the human
body can have.
No example
Some of the respondents in the field of “reason of prescription” or their
comments mentioned severity of depression or their symptoms, such as:
“The depression is so terrible that I am very keen to give Lexapro a fair try.”
Some of the respondents mentioned type of their depression in the field of
“reason of prescription” or in the comments.
Most of the respondents in the filed of “duration/dosage” reported duration of
antidepressant’s usage.

3.3.3 Generating codes (themes) using inductive approach (open coding)
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Our regular team meetings enable us to discuss the proposed ideas, discover patterns, and
an impression for alternative viewpoints, thus ensuring that one researcher’s particular
perspective did not dominate and that agreement upon codes (themes) is a team conclusion. We
revised the initial framework by defining new themes and refining the existing codes to
incorporate unfitted passages of comments. We revised the initial framework by defining new
themes to incorporate unfitted passages of reviews.
Patients in the review posts stated their experiences with withdrawal symptoms (WD) and
perceived distress from WDs. They also included experiences with withdrawal and
discontinuation. Moreover, patients might express their overall attitude and pre-treatment
concern with medications. They also may have some suggestion for readers about the quality of
the drugs.
Table 3.5 demonstrates new themes developed through the process of the inductive approach
(open coding).
3.3.4 Developing the final analytical framework by refining the themes
The process of refining, applying, and re-refining themes was repeated until no new
themes (codes) was generated. To develop the final analytical framework, we took the following
steps:
1) Each theme in the predefined framework that did not fit with information provided in
reviews was excluded from the final framework. For example, we removed “healthcare
setting,” “stigma and cultural related factors”, “educational level”, and “dosage of
medication”.
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Table 0-5 New Themes Generated Through the Process of Inductive Approach (Open Coding)
New Themes

Sub-Themes

Withdrawal
symptom

Examples
“I weaned slowly from 150mg to 75 to 37.5 and off. I feel nauseous
alot and my depression and social anxiety has returned almost
100%.”
“Do not wean off effexor too soon as i had one very bad day and
experienced mild halloucinations.”
“Could miss a dose or two and no problem.”
“Trying to come off of the medication is very difficult.”

Perceived
distress from
Withdrawal
Symptoms

Low (tolerable)
High
(intolerable)

Overall attitude

Positive

“I think that this drug is great, but only for certain people.”

Negative

“This drug is just a poison.”
“This drug ruined my life.”
“My depression mostly manifested in an inability to start new
projects, rather than any feelings of sadness.”
“I used to be so depressed and anxious, that I didn't want to leave
the house. I have a long history of depression and anxiety.”
“I would definitely recommend Effexor XR.”
“Do not take this medication!!!!”
“I stopped this drug after two days.”
“Cutting the dose in half,When I went down to taking none,
experience withdrawal effects.”
“Can not miss a single dose or I feel awful.”
“I experience when missing a dose.”
“I have insisted on stopping the effexor, and now the doctor is
pushing pristiq (the "new and improved" effexor).”
Switched to Luvox which I am finding much more beneficial.”
“I think I m going to quit.”

Drug indication

Recommendation
to others
Experience of
Withdrawal

Positive
Negative
Discontinuation
Weaning off
Missing dosages
Switching
Decision about
discontinuation

Dosage/duration
Experience with
Other
medications
Problem with
financial support
Problem with
social support
Not applicable

“I started out on Effexor XR 75 mg, and was slowly raised from
there to Effexor XR 300 mg. Then I was changed to the generic
Venlafaxine XR 300 mg.”
“I was given zoloft from my pyschiatrist and started at 50mg per
day and was steadily increased to 100mg.||| the doctors increased
my dose to 150mg.”
“Started taking it after Prozac and (can't remember the name) made
my stomach hurt so bad.”
“ I did a rapid decline on my cymbalta because I lost my
insurance.”
“ Thankfully I have a wonderful husband who helped me past the
side-effects.”
“Hope the comments help and good luck.”
“I honestly can't tell a difference when I am on or off of Effexor
XR.”

2) If a predefined or a new theme fit in less than 5% of information provided in reviews, we
excluded them from or merged them with other themes in the final framework. Similarly,
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“affordability”, “partner support” and “patient insight about depression” were excluded
and “general concern and necessity” was merged with “overall attitude”.
3) All codes that were conceptually related and subjectively difficult to distinguish between
their applicability to a passage of text were combined in the final framework.
Accordingly, “perceived necessity” and “perceived effectiveness” are conceptually related
and subjectively difficult to distinguish in application to passages of text, therefore they
were combined in the final framework as “perceived effectiveness”. For example, the
following passage can be labeled as both “perceived effectiveness” and “perceived
necessity”.
“All in all, I love it. I have not have a depressed moment since I've been on it, approx. 8
month”.
4) Although ADRs and withdrawal symptoms are conceptually related and both reflect
adverse drug reaction, we distinguish between them as two separate codes in the final
framework. A patient may receive minimal distress from an antidepressant’s side effects,
but perceive severe withdrawal symptoms during the process of discontinuation, which
may negatively affect the patient’s attitude. Distinguishing ADRs from withdrawal
symptoms is important from the perspective of clinical trials and interventions designed
specifically to help patients manage the process of a drug’s discontinuation.
5) Perceived concern for the prescribed drug includes passages of text, in which reviewers
expressed their perceived distress from ADRs, WDs, or the overall distress they
experienced with the drug. Thus, we defined two new codes “perceived distress from
ADRs” and “perceived distress from WDs” to express perceived express towards ADRs
and WDs. For the passage of text in which a patient expressed overall perceived distress
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from a drug without distinguishing it for WDs and ADRs, we assign it to the code
“overall attitude”.
6) Some patients directly mentioned how the information obtained from online sources
including online messaging boards influenced their attitude toward antidepressants and in
turn their behavioral reaction. This information can provide important evidence about the
impact of an online sources on shaping attitudes toward medications. However, because
of the paucity of the information, we did not define any new theme covering this type of
information in the final framework. The following provides examples of such sentences:
•
•

“I don’t want all those withdrawals I m reading about”.
“I was so scared to take it that I delayed it because I read all the comments on
this site”.

Table 3.6 presents codes and sub-codes in the final framework, each with a brief
explanatory description and examples from reviews.

Table 0-6 Themes (items) in the Fianl Analytical Framework with Description and Example from Patients
Comments

64

Code
Adverse Drug
Reaction

Perceived
distress from
ADRs
(ADR-PD)

Sub-codes
Presence

Description
If patient reported explicitly he experienced
side-effects with or without listing the ADRs
in the sentence/comments

Example
“I couldn't take Effexor XR. It gave me
horrible nightmares and I kept waking
up.”

Absence

If patient reported “they did not experience
any ADRs”

“I did not have any side-effect.”

High

- Explicit mentions: If patient explicitly
mentioned that they suffered from ADRs,
- Functional problems: If patient reported
functional problems associated with ADR,
such as limitation in daily functioning, social
activities, and work performance
- Qualifiers indicating severity: If patient
used any qualifiers indicating severity of the
symptoms. Such as severe, debilitating,
intolerable.
- Severe ADRs: If patient reported severe
ADRs having negative impact on patient
quality of life, such as suicidal
ideation/attempt, self-harm, bed-ridden.
Patient hospitalization or emergency visit
also shows the presences of ADRs causing
high-perceived distress.
Explicit mentions: If patient explicitly
mentioned that the ADRs were tolerable.
Qualifiers indicating mildness: using
Qualifiers indicating mildness of ADRs, such
as slightly, mild.
Qualifiers are indicating non-persistency:
Using qualifiers indicating non-persistency of
ADS, given that ADRs are NOT associated
with qualifiers indicating severity of ADRs.
No experience of ADRs: If patient explicitly
mentioned they did not experienced any
ADRs.
If patient complained about occurring new
symptoms occurred in the process of dosage
reduction, discontinuation, or missing
dosages (unintentional withdrawal) of the
medication, with or without listing the WDs
symptoms

“The side effects are intolerable.”
“Have been able to work (software
developer) if attempting this drug
during work week.”
“Severe nausea and dizziness.”
“That drug caused nausea and increased
suicidal thoughts.”

Low

Withdrawal
symptoms
(WDs)

WD-perceived
distress
(WD-PD)

Presence

Absence

If patient reported that they did not

High

If patient mentioned they a) suffered from
withdrawal symptoms, b) and/or they
reported functional problems associated with
the WDs, c) and/or they used qualifiers
indicating severity, d) and/or they mentioned
severe WDs, the WD is high.

Low

a) If patients explicitly mentioned that
withdrawal symptoms were tolerable, b) used
indicators showing low perceived distress, c)
used qualifiers showing tolerability of the
symptoms, d) using qualifiers showing nonpersistency of the symptoms, given that the
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“Any side effects were, for me,
tolerable compared to the benefits.”
“Mild headache”
“Headache for two days, but severe
headache for two days indicates highperceived distress.”
“The withdrawal made me very dizzy.”

“I weaned slowly from 150mg to 75 to
37.5 and off. I feel nauseous alot and
my depression and social anxiety has
returned almost 100%.”
“Do not wean off effexor too soon as i
had one very bad day.”

“The withdrawal symptoms are
horrible.”
“I was in bed for about one week.”
“I missed a dose yesterday, and now I'm
nauseous.”
“ I can not function. Feel I am
poisoned.”
“The withdrawal side effects especially
brain flashes or brain zap was VERY
PAINFUL.”
“Withdrawal was fine.”
“When I stopped the drug, I had mild
dizziness.”
“I experienced headache for few days
after reducing the dosage.”
“I had no experience of withdrawal

Effectiveness
(EF)
Ineffectivenes
s (INF)
Patient –
physician
interaction
(PPI)

Positive
(P)

Negative
(N)

Lack of
knowledge
(~KN)

symptom was tolerable, e) explicit mention of
no experience of withdrawal symptoms.
A drug is effective, if patients reported that
his health condition has been improved or his
symptoms were treated after drug
consumption.
A drug is ineffective; if patient reported that
his/her health status did not improve, became
worse, or still has the same symptoms.
If patient’s express of communication with
providers indicated implicitly/explicitly that
patient has high level of trust in providers and
she/he was satisfied with communication with
providers.

- If patients express of communication with
providers indicated implicitly/explicitly that
patient were not satisfied with healthcare
providers.
- Patient may complain about provider’s
failure in providing sufficient information or
non-effective communication, such as
provider’s failure to involve patient in the
process of decision-making or treatment plan.
Some patients may complain that they did not
receive sufficient information about ADRs or
WDs symptom associated with the drug and
and the mechanism of management of the
ADRs/WDs.
Patient may indirectly complain about lack of
knowledge by asking questions in the forum
or mentioning that they did research on the
web to gain more information.

Experience of
WD

General
attitude

symptoms.”
“For the first few weeks it helped me
feel better.”
“It did not help me at all.”
“Success with these meds truly depends
on staying in touch with your
physician.” (Implying trust in
physicians)
“My doctor and I decided to stop taking
it.” (implying providers involved
patient in the process of decision
making), which can lead to patient
satisfaction.
“Dr. s do not understand the crazy side
effects of starting this class of drugs.”
(Implying patient’s complaint about
physician’s lack of knowledge)
The doctor still claims that 30 mg is not
even considered a therapeutic dose, but
I know what works. (physician failure
to include patient treatment preference
in the process of decision making).
“Cannot get straight answer from
anyone regarding how long these
withdrawal symptoms will last.”
“No one informed me of the withdrawal
nightmare.”
“TODAY I'd like to know if my recent
muscular twitches are related to this
medicine.”
“I wish I had been smart enough to do
research on Effexor BEFORE I went on
it.”
“When I miss a day I feel very spaced
out, thick, groggy, sad.”
“If I don’t take the medicine at the same
time every day or forget a day, I will
experience withdraw and its horrible!”
“I had to stop taking it.”
“I had low blood pressure for about 2
weeks after I stopped taking it.”

Unintentio
nal WD
(DXD-F)

If patient explicitly mentioned that they
forgot to take medication (missing dosages)
or run out of medication.

Intentional
WDStopping
(DXD-S)
Intentional
WDweaning
off
(DXD-W)

If patient explicitly mentioned that they
stopped the medication.
If patients explicitly mentioned that they are
weaning off (tapering off) the medication.

“I have been tapering from 60 mg per
day.”
“I'm stopping slowly.”

Intentional
decision
for WD
(DXDDec)
Positive
(P)

If patient explicitly mentioned that they
decided to stop or wean off the medication.

“However after dealing with this acne
I'm going to try another med.”

If patient’s general attitude towards the drug
is positive.

“ I really like this drug, it changed my
life.”
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toward
medication
(ATT)
Patient
suggestion to
readers about
drug

Negative
(N)

If patient’s general attitude towards the drug
is negative (ATT-N).

“ I hate the drug, it completely ruined
my life.”

Positive
(P)

If patient’s suggestion to a reader (other
patients) is positive.

(sug)

Negative
(N)

If patient’s suggestion to a reader (other
patients) is negative.

“ Zoloft is the best option for
depression.”
“ Ask your doctor to give you this
drug.”
“Please be aware of the drug and its
consequences.”

Dosage/durati
on
Lack of social
Support
(~SS)
Lack of
Financial
Support (FS)
(~FS)
Other drugs
Other patients
Drug
Indication
(DI)

If patients talked about dosage or duration of
the drug, it will be labeled as positive.
If patient complained that he/she did not
receieve any social support for managing
ADRs or process of discontinuation
If patients reported that because of lack of
financial support, they had to stop the
medication permanently or temporarily.

“My doctor prescribed 25 ml for me.”

“If patient discussed other drugs in the
review.”
If a reviewer explained other patient’s
experience with medication.
Any sign or symptom that patient clearly
mention that it was the reason for drug
indication and/or it was treated by the
medication

“I used triazolam for Insomnia.”

“ My husband did not understand me.”
“ I had to stop the medication because it
was expensive.”

“ My son was for three years on this
drug, be he did not feel better.”
“my anxiety disappeared because of
Zoloft.”

Phase 4
3.4 Applying the Final Analytical Framework to the Drug Reviews
The final analytical framework has been applied to all of the drug reviews in the sample.
We only conducted data analysis on free text of each review posts that were available in both the
side-effects field and comment field for each review (see table 3.1 for the structure of a review).
The majority of drug review posts are composed of multiple sentences that each covers various
aspects of patients’ experiences with drugs, which were explained in Table 3.6. Therefore, we
used sentences as the basic unit of analysis. In addition, data analysis at the level of sentences
ensureed that we did not miss any important passage that can be fit to the codes in the analytical
framework.
The reviews are written in colloquial English language, in which patients mostly did not
follow proper grammatical and punctuation rules. Duplicate punctuation, applying wrong
punctuation as a sign of sentence completion, phrase construction irregularities, and
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abbreviations are common in the review posts. The reviews may also include personal
information, such as phone numbers, emails, or URLs. Therefore, before applying the framework
to the data, we pre-processed data to remove the noisy patterns and personal information from
the data set.
3.4.1 Data Pre-processing
Processing of the data was composed of text-cleansing and sentence boundary detection.
In the first step, we formulated regular expression rules to remove: 1) the personal information
including emails, phone numbers, and URLs from the reviews, and 2) the noisy patterns in the
reviews’ structure. Table 3.7 shows some nois patterns in the reviews and the regular expression
codes for handling those issues. We did not remove emoticons from sentences, because they may
represent perceived distress from a medication’s adverse effects or satisfaction with a
medication. For example, in the following sentence, the emoticon represents antidepressants
effectiveness. “I quit this drug and started on LAMICTAL which saved my life I now feel
content and complete. :-)”.
To split the reviews into sentences, after removing the noisy patterns, we used the opensource Natural Language Toolkit (NLTK) (Bird, Steven 2006). We also used NLTK for sentence
tokenization. Statistics on the review posts, the posts’ sentences, and tokens are presented in
result section.
3.4.2 Annotating sentences using analytical framework (sentence labeling)
3.4.2.1 Developing guidelines. To maintain consistency and uniformity of sentence
labeling across the whole sample of reviews, we developed guidelines using codes introduced in
the final analytical framework, their definitions, and examples from the drug reviews (Table
3.6).
68

Table 0-7 Examples of Regular Expression codes for Reducing Noise Patterns in Review Posts
Noisy patterns
Inserting space after full stop
punctuations and start of a new
sentence
Eliminating Emails
Replacing dot before parenthesis
with space
Removing repeated punctuations
from end of a sentence.
Replacing “.” with “,” when list of
side effects are separated from
each other with dot.
Replacing hyphen with dot when
hyphen indicating full stop of a
sentence
Replacing comma with dot, when
comma indicating full stop of a
sentence
Replacing dot after numbers when
numbers indicating order of items
in a list.

Inserting space between
parenthesis and the followed
words.

Replacing ( - , ) before overall
with dot

Respondents did not use any
punctuation to indicate sentence
stop.

Incomplete sentences

Example
I have suffered many side effects
from the prednisone used to treat
the symptoms.I am just now
starting to feel better.
com.uk@hotmail.comsevere

Regular expression code
comments = re.sub (r'([a-zAZ])([\.?!])([a-zA-Z])',r'\1\2 \3',
comments)

But about a year later I tried
others and could tolerate them
much better. (Such as Lexapro
and Prozac.). I hate it.
Think menopause is a huge factor
in this....i have only been on
generic zoloft for about a week
and a half
Night terrors. Vivid dreams.
Nightmares. auditory
hallucinations everyday!!!!!
never take this drug!!!

Comment =
re.sub(r'\.(\s*?\([^)]*\)\s*\.)', r'\1',
Comment)

Severe teeth clenching/TMJ
which caused excruciating
headaches - clenching came on
right after taking the dose and
would gradually wear off
Effexor People are still having
problems with this medication
even after being off of it for 8
months or more, Please don't
take this medication.
After two to three hours vomit 2.
Stiff muscles (Lack of oxygen?)
3. Spacey, out of sync with time
(as in Where did that tree come
from? What am I doing?) 4.
Weird, (as in How did that tree
get there?). 5. Weak muscles
"""Was deadly sick for 2 wks and
he kept me on it regardless,
upped the dosage three times
over a year because it wasn't
working(duh, it was my
thyroid!)That dr. is history, btw!
This time, I was very leary of
taking anything."""
and I was only on 2,5 months overall - DOES do what it is
supposed to do - you need to
weight whether it is worth the
side effects.
I was hoping it would eventually
go away so I continued to take it
and after the 6th day of the same
intense side effects I finally had
to just chunk them in the trash.
i recommend the cookies.. PS.. i
have not gained any weight.. and
if
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comment = re.sub (r'([,.;:!?-])\1+',
r'\1',comment)
comment = re.sub(r'\.
(\s*(?!(?:i|she|he|He|She|I|we|We
|They|they|it|It|You|you)\b)
\w+(?:\s+\w+)?\s*)(?=[^\w\s]|$)'
, r',\1', comment , flags=re.I)
Comment = re.sub (r'(\s+)(\-)(\s+)',
r'\1.\3 ', comment )

Comment = re.sub (r'(\s+)(\,)(\s+)',
r'\1.\3 ', comment )

comment = re.sub(r'(\d)\.(\s?[a-zAZ])',r'\1) \2' ,comment)

comment = re.sub(r'(\))(\w+)',r'\1 \2'
,comment)

comment= re.sub(r'[,](\s*[oO]verall?\s+)',r'. \1'
,comment )
No solution

No solution

3.4.2.2 Annotation environment. We used Microsoft Excel for developing the framework

of annotation. The framework consists of sentences of post reviews arranged in rows and the
defined items for sentence labeling arranged in columns. Each sentence was identified by the
associated drug name followed by the review post id and sentence index indicating the position
of the sentence in the review post. Annotators read the sentences and if a sentence fit into items,
they entered 1 in the corresponding cell. The defined items in the framework were not mutually
exclusive. In other words, a sentence may be coded as more than one individual item. For
example, the following sentence was coded as both “effectiveness” and “perceived distress from
ADR- low tolerability”:
“ It really helped me, however I suffered from side effects.”
Therefore, we coded it for both codes. Table 3-7 and Figure 3-2 presents
a snapshot of the coding environment.

Table 0-8 A Snapshot of the Coding (Annotation) Environment
Drug_ID
effexorXR
.217
effexorXR
.217
lexapro.40
lexapro.40

Sentence
_index
4
5
1
2

Sentences

ADR

WD

EF

INF

“I started on on a low dose and gradually
increased to 150 mg.”
“I feel so much better taking this drug.”

0

0

0

0

Other
s
1

0

0

1

0

0

“Lack of care for anything important in my
life.”
“Lack of feeling for anything, just lived day
by day.”

1

0

0

0

0

1

0

0

0

0
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3.4.2.2 Coding (annotation) Process. Four coders (annotators) participated in the
annotation process. All the coders possessed a minimum qualification of M.Sc. degree in healthrelated studies. Two coders were pharmacy students and two had backgrounds in public health
and health sciences.
We performed an interactive training for “sentence labeling” guidelines that involved
mutual discussion between annotators to address the vague definition of items and conflicts in
understanding each rule. We followed this step by refining the guidelines’ definitions, rules and
examples.

Figure 0-3 an expert of final analytical framework and comment analysis based on the framework
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The review sample contains 887 posts for the four drugs, Zoloft (210), Lexapro (218), Cymbalta
(230), and Effexor XR (229). According to the method by which the sample was created, for
each drug, the reviews were divided into five subsets according to the rating value provided by
the patients, which ranged from 1-5. Overall, we had 20 documents (spreadsheets)
that were divided into three non-overlapping subsets, subset 1 (7 documents), subset 2 (7
documents), subset 3 (6 documents). Three of the coders proceeded with each of these sets. The
fourth coders coded subset 4, which contained all documents. The review post sentences in each
document were annotated by two annotators. The sentences in each document were coded by
strictly applying the guideline's rules.
3.4.2.3 Calculating inter-annotator agreement. To test reliability of themes defined in
the final framework, we calculated inter-coder agreement between pairs of annotators annotating
each file. Assessment of inter-annotator Agreement (IAA) demonstrates consistency among
observational ratings provided by multiple coders. In addition, the inter-coder agreement
indicates to what extend codes are defined firmly and precisely to exclude all unrelated passages.
To calculate IAA, Kappa statistics are used to measure the observed level of agreement
between coders for a set of nominal ratings and corrects for agreement that would be expected by
chance, providing a standardized index of IRR that can be generalized across studies. The degree
of observed agreement is determined by cross-tabulating ratings for two coders, and the
agreement expected by chance is determined by the marginal frequencies of each coder’s ratings.
Kappa is computed based on the equation where P(a) denotes the observed percentage of
agreement, and P(e) denotes the probability of expected agreement due to chance” (Hallgren,
2012):
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𝑘=

𝑃 𝑎 − 𝑃(𝑒)
1 − 𝑃(𝑒)

Possible values for the Kappa coefficient ranges from -1 to 1, where 1 indicates complete
agreement, 0 indicates completely random agreement, and -1 indicates complete disagreement.
Moreover, according to the instruction for interpreting Kappa data provided by Landis and Koch
(1977), 0.0 to 0.2 indicates “slight agreement”, 0.21 to 0.40 indicates “fair agreement”, 0.41 to
0.60 indicates “moderate agreement”, 0.61 to 0.80 indicates “substantial agreement”, and 0.81 to
1.0 indicates “almost perfect” or “perfect agreement”.
Hayes and Krippendorff (2007) introduced more conservative instruction for
interpretation of Kappa values. They specified that Kappa less than 0.67 agreement should be
discounted from analysis, variables with Kappa between 0.67 and 0.80 should be tentatively used
in analysis, and variables with Kappa above 0.80 can be used for definite conclusion. Despite
this instruction, in practice, variables with Kappa less than 0.67 are often retained in studies.
Accepting or discounting a variable with Kappa less than 0.67 for testing hypothesis in
qualitatively analysis strongly depends on a study’s research question and methodology.
To report IAA agreement calculated using Kappa, the following items should be
considered:
1) The metric in which a variable was coded (e.g., nominal vs. ordinal, interval, or ratio);
2) design of the study (e.g., whether all subjects vs. a subset of subjects are rated by
coders);
3) Intended purpose of the IAA estimate (e.g., to estimate the reliability of individual
coders’ ratings vs. the reliability of the mean ratings from multiple coders);
4) Reporting both the statistic and its computational variant (Hallgren, 2012).
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For the purpose of our study, we calculated Kappa statistics based on the following
criteria:
1) The metrics in which all variables (codes) were coded were nominal variables.
2) Each file was double coded.
3) The intended purpose of the IAA estimate is to calculate reliability of individual coders.
4) To calculate the IAA agreement, we used cohen_kappa_score from module of
sklearn.metrics in python. This function uses the statistical method introduced by Artstein
and Poesio (2008).
Because the defined codes are not mutually exclusive (a passage may be coded into more
than one individual theme), we coded them such that each individual code represented a separate
binary variable (we dichotomized each variable (themes) into a binary variable, i.e., coded as ‘1’
for present and ‘0’ for absent). Using this procedure, we reduced the comparison into a 2*2 table
based on whether each of the two coders reported the code as present or absent for each variable.
Table 3-9 shows the IAA for each code in the final framework, and examples
of disagreement. For ADRs and withdrawal symptoms (WD), we decided to
exclude all sentences with general mentions of these two items, such as "side-effects" in the
sentence: “I really suffered from side-effects." For both drug effectiveness and ineffectiveness,
we decided to include only sentences that explicitly referred to a drug's success or failure in
improving or deteriorating a patient's symptoms and general health. For example, the sentences:
“I feel much worse after using the drug” should be labeled as “Ineffectiveness”, and the sentence
“I had a really bad headache and dizziness, after my doc increased the dosage”, should be labeled
only as “ADRs”, not both ADRs and Ineffectiveness. However, some annotators labeled
sentences with mentions of ADRs as ineffectiveness, leading to a lower IAA for this item
compared to other items.
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Table 0-9 Computed IAA for each Themes in the Sentence Classification Component with Examples of
Disagreement
Items
ADR

IAA
0.81

WD

0.69

EF

0.82

INF

0.65

DI

0.91

ADR-PDhigh

0.84

ADR-PDlow

0.89

“Night sweats, trouble sleeping, but all of these gone away
after a few weeks.”

WD-PDhigh

0.85

“When i miss a day i feel very spaced out, thick, groggy,
sad.”

WD-PDlow

0.83

PPI-P

0.50

0.59

~KN

0.64

DXD-Dec

0.61

DXD-S

0.75

DXD-W

0.65

DXD-F

0.88

ATT-N
SUG-P
SUG-N
Dosage/d
uration
~SS
~FS
Other
drugs
Other
patients

Annotator 1
ADR

Annotator 2
WD

WD

Others

“Helped a great deal then put on the generic and had a
totally negative reaction.”
“At the end of 6 weeks I still felt no difference but my best
friend said they noticed a difference.”
“I really didn’t think that I was depressed, but I think since
taking the lexapro, my mod has lifted.”
“I'd rather be normal sized and anxious than overweight.”

EF

EF & INF

EF

INF

EF

EF & DI

ADR, SS,
ADR-PDhigh
ADR,
ADR-PDlow
WD

ADR, SS

“I only experience a little nausea/dizziness if I miss a dose.”

ADR
WD

WD-PDhigh
WD

WD

WD-PD-low

PPI-N

ATT-P

Example of disagreement
“I stopped taking the lexapro, the anxiety has lightened a
little bit, but the crying hasn’t.”
“However, I have tried to taper and quit several times and
CAN’T.”

“My doctor switched my dosage time to morning and I noticed
a world of change.”
“I called my dr. office they told me to drop it down to 2.5 until
they could see me.”
“Every time I mentioned this to the doctors their only advice
was to up the dose.”
“This drug should not be given to anyone without the doctor
notifying family/friends.”
“I am going to stop the medication, because of severe sideeffects”
“The withdrawal was horrible, I had to stop working for two
weeks.”
“I am in the process of discontinuation, be careful about
withdrawal.”
“ I run out of medication for few days, I felt horrible.”
Not double coded– Removed from the final analytical
framework
Not double coded – Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
Not double coded– Removed from the final analytical
framework
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PPI-P

Others
Others

PPI-N

PPI-A

KN

Others

DXD-Dec

DXD-S

DXD-S

Others

DXD-W

DXD-S

DXD-S

DXD-F

PPI-P

Most of drug review posts do not include any explicit indicators that could be used to
measure patients’ satisfaction with providers. For example, this sentence: “I talked to my doctor
and he immediately suggested I come off of it”, does not clearly imply the patient’s attitude
towards his or her provider. A patient may conclude that his or her provider did not have
sufficient knowledge about treatment or may conclude that the provider considered his or her
concern. This vagueness leaded to high rate of observational error and and low rate of IAA.
For the variable, “complaining of lack of knowledge”, we decided to include patients
reports for searching on the WEB for ADRs or WDs or advise to readers to gain information
about ADRs or WDs as the sign of lack of knowledge. However, some of the coders did not take
into account this indicator as sign of patients’ lack of knowledge, causing a lower IAA for this
variable.
3.4.2.4 Resolving disagreement. Annotators' observational errors occurred due to
differences in annotators' interpretations of the guidelines and the differences in their
interpretations of the review posts. A program was written to scan for instances of disagreement.
Instances of disagreement were then reviewed and discussed by the same annotators who
annotated the respective document earlier. For a specific item, annotation was added or removed
if it was marked by any of the annotators, given that they both agreed on the decision.
Otherwise, the sentences were labeled as others. The harmonization was performed over the
complete corpus in the presence of annotators.
Phase 5
3.5 Entity Identification
The focus of the first phase of the data analysis was on examining the qualitative aspects
of knowledge (e.g., features, properties) using analytical frameworks. While the focus of this
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phase, entity identification, is to extract medical entities including adverse drug reactions
(ADRs), withdrawal symptoms (WDs), and drug indicators (DIs), and qualifiers representing the
severity (QS) and persistency (QP) of ADRs, WDs, and DIs.
Identification of ADRs and WDs from consumer health posts can directly provide a list
of various types and frequency of ADRs and WDs associated with psychiatric medications. The
ADRs and WDs may not be detected by clinical trials or post-marketing surveillance systems
established by regulatory agencies, such as the Adverse Event Reporting System (AERS) of
Food and Drug Administration (FDA). In addition, it also enables the generation and testing of
hypotheses related to the association between different type of ADRs and WDs and
discontinuation, adherence, and attitude.
In the sentence-labeling phase, we labeled sentences for presence of ADRs, WD, and
DIs. In this phase, we were able to select sentences with mentions of these entities and then
proceed with the process of identification.
3.5.1 Guidelines for entity identification
Guidelines of entity identification includes the entities' definitions and rules for
proper identification of the entities. Table 3-10 includes definitions of entities and rules for
entities identification. The rules are related to patients' certainty in linking ADRs or WDs with
drugs, identifying patients’ subjective complaints and functional problems, as well as excluding
unnecessary context such as simile and metaphors from the span of ADRs, WDs, and DIs.
Identifying patients’ subjective complaints is important because they may reflect subtle
physiological, psychological, or cognitive ADRs associated with drugs. For example, “feel
like I could not stop moving” reflects patient restlessness, which is a sign of akathisia (ADR of
psychiatry medications). As another example, “body move in coordination with other people's
77

bodies” (Echopraxia) indicates an extrapyramidal symptom. Any of these symptoms have
pharmacologically related affective components that may lead to a patient’s negative perception
of drugs and eventually drug non-adherence.
Identifying functional problems in drug review posts is also significant, not only for
understanding how ADRs influence patients' normal daily activities and interpersonal
relationships, but also for estimating the indirect cost associated with the ADRs. Overlooking
functional ADRs when patients suffered from them has significant negative affects on expected
clinical outcomes from medications. Moreover, collecting this information also
enhances clinicians' abilities to predict the impact of ADRs on patients’ functionality, such as
limitations on daily activities and social participation and restriction on work performance.
Hence, they will be able to design more effective interventions targeting patients' attitude and
adherence towards medications. The significance of representing signs or symptoms as
functional problems is explained in detail in the International Classification of Functioning,
Disability and Health (ICF) documents (World Health Organization 2010) (Giannangelo et al.,
2005) . The identified ADRs, WDs, and DIs were categorized as physiological (Phys),
Psychological (Psycho), Cognitive (Cogn), and functional problem (FP).
3.5.2 Entity identification process
Four annotators participated in the process of identification and extraction of the three
entities explained in table 3-10. We first selected the sentences with labels of ADRs, WD, and
DIs and exported them to new excel spreadsheet documents. In the second step, the documents
were divided into three sets and each set was reviewed by an annotator for entity identification.
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Table 0-10 Entities' Definitions and Identification Rules with Examples
Entit
y
ADR

Definitions

Example

Rules for identification

Example

Any sign or
symptom that
the patient
explicitly
associated it
with drug
consumption,
except the
phase of
dosage
reduction and
discontinuation
.

My doctor
increased my
dose and I felt
severe dizziness
(ADR).

WD

Any sign or
symptom that
patient
explicitly
associated it
with the phase
of dosage
reduction and
discontinuation
of a drug.

“Trying to come
of has gotta be
worse than
heroin,
Uncontrollable
rage,(WD) and
lots of
emotional
attachment with
partner(WD).”

1. It caused hair loss
and stomach bloating
(ADR), however I am
not sure that hair loss
(not ADR).
2. It certainly erased
the anxiety, but I
hardly feel human
anymore. (ADR)
3. I would just stay
around and do nothing
all day (ADR)
4. “Very hard to take
a deep breath (ADR)
like someone is
squeezing my lungs.
(Simile –non
necessary)
5. The anxiety (ADR)
was debilitating. I also
had severe headache
(ADR), but the anxiety
(ADR) was worse.
6. Anxiety is now
though the roof
(qualifier-severity)
6.2. Constant
(qualifier-persistency)
bad (qualifier-severity)
headaches

DI

Any sign or
symptom that
patient
mentioned as
the reasons for
drug
consumption/p
rescription.

“My depression
( DI ) disappeared
after drug
usage.”

1. Certainty: If a patient is not
confident about the association
between ADR/WD and drug, the
ADR/WD is not extracted.
2. Subjective complaints: If
ADR or WD was expressed as
subjective complaints, it should
be extracted with the entire
necessary context.
3. Functional problems: if
patient mentioned his complaint
as a functional problem, such as
problem with daily functioning
and social activities, it should be
extracted and labeled as
ADR/WD.
4. Excluding simile and
metaphor: If a patient used a
simile or metaphor to provide
information about his/her
feelings towards ADR/WD/DI
that simile or metaphor should
not be extracted.
5. Duplicates: Duplicate
ADR/WD/DI in a sentence
should be independently
extracted, that is, all the
occurrences of the entities are
identified.
6. Qualifiers: If ADR/WD/DI is
associated with qualifiers
presenting severity or
persistency of that entity, the
qualifier needs to be identified.
1. Treated symptoms: a patient
may also mention a
sign/symptom that was relieved
by drug consumption. That sign
or symptom is also a drug
indicator.
If a patient’s sign/symptom
became worse because of drug
consumption, the sign/symptom
should be labeled as both DI and
ADR of the drug.

This drug reduced my
sense of guilt (DI).

For the purpose of calculating inter-annotator agreement for entity identification, the
entire dataset was reviewed by the fourth annotator. Entity identification and extraction was
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conducted based on the rules specified in the guidelines. We did not extract general mentions of
entities, such as “side-effects” and “withdrawal” in the sentences. For example, in these
sentences, “I really suffered from side-effects," and "withdrawal seems impossible", side effects
and withdrawal were not extracted.
Prepositions and possessive adjectives were excluded to improve consistency in spans
of identified entities. For example, in “my anxiety became worse,” my was not extracted as part
of anxiety. In the last step, the disagreement between annotators for the identified entities were
resolved by Dr. Fontelo (a PhD committee member).
3.5.2.1 Calculating Inter-Annotator agreement. To calculate inter-annotator agreement,
we used pair-wise agreement between the annotators using the following formula (MetkeJimenez & Karimi, 2015):
𝐴𝑔𝑟𝑒𝑒𝑚𝑒𝑛𝑡 𝐴! , 𝐴! =

𝑚𝑎𝑐𝑡ℎ (𝐴!, 𝐴! , 𝛼, 𝛽)
𝑚𝑎𝑥 (𝑛!! , 𝑛!! )

Where Ai represents the set of data annotated by annotator i; Aj represents the set of data
annotated by annotator j; nA is the size of identified entities in Ai and nA is the size of identified
i

j

entities in Aj; Max (nA , nA ) is the maximum number of identified entities; 𝛼 parameter presents
i

j

span strictness of identified entities and 𝛽 parameter represents tag strictness of identified
entities. Since entities were identified from the sentences with predefined labels (tags), by
default, they have the label of the sentences. Therefore, we excluded parameter 𝛽 from the
calculation. For parameter 𝛼, we set the span on strictness. Therefore, the identified entities
must match exactly. For example, for identifying ADRs from this sentence: “the headache was
terrible”, if annotator A identified “headache” as a side-effect, and annotator B identified
“headache was terrible” as a side-effect, then the matching between annotators A and B is “0”.
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The computed pairwise agreement for strict match are 0.86 for SFX , 0.81 for WD and 0.91 for
SS, with the average 0.86 for the entire corpus. The reason for applying pairwise agreement (PA)
for computing IAA rather than conventional measures, such Kappa, is that PA is calculated at the
level of entities. Since the identification task requires identifying the entities and determining
their correct boundaries, the chance agreement is effectively zero.
Phase 6
3.6 Terminology Association (Entities Normalization)
While sentence classification and entity identification in drug review posts have
significant implications for text mining and machine learning systems focusing on information
retrieval, mapping patient expressions of these entities to the language of health professionals
fills the gap between a layperson expressions and professional expressions of medical entities.
This translation may benefit the generation and testing of medical hypotheses by providing
unambiguous and standard information for statistical data collection and analysis.
Terminology mapping typically involves identifying terms used by healthcare consumers
and mapping them to their equivalent concepts available in medical standard vocabularies. This
process is also referred to as normalization in other research (Karimi et al., 2015). An example of
such normalization is CADEC corpus, in which the identified entities from drug review posts
were mapped to SNOMED-CT, MEDRA, and ATM (Karimi et al., 2015).
To normalize the entities in our corpus, we mapped the identified entities including
ADRs, WDs, and DIs to their corresponding concepts in both the Unified Medical Language
System Metathesaurus (UMLS Meta) and the Systematized Nomenclature of Medicine–Clinical
Terms (SNOMED-CT).
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UMLS Meta is a compendium of many standard medical vocabularies that provides a
mapping structure among vocabularies, allowing one to translate among various terminology
systems. UMLS Meta is organized by concepts. Each concept is assigned one or more semantic
types (categories) and a Concept Unique Identifier (CUI). Semantic type covers a broad category
of medical concepts, such as sign/symptoms, mental or behavioral dysfunction, and intellectual
products. Different lexical representations of the same concept can be identified by CUIs. UMLS
Meta has been used for identification and retrieval of medical entities from clinical and
biomedical literature and clinical notes in Electronic Health Record (EHR) Systems . Automatic
extraction systems built on UMLS Meta, such as MetaMap, have demonstrated high recall and
precision for identifying medical entities in biomedical literature and clinical notes (Fung, Jao, &
Demner-Fushman, 2013). However, as Nikfarjam et al. (2015) showed, MetaMap performance
in entities identification (ADRs and drug indications) from consumer health posts showed 47%
precision and 39% recall on corpuses from the “Daily Strength” forum and Twitter. Mapping
ADRs and drug indications to UMLS Meta, in addition to the normalization benefit, reveals
consumer health vocabulary that have not been covered by medical terminologies.
SNOMED CT is considered to be the most comprehensive, multilingual clinical
terminology in the world. The primary purpose of SNOMED CT is to encode the terms available
in health information to support effective clinical recording for improving patient care.
Accordingly, it is intended to provide a core general terminology for EHR systems. Mapping
layperson expressions of medical entities to SNOMED-CT supports seamless information
sharing between Personal Health Record (PHR) systems and EHR systems. In addition, Mapping
to SNOMED-CT as the most comprehensive standard terminology supports providing an
unambiguous data collection for statistical analysis. Moreover, mapping data to both UMLS
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Meta and SNOMED-CT reveals the deficiency of SNOMED-CT in covering patients’
expressions of medical terms compared with other terminologies in UMLS Meta.
3.6.1 Guidelines for Terminology Association
The process of mapping laypersons’ expressions of medical entities to professional
expressions is based on an assumption that consumers’ and professionals’ terms express the
same underlying concepts. For example, the consumer term “feeling sick to my stomach”
expresses the same concept as the professional term as “nausea”. By considering this
assumption, most research on normalizing consumer health vocabularies has focused on the
terms rather than the underlying concepts that the terms carry (Keselman et al., 2008). However,
proper mapping involves both syntactic and semantic mapping between terms. For semantic
mapping, we need to understand the conceptual models in both professional and consumer terms,
which can be mostly identified in a term’s definition and a term’s context. Accordingly, for this
study, we applied the process of entity expression mapping to both UMLS Meta and SNOMEDCT by creating a guideline taking into account their potentially different conceptual models.
The guidelines have been constructed based on the reviews of clinical trial studies
targeting ADRs of psychiatric mediations and qualitative studies investigating the themes of
patients’ experiences with the drugs. We reviewed literature concerning three types of ADRs
associated with psychiatric medications, including physiological, psychological, and cognitive.
Each set of these studies contains descriptions and clinical features associated with a specific
ADR or a group of ADRs that were mostly developed based on clinical trial reports. Studies that
focus directly on patients’ experience reports mostly attempted to classify the experiences
by broad themes. The identified themes are usually equivalent to medical concepts used in
professional settings. Here, we provide examples for each set of studies associated with a type of
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ADR and how they can be used for translating patients’ reported experiences to professional
terms.
1) Example of Physiological ADRs: Psychiatric medication can cause Akathisia (Salem,
Nagpal, Pigott, & Lucio Teixeira, 2017), which is described with the following clinical
features: feeling of inner restlessness, compelling need to be in constant motion, as well as
motor restlessness, such as “inability to sit” or “feeling the need to pace”. These underlying
concepts of Akathisia, patients’ expressions of ADRs indicating inner restlessness, such as
“feel like I was inside screaming” and motor restless, such as “ I am not able to sit” could be
translated to Akathisia. Another example of ADRs is “brain shivers”. Brain shivers are a
sensation of “sudden shake, vibration, tremor, jolt” in addition to electric shock that
patients feel in the brain and that mostly occur due to missing dosages or discontinuing the
drugs abruptly. Other terms that have been used to describe this symptom are “electric brain
thingies,” “brain zaps,” and “brain flips” (Aronson, Jeff 2005). Hence, any mentions of
these terms with the same underlying concept, such as “feeling electrical shock in the brain”
in the review posts can be translated to “brain shivers”.
2) Example of Psychological ADRs: Psychiatric medications are associated with a general
syndrome of indifference as a behavioral syndrome and as an emotional syndrome (Sansone
& Sansone, 2010). Behavioral indifference, a clinical feature of “apathy”, is manifested by
patients’ lack of desire to engage in activities, lack of desire to make any
changes, not caring about anything, or similar symptoms. Therefore, any terms reflecting
behavioral indifference can be translated to “apathy”. For example, “ just don't care”, and
“just lived day by day” are equivalent to apathy. The emotional aspect of indifference is
characterized by a restricted range in expressing emotions and feelings, a sense of blunting
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the emotions, or of feeling numb. Accordingly, clinical features of emotional indifference
could be described by two main concepts, “blunted affect” and “lack of capacity to feel
emotions”. Therefore, any patients’ expression reflecting the restricting range of emotion
could have the same underlying concepts. For example, “very slow to excite”, “ dull mood”,
“want to express myself and cry but cannot” can be translated to blunted affect.
3) Example of Cognitive ADRs: Executive dysfunction as a cognitive ADR of psychiatric
medication is associated with the inability to initiate and follow processes of completing a
task, such as problems with initiating a task, problems with organizing a task, or problems
with switching between tasks. So, any patient’s complaints reflecting the underlying
concepts of executive dysfunction, such as “cannot follow through on simple tasks” can be
translated to “executive dysfunction”.
3.6.2 Creating a dictionary
To reduce the time to accomplish the mapping the identified ADRs (SFX and WD) and
drug indications to UMLS Meta and SNOMED-CT, we first developed a dictionary using 2,100
mentions of ADRs extracted from 240 review posts. First, we looked for syntax mapping of the
identified entities with UMLS Meta concepts using the UMLS API. If a syntax match was not
available, we translated the colloquial expressions of ADRs to proper professional medical terms
using the guidelines, and then we selected a proper UMLS Meta concept for the term. To ensure
the selected UMLS Meta concept reflects the original term, we checked the parent terms of each
concept to ensure that the UMLS Meta concept and the SNOMED-CT concept associated with
it do not carry additional meaning. The additional meaning would be inherited from the parent
terms that are not related to the patients' experience with the medication. This dictionary was
reviewed for accuracy and was set as the reference code for mapping the identified entities to
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both UMLS Meta and SNOMED-CT. We updated the guidelines and the dictionary periodically
to include new expressions of ADRs and indicators.
3.6.3 Procedure of mapping
The mapping procedure and selecting the proper UMLS Meta and SNOMED-CT
concepts was conducted based on the following procedure. Annotators used the UMLS
Terminology Services, UTS browser (2017) for the finding proper UMLS and SNOMDCT concepts.
1) Search for syntax matching by setting “search type” on “normalized word” and sources on
“all sources”.
a) In the case of a unique concept result, evaluate the concept using the requirements for
a proper concept (Table 3-11).
b) In the case of multiple concepts results, select the proper concept using the
requirements for a proper concept (table 3-11).
c) In the case of no concept returned, go to step 2 if the original term is associated with a
qualifier. Otherwise, go to step 3.
2) Search for a partial match by removing qualifiers associated with the original term.
a) Follow sub-steps “a” to “c” specified in step 1.
3) Search for a synonym using the guideline of the terminology mapping
a) Follow sub-steps “a” to “c” specified in step 1.
Figure 3-3 shows the detail of the procedure for identifying proper UMLS Meta and
SNOMED concepts for the identified entities. Table 3-11 presents the requirement for selecting
proper UMLS Meta and SNOMED-CT concepts. In the case of availability of multiple UMLS
Meta concepts for the original term, the proper concept needs to include the expressions of the
most recent versions of SNOMED-CT. If multiple UMLS Meta candidates met the mentioned
requirements, the proper UMLS Meta concept has a SNOMED-CT expression that is closest to
the original term. Using the flowchart (Appendix A) and requirements for finding proper
concepts, we mapped identified entities to both UMLS and SNOMED-CT concepts.
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Table 0-11 Requirements for Selecting Proper UMLS and SNOMED CT Concepts
Requirement
s
(1)
Definition

(2) Semantic
type

(3)
Hierarchical
structure
(ancestors
and children)

Description

Example

- Definition of a proper concept should cover
patient’s specific physiological, behavioral,
emotional, cognitive, or functional problem.

For patient complaint “takes a long time to
get to sleep”, UMLS concept: “initial
Insomnia”. “Sleeplessness” is not correct,
because it includes all phases of insomnia.

- If the patient did not specify the severity or
type of a reported adverse effect, we used the
most general concept (code) that represents the
patient ‘s reported problem.
The semantic type of proper concept includes
“finding”, “sign or symptom” or “mental or
behavioral dysfunction”. However, in some
cases, other semantic types, such as
“individual behavior” for concept “aggressive
behavior is a proper map.
The SNOMED-CT concept should not convey
additional meaning inherited from ancestors
(parents) that are not related to patient’s
complaint.

(4) Including
SNOMEDCT concept

In a case of existing multiple UMLS
candidates, the preferred concept is a concept
that includes the most recent SNOMED-CT
concept.

(5) Syntax
match with
SNOMEDCT concept

In the case of existing multiple UMLS
candidates meeting requirement (1), (2), and
(3), the preferred match has SNOMEDConcept that syntactically match with the
original term.

For the patient complaint “inability to
eat”, Aphagia [C0221470] is not a proper
map, because the concept is linked to
ancestors of swallowing finding in
SNOMED-CT. While the patient with
depression does not have any problem
swallowing, they have a problem with loss
of appetite. So [C1971624] “Loss of
appetite” is a proper map.
For the patient complaint “memory loss”,
“Amnesia [C0002622]” compared with
“Memory loss [C0751295]” is the proper
concept, because memory loss includes the
obsolete version of SNOMED-CT concept.
For example, for the patient complaint
"restlessness", the UMLS concept
candidates are “Agitation [C0085631]”,
Restlessness [C3887611], Psychomotor
Agitation [C3887612], and Akathisia
[C0392156]. The proper match would be
“Restlessness [C3887611]” due to
including the SNOMED-Concept preferred
term (PT) with the same syntactic match.

There were some cases in which a UMLS Meta concept that is the best match for an
original term lacks SNOMED-CT concept. In this case, we searched for another UMLS Meta
synonym concept that is expressed in SNOMED-CT. For example, for the original term “Zombie
like”, the closest UMLS Meta concept is “Felt like a zombie [C0857486]”, which has no
SNOMED-CT expression. In that case, we used UMLS concept “Emotionally detached
[C0233754]” that include SNOMED expression.
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Figure 0-4 Flowchart of Finding Proper Concept for Layperson's Expression of Medical Entities
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Table 3-12 provides example of mapping layperson expressions to both UMLS and
SNOMED-CT.
Table 0-12 Examples of Mapping Entities to both UMLS and SNOMED-CT Concepts
drug_id

Sen original Term UMLS (1)
SNOMED-CT (1)
_Id
cymbalta. 1
Felt sick
C0857027 / Feeling No code
124
Sick /Sign or
Symptom

lexapro.1 3
2

"zombie"
like

C0857486/ Felt like no code
a zombie/ Finding

cymbalta. 2
12

loose my
friends

C0524322 / Personal
relationship
breakdown / Humancaused Phenomenon
or Process
C0013144/
Drowsiness/ Finding

cymbalta. 1
131
Effexor.7 1
8

effexor.9 2
7

effexor.1 7
1

Personal relationship
breakdown (finding)
[A3626907/SNOME
DCT_US/FN/105414
008]
Excessive
Drowsy (finding)
sleepiness
[A3406202/
SNOMEDCT_US/
FN/271782001]
minor muscle C0037763 / Spasm/ Spasm (finding)
spasms
Sign or Symptom
[A3712892/
SNOMEDCT_US/
FN/45352006]
Sweating like C0700590 /
Excessive sweating
crazy all the Increased sweating / (finding)
time
Sign or Symptom
[A3440966/
SNOMEDCT_US/
FN/52613005]
Brain zap
no concept
no concept

UMLS (2)

SNOMED-CT Qualifier
(2)
C0231218/ M Undifferentiate
alaise / Sign d illness:
or Symptom Vague ill
health
(finding)
[A3771172/SN
OMEDCT_US/
FN/248282002
]
C0233484 /
Emotionally
Emotionally detached
detached /
(finding)
Finding
[A3413164/SN
OMEDCT_US/
FN/24936000]

Excessive
(QS)
Minor (QS)

All the time
(QP)

Phase 7
3.7 Usability of the Dataset (Corpus)
Development of structured data from drug reviews in consumer health posts has several
implications in the area of natural language processing, such as improving performance of text
mining algorithms, and generating and testing medical hypotheses. In the next phase we show
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how the dataset can be used for testing hypotheses concerning patients attitudes toward
antidepressants.
3.7.1 Identifying the underlying factors affecting patient attitude towards drugs
The following hypotheses were formulated based on the availability of information in the
dataset generated through phase 3 (developing the analytical framework) and phase 4 (applying
the analytical framework) and literature review focused on measuring association between
pharmacological treatment factors, healthcare system factors, social-cognitive and psychological
factors, patient-related factors, and depression factors with patients attitudes towards
antidepressants. The list of hypotheses is as follows:
-

Testing association between personal variables and attitude
1.

Age:
a) H0: There is no association between age and attitude.

2.

Gender:
b) H0: There is not association between gender and attitude
Testing association between clinical variables and attitude:

1.

Duration:
c) H0: There is no association between duration and attitude

2.

Drug Effectiveness:
a) H0: There is no association between drug effective-ness and attitude.

3.

Drug ADR:
a) H0: There is no association between drug adverse reaction and attitude.

4.

ADRs-PD:
a) H0: There is no association between perceived distress received from
ADRs (ADRs-PD) and attitude.

5.

LK:
a) H0: There is no association between Lack of knowledge and attitude.
If this null hypothesis was rejected, the following null hypothesis will be tested:

6.

WD-EXP:
a) H0: There is no association between experience of withdrawal (WD-EXP) and
attitude. Experience of WD includes any experiences of intentional (Weaning
off or stopping) or unintentional (missing dosage) withdrawal of a drug.
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7.

PPI:
a) H0: There is no association between patient physician interaction (PPI) and
attitude.
In addition to the hypotheses, the relationship between variables modeled to specify the

significance of each variable in forming a patient’s attitude towards antidepressants. We also
hypothesized that:
1.

ADR-PD and drug effectiveness are the most significant factors affecting patients
attitudes toward antidepressants.
3.7.1.1 Preparing the dataset for testing hypotheses
To increase the accuracy of data analysis and enhance the level of inter-annotator

agreement (IAA) between coders, the unit of analysis was set at the sentence level rather than the
whole review. Therefore, for an individual review, there may be multiple occurrence of the same
variable (code). For testing hypotheses, we reduced the multiple occurrences to a single one
indicating presence or absence of a variable in the drug review.
A single drug review may be coded for contradictory codes, such as both “Effectiveness”
and “Ineffectiveness”. That is, a patient may find medications effective for a certain point of
time, such as acute phase of treatment, but in the maintenance phase, they may not be satisfied
with the drug. Therefore, for reviews coded as both “effectiveness” and “ineffectiveness”, we
recoded both effectiveness and ineffectiveness.
In addition, a review may be coded for both ADR-PD as high and ADR-PD as low. That
is, in one part of his or her review, a patient may report an ADR was severe and has debilitating
effects on quality of life, while another ADR may be mild and does not have such an effect. For
such reviews, I only include ADR-PD-high, because overall, ADR-PD for patient is high.
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Table 0-13 Lists of the Variables, Possible Values, and Limitations Associated with each of them for
Measuring Patient Attitude toward Antidepressants
Variables
ADR

Possible values
Presence
Absence
Unknown: no explicit report on presence or
absence of ADR.

ADR-PD

-

High
Low
Moderate: when patient did not use any
indicators showing the perceived distress
was high or low, then it is moderate.

WD

-

Presence
Absence
Unknown, if patient reported they
experience intentional or unintentional
WDs, but no explicit report on presence
or absence of ADR.

WD-PD

-

EF

-

High
Low
Moderate: patient did not use any indicators
showing the perceived distress was high or
low, then it is moderate.
EF: drug was effective,
INF: drug was ineffective
EF-INF: patient reported both effectives
and ineffectiveness of the drug during the
process of treatment.
Unknown: no explicit report on EF or INF
of the drug.

-

LK

-

WD-EXP

DXD-Dec: existence of any indicators
showing the patient’s decision for
discontinuation, such as “I am going to stop”
DXD-WD: existence of any indicators
showing patient experienced process of
discontinuation, such as “weaning off” or
“tapering off”.
DXD-S: existence of any indicators showing
patient already stopped the medication, such
as “stopped”.
DXD-F: existence of any indicators showing
patient experienced withdrawal
unintentionally, such as “missing a dose”
Patient perceived communication-positive
Patient perceived communication-negative
Unknown: no explicit report on patients’
satisfaction with healthcare providers.

PPI

Presence
Absence

Limitations for measuring attitude
1) The patient might fail to distinguish between ADRs and
WDs and report all sign/symptoms associated with
drugs as ADRs
2) For some reviews, there is no explicit report on
presence or absence of ADR.
1) AD-PD involves only three level of distress. These
categories do not include nuance difference for ADRPD for patients.
2) The definition for ADR-PD may be incomplete and do
not include all the cases for ADR-PD-high. For
example, persistency of ADRs indicates ADR-PD for
some patients, while in definition we did not include it
as sign of ADR-PD.
1) Patient may fail to distinguish withdrawal from ADRs
and therefore did not report all WDs.
2) Patients who experienced the WD, there is no explicit
report on the presence or absence of WD.

WD-PD is subject to the same limitations explained for
ADR-PD

1) Patients may fail to realized drug effectiveness because
of the high perceived distress received from ADRs.
2) A patient may fail to report drug effectiveness, because
there is no request for reporting it in the healthcare
forum.
3) The definition for drug effectiveness may not be
complete. For example, a patient might attempt to show
drug ineffectiveness through reporting ADR or ADRPD.
1) A Patient might fail to report their lack of knowledge or
conducted search to gaining information about
ADRs/WDs.
2) Definition for complaining about lack of knowledge
may be incomplete.
Patient might fail to report intentional or unintentional
withdrawal from drug.

1) Most of the patient did not declare any information
about their perspective with providers.
2) Patient mentions of communication did not clearly
convey their attitude toward providing, causing high
disagreement between annotators (coders) for this
variable.
3) This variable was defined as binary variable, which may
92 not reflect the slight differences between patient attitude
toward medication.

Table 3-13 lists the variables, possible values, and limitations associated with each
variable for measuring patient’s attitude toward antidepressants.
3.7.1.2 Strategy for handling missing values
To handle the missing values, we adopted different imputation methods regarding the
nature of the missing values for each variable. There are three assumptions for handling missing
data:
a) Missing completely at random (MCAR): “When observations of a variable are missing
completely at random, the missing observations are a random subset of all observations; the
missing and observed values will have similar distributions”(Bhaskaran & Smeeth, 2014). In
other words, the absence of data is unrelated to other variables in the model.
b) Missing at random (MAR): “Missing at random means there might be systematic
differences between the missing and observed values, but these can be entirely explained by
other observed variables” (Bhaskaran & Smeeth, 2014) . In other words, MAR means that the
variable having missing data can be fully accounted for variables on which we have full
information.
c) Missing not at random (MNAR): MNAR is data that absence is neither MAR nor
MCAR. For example, if a patient fails to report their review for drug because of difficulty of
filling the form or fear of breaching confidentiality, the missing values are MNAR.
The following strategies have been used for handling the missing values from the dataset.
1)
2)

•

Elimination of drug reviews
Eliminating reviews with no text; accordingly five reviews were eliminated
Eliminating reviews that did not include any information for the variables for
testing the hypotheses; accordingly seven variables were removed from the
sample.
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3)

We removed the variable “PPI” from the analysis, because of the low IAA
calculated using Kappa method and high number of missing values. The IAA
for PPI-Positive (0.5) and PPI-Negative (0.59), with overall 0.55 for PPI.

•
1)

Imputation of missing values
Age: The assumption for missing values for imputing missing values for this
variable is MCAR. It was assumed that the missing value has the same
distribution of the observed values. Therefore, we used mean of data to fill in
the missing values.

2)

Gender: The assumption for imputing missing values for this variable is
MCAR. Because this data is categorical, we used the mode of the variable to
impute the missing values.

3)

Duration of usage: The assumption for imputing missing values for this
variable is MACAR. Because the data is very skewed, the median of data for
this variable was used for data imputation, rather than the mean of the data.

4)

ADR: The assumption for imputing missing values for this variable is MNAR.
If patient did not explicitly reported any ADRs, I assumed that ADR is
presence for the patient.

5)

ADR-PD: The assumption for imputing missing values for this variable is
MNAR. According to the definition, a perceived distress from ADR is high, if
ADR is associated with qualifiers indicating severity or debilitating effect on
patient’s daily life. On the other hand, the perceived distress is low, if ADR is
associated with qualifiers indicating mildness of the ADR. The detail definition
of these two variables is presented in Table 3-6. Accordingly, if the indicators
are not available, the ADR-PD was coded as “NA” (missing value), which may
imply that patients found the ADR neither severe, nor mild. Therefore, we
imputed the missing values as “moderate”.

6)

EF: The assumption for imputing missing values for this variable is MAR. For
imputing missing values for this variable, the following procedure was
conducted:
1.

Drug reviews with missing values were eliminated from the dataset.
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2.

The association between EF and ADR-PD, WD-experience, LK, age,
gender, and duration were computed using the Chi-square test.

3.

Regarding the variables associated with variable EF, K-nearest
neighborhood (KNN) was used for the whole dataset to impute the
missing values.

7)

WD-Experience: WD-experience includes the patient’s intentional and/or
unintentional withdrawal of WD, including variables “DXD-S”, “DXD-W”,
and “DXD-F”. The assumptions for coding these variables were, if the patient
explicitly reported experience of intentional or unintentional discontinuation,
then WD-Experience is “presence”, otherwise the WD-Experience is
“absence”. Accordingly, there was no missing value for this variable.

8)

LK: For variable lack of knowledge (LK), if a drug review includes any
indicators showing lack of knowledge (table 3-6), the review was coded for
LK-presence, otherwise the LK-absence. Accordingly, there was no missing
value for this variable.

3.7.2 Testing Association between ADRs and Attitude
Identifying ADRs that are significantly associated with negative attitude towards
antidepressants is important from the clinical perspective. It is important that healthcare
providers understand whether exposure to different type of ADRs can increase the risk of
developing negative attitudes and consequently non-adherence behavior in patients.
To measure the association between antidepressants’ ADRs and attitude or adherence, the
Antidepressant Side-Effect Checklist (ASEC) (Uher et al., 2009) has been used. The ASEC was
constructed as a self-report scale to measure twenty-one physiological antidepressants’ ADRs.
For each item, the patient can specify whether a symptom (if present) is likely to be linked to
antidepressants adverse effects (yes or no).
Patients’ expression for ADRs in a healthcare forum are associated with wide semantic
variation, leading to limitations in statistical analysis for testing hypothesis related to different
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ADRs and attitude. This study normalized the semantic variability of ADRs by mapping them to
UMLS Meta concepts. The details of the normalization was provided in “3.6 Terminology
association”. Expressions of ADRs were mapped to the closet syntax match in both UMLS and
SNOMED-CT. Therefore, some ADRs maybe syntactically different, but semantically related
UMLS Meta concepts. For example, “headache” (mapped to the UMLS Meta concept “[
C0018681] Headache”) and “severe headache” (mapped to UMLS Meta concept “[C2957106]
severe headache”) are semantically related. For each ADR mentioned in the ASEC, we grouped
semantically related UMLS Meta concepts. In the next step, we calculated the total frequency of
items in each group, and then tested associations between each group of ADRs and patients’
attitudes toward antidepressants.
3.7.3 Statistical Methods
For testing hypothesis for this study, we used Chi-square, ANOVA, and ordinal logistic
regression.
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Chapter 4: Results
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4.1 Dataset Statistics
The original sample size was calculate using formula for calculating sample size, which
was 892 reviews, with 432 in the SSRI class (Zoloft (213) and Lexapro (219)) and 460 in the
SNRI class (Cymbalta (231) and Effexor XR (229)). Five posts were excluded from the sample,
because they lacked any content. Table 4.1 shows statistic for sample of this study.
The final sample is almost equally divided between SSRI and SNRI classes. Table 4 shows
demographic information of the whole sample, as well as each class of drugs separately. Almost
50% of the reviews was recorded by patients who were satisfied with drugs, while 33% of
patients were dissatisfied with the drugs, indicating that patients with negative experience are not
dominant in this healthcare forum. 68% of the posts were posted by patients with age less that
40. This is possibly due to higher access to Internet in young patients and their willingness to
report their experience with medications. The gender proportion in the sample for female is
significantly higher than for male for both classes of drugs. Duration of usage is highly skewed
due to the effect of outliers. Posting reviews after 1 day of treatment may indicate high concern
of patients about the treatment.
4.2 Statistics on Developing and Applying the Analytical Framework
For the first phase of this study, the framework method was used to provide structured
data from text-based consumer reviews of the antidepressant drugs specified in this study. In the
framework method, a hybrid approach of inductive and deductive analysis was applied for
coding and theme development. In the deductive approach, a comprehensive set of articles and
self-report scales (questionnaires) that has been used in studies with focus on measuring patients’
attitudes towards antidepressants and psychiatric medications have been reviewed to identify the
important factors affecting patients attitudes towards antidepressant medications. The identified
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factors were categorized into five major categories, including pharmacological treatment,
healthcare systems, psycho-social factors, patients-related factors, and disorder related factors.
The factors were used for building the initial Framework of analysis.
Table 0-1 Dataset Statistics
Dataset statistics
Sample Size
No. of reviews with text
Time span
Attitude
Attitude
Attitude
Attitude
Attitude
Attitude
Gender

rated
rated
rated
rated
rated

as
as
as
as
as

1
2
3
4
5

Age

Age range
Age categories
<20
>= 20 <30
>=30 <40
>=40 <50
>=50 <60
<=60
Duration of usage

Duration of usage (range)
Duration of usage categories
< 1 month
>= 1 month < 3 months
>= 3 months < 6 months
>= 6 months < 1 year
>=1 year <2 year
>=2 years <5 years
>=5 years <10 years
>= 10 years

Dataset
892
887
Feb 2001
Sep 2016
3.16
195 (23%)
104 (12%)
152 (17%)
209 (24%)
219 (25%)
F 669 (76%)
M 212 (24%)
Missing value (11)

SSRI
432
428
Feb 2001
Aug 2016
3.33

SNRI
460
459
July 2004
Sep 2016
3

F 310 (72%)
M 118 (28%)
Missing value (4)

Avg. 37
Med. 35
Sd = 12.03
Missing values
(10)
14-83

Avg. 35
Med. 34

F 359 (79%)
M 94 (21%)
Missing value
(7)
Avg. 38
Med. 37

14- 73

14- 83

Avg. 19 months
Med. 5 months

Avg. 17 months
Med. 5 month

1 day- 16 years

1 day - 20 years

49 (6%)
242 (27%)
249 (28%)
200 (23%)
106 (12%)
33 (4%)
Avg. 18 months
Med. 5 month
SD. 31.7 (month)
1 day - 20 years
215 (24%)
116 (13%)
120 (14%)
125 (14%)
82 (9%)
128 (15%)
66 (7%)
27 (3%)
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300 drug reviews were coded using the codes (themes) at initial analytical Framework.
Using inductive approach (open coding), passages of text that did not match into the codes in
initial framework were discussed for more analysis in weekly meeting. Overall, eleven new
themes were identified, including withdrawal symptoms, perceived distress from withdrawal
symptoms, experience of withdrawal (intentional and unintentional discontinuation), decision for
discontinuation, recommendation to others for the drug usage, experience with other
medications, drug indications, problem with financial support, problem with social support,
overall attitude toward medications, and recommendation to others.
The codes (themes) generated using deductive and inductive approach were refined by
availability of patient expression for each theme, difficulty in differentiating between themes,
and also relevance of the theme to measuring attitudes towards antidepressants. The final
analytical framework includes 29 themes. Table 4-3 lists the themes in the final analytical
framework. To improve consistency of annotating (coding) using the analytical framework, the
reviews were split to sentences. The detail of splitting drug reviews to sentences was explained
in the methodology section.
Table 4-2 presents statistics on posts, sentences, and tokens. In average, patients on
SNRI drugs had longer posts, 7.1 vs. 6.4 for number of sentence, and 117.5 vs. 103.3 for number
of tokens. In average, patients on SNRI drugs had longer posts, 7.1 vs. 6.4 for sentence length,
and 117.5 vs. 103.3 for tokens. However, the range of sentence number in SSRI drug is higher
than SNRI drugs.
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Table 0-2 Statistics on Frequency of Posts, Sentences, and Tokens
Corpus

SSRI

SNRI

887
6004
6.77
1-35
98186
110.7

428
2749
6.42
1-35
44237
103.36

459
3255
7.1
1-25
53949
117.53

No. Posts
No. Sentences
Avg. posts length (sentence)
No. Sentences (range)
No. Tokens
Avg. Posts length (word)

Table 0-3 Frequency of Themes after Resolving Disagreements for the Whole Dataset
Themes (variables)
ADRs
WD
EF
INF
DI
PPI
PPI-P
PPI-N
KN
ADR-PD-low
ADR-PD-high
WD-PD-low
WD-PD-high
Decision for Discontinuation (DXD-dec)
Intentional Discontinuation (DXD-S)
Intentional Discontinuation-(DXD-W)

Corpus
2004
279
1078
308
806
280
55
87
70
404
976
61
355
49
212
93

SSRI
985
64
575
143
422
121
26
34
18
193
455
27
66
17
103
38

SNRI
1019
215
503
165
384
159
29
53
52
211
521
34
289
32
109
55

Unintentional discontinuation (DXD-F)
ATT-P (overall attitude towards drugPositive)
ATT-N (overall attitude towards drugNegative)
Suggestion to others (positive)
Suggestion to others (negative)
Dosage
Other patient
Lack of social support (SOS)
Lack of financial support (FS)
Other drugs
others

58
58

15
34

43
24

223

72

151

39
84
277
10
2
18
374
778

24
33
151
6
0
4
181
309

15
51
126
4
2
14
193
469

Table 4-3 shows the counts of annotated variables (themes) for the complete corpus and
for both psychiatric categories of drugs separately. 33% of sentences included information about
adverse drug reactions in the sample. 17% of the sentences provided information about drug
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effectiveness, and only 5% of the sentence included information for patients’ perceptions about
healthcare providers. This information indicates that this data source is a rich source to evaluate
pharmacological aspects of psychiatric medications, but not a rich source for patients-physician
interaction. Comparing the frequency of sentences including negative recommendation about
drug usage (84) to readers with frequency of sentences providing negative suggestion (39)
indicates that patients with negative experiences with drugs are more likely to suggest others not
to use the drugs. 12% of the sentences did not provide any informative information for the items
(codes) defined in the final analytical framework.
To reduce the complexity of final analytical framework, themes that were directly related
to patients’ attitudes were eliminated from the Final analytical framework. Therefore, ATT-P,
ATT-N, Suggestion to others (positive) and Suggestion to others (negative) were removed from
the framework. In addition, themes “dosage” and “other patients” were removed from the final
analytical framework because they do not provide any information for the patients’ attitudes
towards medications. Lack of social support (SOS) and Lack of financial support (FS) were also
removed from the analytical framework because of high missing values for the themes.
Using the analytical framework, all the sentences were double coded by participation of
four annotators with health-related background. The inter-annotator agreement (IAA) was
calculated using Kappa. The Average IAA for the whole dataset was 0.75 with the lowest IAA
for patient-physician interaction-positive attitude (0.5) and highest IAA for Drug indication
(0.91).
4.3 Statistics on Summarized Dataset
Because annotation of comments were conducted at sentence level, an individual drug review
maybe annotated several time for availability of a theme (code). To summarize annotation at
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comment level, multiple expressions of a theme were reduced to a single one for a review posts.
For example, several sentences in a drug review maybe annotated for the presence of ADRs, but
at the level of a review (comment), we reduced it to the single presence of the theme (ADR). We
summarized the whole dataset at the level of drug review using this strategy. All themes were
considered as variables. Table 4-4 shows the variables and their frequency. Limitations of each
variable for measuring patients’ attitude toward drugs and the strategy for filling missing values
were discussed in the methodology section.
Table 0-4 Statistics on Variables Used for Testing Hypotheses
Variables
ADR
Presence
Absence
ADR-Perceived distress
High
Low
Medium
Drug Effectiveness
EF
EF-INF
INF
Patient-Physician Interaction
Negative
Positive
Negative-positive
Missing value:
Complain of lack of knowledge
Presence
Absence
Experience of Withdrawal (Intentional and/or Unintentional)
No Experience
Experience
Unintentional withdrawal
No report
Reported
Intentional Withdrawal
No report
Existence of report on intentional withdrawal
Report on Intentional withdrawal and decision for withdrawal
Existence of report
No-report
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Frequency
823
56
483
166
230
524
120
235
47
62
4
766
60
819
508
371
831
48
639
240
275
604

4.4 Testing Hypotheses
4.4.1 Measuring association between variables and levels of attitude
To measure association between variables and levels of attitude, Chi-Square has been
used for categorical variables and Anova was used for continuous variables. Table 4-5 lists the
variables, related hypothesis, the type statistical test used for testing hypothesis, and P-value. For
this study, P-value was set on 0.05. All the analysis was conducted using RStudio, version
1.0.153.
We reject the null hypotheses for variables ADR experience, ADR-Perceived distress,
Drug Effectiveness, Complaint of lack of knowledge (LK), Duration of usage, Experience of
Withdrawal (Intentional and/or Unintentional), and Intentional Withdrawal (weaning off and
stopping the medications). In fact, these variables are significantly associated with patients
attitude towards antidepressants.
For two variables age and gender, there is not enough evidence to reject the null
hypothesis. So we conclude that these two variables are not significantly associated with
attitudes towards antidepressants specified in this study.
Table 0-5 List of Variables, Hypothesis, Statistics Test, and computed P-values
Variables

Hypothesis

ADR Experience

ADR and attitude are
independent variables.
ADR-Perceived distress
and attitude are
independent variables.
Drug Effectiveness and
attitude are independent
variables
LK and attitude are
independent variables.

ADR-Perceived distress

Drug Effectiveness

Complaint of lack of
knowledge (LK)
Experience of
Withdrawal (Intentional
and/or Unintentional)
Intentional Withdrawal

WD-Experience and
attitude are independent
variable.
Intentional Withdrawal
and variable are

Statistic
method
Chi-square

Values

P-value

X-squared
= 31.11
X-squared
= 231.6

2.907e-06*

Chi-square

X-squared
= 548.52

< 2.2e-16*

Chi-square

X-squared
= 59.358

3.957e-12*

Chi-square

X-squared
= 55.624

2.404e-11*

Chi-square

X-squared
= 64.009

4.161e-13*

Chi-square
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< 2.2e-16*

independent variable.
Gender

Age
Duration of usage

Gender and attitude are
independent variables.
Age and attitude are
independent variables.

Chi-square

Duration of usage and
attitude are independent
variables.

ANOVA

ANOVA

X-squared
= 2.6812
F-value=
0.7183

0.6125

F-value=
43.665

6.756e-11*

0.3969

Figure 4-1, Figure 4-3, Figure 4-4, Figure 4-5, Figure 4-7, Figure 4-9, Figure 4-11, Figure
4-13 shows distribution of “gender”, “age”, “duration”, “experience of ADRs”, “perceived
distress from ADRs”, “drug effectiveness”, “withdrawal experience”, “complaint of lack of
knowledge” for each level of patients attitude respectively.
Figure 4-2, Figure 4-6, Figure 4-8, Figure 4-10, Figure 4-12, Figure 4-14 shows
frequency of “gender”, “experience of ADR”, “perceived distress form ADRs”, “drug
effectiveness”, “withdrawal experience”, and “complaints for lack of knowledge” for each level
of attitude.
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Figure 0-1 Distribution of gender for each level of patients attitude

Figure 0-2 Frequency of gender for each level of attitude
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Figure 0-3 Distribution of age for each level of attitude

Figure 0-4 Distribution of duration of usage for each level of attitude
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Figure 0-5 Distribution of presence and absence of ADRs for attitude levels

Figure 0-6 Frequency of ADR for each level of attitude
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Figure 0-7. Distribution of perceived distress from ADRs (high, low, medium)

figure 0-8 Frequency of perceived distress from ADRs
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Figure 0-9 Distribution of drug effectiveness

Figure 0-10 Frequency of drug effectiveness
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Figure 0-11 Distribution of withdrawal experience for levels of attitude

Figure 0-12 Frequency of withdrawal experience for each level of attitude
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Figure 0-13 Distribution of complaints for lack of knowledge

Figure 0-14 Frequency of complaints for lack of knowledge for each level of attitude
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4.4.2 Developing a predictive model
To find the best fitting model to describe the relationship between the independent variables
(outcome variables ) and attitude (dependent variable), we used ordinal logistic regression. We
used polr command from the MASS package in R to estimate an ordered logistic regression
model. The command name comes from proportional odds logistic regression, highlighting the
proportional odds assumption in the model. “Polr” uses the standard formula interface in R for
specifying a regression model with outcome followed by predictors.
For developing the model we did not include age and gender, because they are not
significantly associated with patients attitude toward antidepressants. The following equation
shows the relationship between independent and dependent variables:

Attitude ~ Experience of ADR + ADR_ Perceived distress + Effectiveness +
Experience of WD + duration of usage+ lack of knowledge

Table 4-6 shows the coefficient, standard error, and p-value for the outcome variables for this
model.
Table 0-6 Values of statistical model
Variable
ADR_Experienced (1)
ADRPD (low)
ADRPD (medium)
EFINF (EF-INF)
EFINF (INF)
ExperienceWD (1)
Lack of knowledge 1
Duration

Co-efficient
-0.511989943
1.938705530
0.804059699
-0.870736633
-3.979180295
-0.700315050
-0.433608481
0.000259638

Std. Error
1.170552e-01
1.876554e-01
1.584470e-01
1.945260e-01
2.123201e-01
1.382074e-01
3.215736e-01
8.441442e-05
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P-value
1.220362e-05
5.091863e-25
3.882502e-07
7.598449e-06
2.274740e-78
4.038538e-07
1.775311e-01
2.099712e-03

Table 4-7 shows the confidence interval for the outcome variables in the model.
Table 0-7 Confidence Interval for the Outcome Variables in the Model
Outcome variables
ADR Experienced (1)
ADRPD (low)
ADRPD (medium)
EFIN (FEF-INF)
EFINF (INF)
Experience WD (1)
Lack of knowledge 1
Duration

Minimum
NA
1.5397784239
0.4932958996
-1.2550505954
-4.4199855660
-0.9723098874
-1.0830989795
0.0001209877

Maximum
NA
2.34744346
1.1160166506
-0.4878371728
-3.5554091696
-0.4297849025
0.1830980650
0.0004024088

Analysis of coefficients (Table 4-7) showed that “drug effectiveness” and “perceived
distress from ADRs” are the most significant factors affecting patients’ attitudes toward
antidepressants.
Comparing our findings with findings of literature showed that in line with literature,
“drug ineffectiveness”, “experience of ADR”, and “lack of knowledge” and “duration of
treatment (usage)” are associated with negative attitude towards antidepressants. Demyttenaere
et al. (2004) and (Reilly JL, 2011) showed drug effectiveness is strongly associated with patient
attitude towards antidepressants. For “experience of ADR” several studies found that experience
of ADR is associated with negative attitude towards medications (Dougherty et al., 2009; Murata
et al., 2012; Ng et al., 2012). (Haslam et al., 2005) and (Gabriel & Violato, 2010) found that
patients with more knowledge about their illness and their treatment are likely to be have
positive perception about treatment and, in turn, to be more adherent. Association between
variable “patient-physician interaction” and attitude were not tested, because of low IAA for this
variable and high rate of missing values.
As the results in table 4-5 shows, age and gender are not associated with levels of
attitude. Therefore, we did not include them in the predictive model. The findings are in
agreement with findings of studies conducted by Jacob et al. (2015), (Murata et al., 2012), and
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(Ng et al., 2012). However, our findings for age and gender are contrary to the findings of study
conducted by Prins et al. (2008).
We found “Experience of withdrawal” associated with negative attitude towards
antidepressants. However, this variable was not discussed by literature.
4.5 Statistics on Entities Identification
In the second phase of the study, ADRs, WDs, and DIs were identified and extracted
from sentences that in the first phase of this study were annotated as ADRs, WDs, and DIs. All
the entities were identified by strictly following guidelines covering the rules of identification,
such as patients’ certainty in linking ADRs and WDs to the drugs. In addition to identifying the
physiological, psychological, and cognitive patient complaints about the drugs, the impact of the
ADRs on patients’ daily functioning and social participation were also extracted. Identifying
functional problems is significant for understanding the impact of ADRs on patients’ quality of
life. It is also important for estimating the indirect cost associated with the ADRs (Giannangelo
et al., 2005). Collecting this information enhances clinicians' abilities to predict impact of ADRs
on patients’ functionality and work performance. Hence, they will be able to design more
effective interventions targeting patients' attitude and adherence towards medications.
Four annotators (coders) identified the boundary (span) of the ADRs/WDs/DIs in the
sentences. All the entities were double coded by strictly following the guidelines of entities
identification. The computed pairwise agreement for strict match was 0.86 for ADRs, 0.81 for
WDs and 0.91 for SSs, with the average 0.86 for the whole corpus. The reason for applying
pairwise agreement (PA) for computing IAA rather than conventional measures, such as Kappa,
is that PA is calculated at the level of entities. Since the identification task requires identifying
the entities and determining their correct boundaries, the chance agreement is effectively zero.
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Table 4-8 lists frequencies of identified entities for the total corpus, for each class of
drugs, and for each type of entity separately. From 6,534 identified entities, 73% are ADRs, 12%
are WDs, and 18% are drug indicators. In total, 41% of the entireties were duplicates, with the
highest frequency of duplicates for drug indicators (89%), and lowest frequency for withdrawal
symptoms (20%), indicating that patients mostly use the same medical terms to describe the
reasons for drugs prescription. This result may be due to similar information given by providers
to patients. Physiological entities constitute 59% of the total entities, followed by psychological
entities (35%), Cognitive entities (5%) and Functional problems (2%), showing that the review
posts are not a rich of the impact of ADRs or WDs on patients’ quality of life. For the purpose of
designing more effective medication adherence interventions, it would be useful if healthcare
forums also ask patients to report the impact of drugs on their daily functioning and social
activities. For ADRs and WDs, psychological and cognitive expressions have higher variability
than physiological expressions. That is due to level of subjectivity of these types of entities
leading to creating various phrases by patients to express their subjective complaints. For two
classes of psychiatric medications, SSRI and SNRI, the distribution of ADRs and drug indicators
is almost similar.
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Table 0-8 Statistics on Entity Identification Component for Each Class of Drugs and Type of Entities
Separately
Total
Entiti
es
6,534

Corpusentities

Physiological
All
Unique

Psychological
All
Unique

Cognitive
All Unique

Functional
All Unique

59%
(All)
(3856)
66% (All)
3176

3,83
4

2266

79%
(All)
(236)
77%
(All)
(191)
81

13
6

131 (All)
96%

85

521

51%
(All)
1165
76%
(All)
(804)
372

29
7

155
3
182
6
355

63%
(All)
2422
62%
(All)
2098
880

42

96%
(All)
(82)
40

1218

540

432

110

43

42

180

5

100%
(All)
(26)
5

97%(All)
30

51

83%
(All)
(151)
40

31

72

74%
(All)
263
45

1

1

Unique

ADR
Corpus

4774

338
0

1061

ADRSSRI
ADRSNRI
WDCorpus

2236

1374

2537

1802

592

WDSSRI
WDSNRI
SSCorpus

129

79%
(All),
470
91

463

379

283

218

129

111

21

21

30

29

1168

17% (All)
210

99

1025

95%(All)
19

153
157

30
69

79%
(All)
19
10
9

20

621
547

20%
(All)
210
114
96

24

SS-SSRI
SS-SNRI

61%
(All)
61
20
41

9
11

8
11

568
457

24
7
11
9
12
8
26

14
10

Table 4-9 provides examples of the top 5 identified entities for each type of entities and
class of drugs separately. Overall, ADRs and WDs can lead to debilitating functional problems,
such as restricted work performance, loss of job, poor educational performance, emergency visit,
and hospitalization.
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Table 0-9 The Top Five Identified Entities for Each Class of Drug s and Type of Entities Separately
Physiological –top
(5)
Weight gain (55),
nausea (38), dry
mouth (30),
insomnia (30),
fatigue (25)

Psychological- top (5)

Cognitive- top (5)

Functional - top (5)

vivid dreams(19),
nightmares (9),
increased anxiety (9),
suicidal thoughts(9),
anxiety (9)

Memory loss(6),
brain fog (4),
inability to
concentrate (3), hard
to focus (4),
forgetfulness (2)

SNRIADRs

Insomnia(47),
constipation(37),
weight gain(34),
nausea(32), dry
mouth(28)

vivid dreams(19),
anxiety (14),
nightmares (13), no
sex drive (12), loss of
sex drive(8)

SSRIWithdraw
al
symptoms

Dizziness (7),
upset stomach (3)
,brain zap (2),
nausea (2) , crying
spell (1)

Irritability (4),
suicidal thoughts (2),
aggression (1), crying
spells (1), very
anxious (1)

SNRI
Withdraw
al
symptoms

Dizziness(16),
nausea (11), brain
zaps (8), headaches
(6), dizzy (6)

Mood swings (5),
nightmares (3), moody
(2), feel like a walking
zombie (2),
aggressive (2)

Memory loss (6),
confusion(4),
spacey(3), inability
to concentrate(3),
couldn't focus on
anything (2)
Slight confusion (1)
Severe mental
confusion (1),
Couldn’t concentrate
(1),
Memory sucks (1)
Dissociative episodes
(1), foggy (1), lack of
concentration (1),
confused (1), cannot
think (1), feel spaced
out(1)

Called in sick(2),
impossible to do my
job (1), struggling to
learn new things
(1),unable to
function(1),struggle
just to comb my
hair(1)
Hospitalized (2),
unable to function (1),
loss of friends(1)
unable to work(1),
cannot drive (1)

SSRIDrug
Indicators

Insomnia (4), upset
(2), impatient (1),
fibromyalgia (1),
physical pain (1)

Depression (163),
anxiety (127), anxiety
(32), depressed (15),
panic attacks (14)

SNRIDrug
Indicators

Pain (12), fatigue
(6), insomnia (2),
fibromyalgia (4),
migraines(2)

Depression (185),
anxiety (103), anxious
(9) suicidal thoughts
(6),social anxiety (6)

SSRI ADRs
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intrusive thoughts
(3), obsessive
thoughts (2),
confused (1), racing
thoughts (1), inner
critic (1)
obsessive thinking
(4) Mental clutter(2),
memory loss (1),
rumination (2),
memory loss (1)

Ended up in the er (1),
1/2 weeks in phych
word (1)

can't function (1),
could not drive (1),
Difficulty tidying
house (1), Difficulty
performing shopping
activities (1),
Difficulty performing
educational
activities(1)
lost my job (2),
isolating (1), barely
functional (1),
dysfunctional (1)

Loss everyone in my
life (1), could not
function at work (1),
lost everyone in my
life (1), harsh edge to
my inter-action with
others

4.6 Statistics on Terminology Association
In the third phase of this study, the identified entities were normalized by mapping to
both the UMLS Metathesaurus and SNOMED-CT. This mapping benefits the generation and
testing of medical hypotheses related to associations between ADRs, WDs and patients attitudes
and discontinuation behavior of patients by providing unambiguous and standard information for
statistical data collection and analysis.
To improve accuracy and consistency of mapping, guidelines was developed using
clinical trials addressing the ADRs of the drugs specified in this study and qualitative studies
investigating the themes of patient complaints about the drugs. Each ADR concept is associated
with a set of attributes reflecting patients’ problems. For example, “executive dysfunction” is a
term taken from the clinical trials literature and mapped to the Metathesaurus and SNOMED-CT.
The concept of executive dysfunction as a cognitive ADR is associated with inability to initiate and
follow processes of completing a task, so a patient complaint of “cannot follow through on simple
tasks, can be mapped to “executive dysfunction” as a general concept. The guidelines also includes
the requirements for selecting proper/preferred UMLS and SNOMEDCT concept, and flowchart for
mapping to both UMLS and SNOMED-CT.
Table 4-10 shows statistics for normalization component. The final set contains 698
UMLS concepts for ADRs, showing that out of 3176 unique identified ADRs and WDs, only
14% of them are unique standard medical concepts. On average, for each standard ADR concept,
there is 4.5 layperson expression of ADR/WD, reflecting the challenge of automatic
identification of ADR/WD using standard medical lexicons. From 210 unique identified drug
indicators, 81% are unique standard concepts, showing that patients mostly use the diagnosis
results provided by healthcare professionals to report the reason for drug prescription.
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Overall, all three types of entities (ADRs, WDs, and Drug Indicators) were mapped to
811 UMLS concepts, from Which 154 concepts did not include SNOMED expressions.
Therefore, we attempted to use equivalent medical concept that semantically match the primary
concepts and include expressions of SNOMED-CT concepts. Table 4-11 lists the most frequent
UMLS concepts in the corpus that did not include SNOMED-CT concepts.
This study also identified qualifiers representing severity (QS) and persistency (QP) of
the entities. Identifying the qualifiers can help healthcare providers to estimate the debilitating
effects of ADRs/WDS on patient quality of life and whether they need to use any specific
interventions to improve patient adherence to medication.
Table 0-10 Statistics on Entities Normalized with UMLS and SNOMED-CT Concepts
Entities
ADRs
The five most
frequent ADRs
after
normalization

698

WD
The five most
frequent WDs
after
normalization

218

Drug
indicators
The five most
frequent WDs
after
normalization

171

Physiological
462
Sleeplessness
(171), nausea
(169), weight
gain (148),
lack of libido
(138),
headache (106)
109
Dizziness (43),
nausea (32),
headache (27),
malaise (10),

Psychological
197
Anxiety (92),
detailed recall of
dream (62),
depressed mood
(41), apathy(38),
feeling
suicidal(38)
72
Irritable mood
(16), depressed
mood (11), mood
swings (10),
nightmares (8),
severe anxiety
(6)

Cognitive
42
Foggy feeling in
head (44), unable
to concentrate
(30), amnesia
(19), memory
impairment (15),
forgetful (14)
18
Confusion (4),
unable to
concentrate (3),
mental suffering
(3), Foggy
feeling in head
(2), actual low
self control (1)

46
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Pain (13),
fibromyalgia
(9),
sleeplessness
(14), fatigue
(6), tired (4)

Depressed mood
(444), anxiety
(258), panic
attacks (27),
feeling suicidal
(22), social fear
(17)

Obsessive
thoughts (13),
unable to think
clearly (2)
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Functional
31
Difficulty in daily
functioning (10),
emergency room
admission (9),
social withdrawal
(8), hospitalization
(6), bed-ridden (5)
19
Difficulty in daily
functioning (4),
bed-ridden (3),
restricted work
performance (3),
difficulty driving a
car (2), emergency
room admission
(2).
13
Difficulty in daily
functioning (4),
difficulty
maintaining
relationships (2),
Loss of job (3)

Table 0-11 The Most Frequent UMLS Concepts in the Corpus without SNOMED Expressions
UMLS-Primary Concept

SNOMED
-CT
Primary
Concept

Frequency

UMLS-Equivalent
Concept

SNOMED-CT
Concept

C0859330 / Foggy feeling in

No Code

46

C0683369 / Clouded

Clouded

consciousness / Sign or

consciousness

Symptom

(finding)

C0349446 /
Dissociative trance /
Mental or Behavioral
Dysfunction
C0040822 / Tremor /
Sign or Symptom
C0849963 / Feeling
nervous / Sign or
Symptom
C0233484 /
Emotionally detached
/ Finding

Dissociative trance
(disorder)

head / Finding

C0857507 / Spaced out /
Finding

No Code

34

C0392703/ Shakes/
Finding
C0549209 / Feeling jittery
/ Sign or Symptom

No Code

33

No Code

29

C0857486 / Felt like a
zombie / Finding

No Code

24

Tremor (finding)
Feeling nervous
(finding)
Emotionally
detached (finding)

Table 4-12 shows statistics on the qualifiers indicating intensity and persistency of the ADRs and
WDs. Identifying the qualifiers can help healthcare providers to estimate the debilitating effects of
ADRs/WDS on patient quality of life and whether they need to use any specific interventions to improve
patient adherence to medication.
Table 0-12 Frequency of Identified Qualifiers Associated with ADRs and WDs
Category
Mild

Frequency
112

Moderate

67

Severe

432

Persistent

243

Not-persistent

317

Example
Slight (27), mild (22), a little (14), slightly (10),
minor(5)
Moderate (6), Somewhat (3), semi (2), possibly
some (1)
Extreme (52), severe (40), extremely (17),
horrible (17), terrible (16)
Constant (16), always (13), constantly (11),
chronic (7), chronic (6)
at first(22), occasional(12), in the beginning (12),
sometimes(11), initial(7)

4.7 Testing association between specific type of ADRs and levels of Attitude
After normalizing the ADRs, we tested the association between 21 physiological ADRs with
levels of attitude. The 21 physiological ADRs that were specified in the Antidepressant SideEffect Checklist (ASEC) are dry mouth, drowsiness, insomnia (difficulty sleeping), blurred
vision, headache, constipation, diarrhea, increased appetite, decreased appetite, nausea, problems
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with urination, problems with sexual function, palpitations, feeling light-headed on standing,
feeling like the room is spinning, sweating, increased body temperature, tremor, disorientation,
yawning, weight gain (Table 4-12). For each ADR mentioned in the ASEC, the semantically
related UMLS Metathesaurus concepts were grouped and the association between that group of
ADRs with attitude were tested. In total, 128 unique UMLS concepts for ADRs (out of 698
concepts), which were identified in the phase of entity normalization, were grouped with ADRs
specified in the ASEC questioner. Association between these ADRs and attitude was evaluated
using X-square. For ADRs that the frequency for a level of attitude in the contingency table was
less than 5, Fisher-exact test has been used. The result of the study showed that weight gain,
yawning, disorientation, palpitation, increased appetite, and dry mouth are associated with
patients’ attitude towards antidepressants. While other ADRs in the ASEC are not associated
with patients’ attitudes toward antidepressants.
Table 0-13 Testing Association between ADRs and Attitude
Physiological
ADRs specified in
the ASEC
Questionnaire

Variables

Statistic test

P-value for XSquare
0.07628
0.4051
0.5985

P-Value for Fisher
Exact Test

Headache
Insomnia
Drowsiness
Blurred. Vision

8.4545
4.007
2.7613
6.6146

Dry mouth
Constipation

11.801
1.9675

0.01889*
0.7417

Diarrhea
Decreased
Appetite
Increased. Appetite

7.1359
3.6637

0.1289
0.4534

19.862

0.0005318 *

Palpitation

9.2751

0.05458

Sweating

5.4177

0.2471

Disorientation

10.995

0.02662

0.02323

Yawning

19.116

0.0007457

0.002313

Increased body
temperature
Weight gain

4.4946

0.3432

0.4051

10.488

0.03296

0.1577
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0.06515

Psychosocial ADRs
specified in the
literature

Tremor

4.8804,

0.2998

Problems with
urination
Problem with
sexual functioning
Nausea or vomiting

3.2561

0.5159

23.689

9.218e-05

0.2873

0.9906

Vertigo

3.3951

0.494

Light headed

6.5986,

0.1587

Emotional
indifference
Apathy
Emotionally
detached
Mood Swing

21.131

0.0002983

20.332
24.477

0.0004293
6.407e-05

X-squared =
11.913
23.346

0.01801

32.532

1.489e-06

18.661

0.0009162

0.0004507

25.283,

4.413e-05

4.413e-05

Anxiety

Cognitive ADRs
specified in the
literature

Problem with
Motivation
Difficulty in
concentrating
Memory problem

0.3724

0.5618

2.224e-05

0.000108

The result of studies conducted by De las Cuevas et al. (2014) using ASEC questionnaire
also showed that “weight gain” and “dry mouth” associated with patient adherence toward
medications.
In addition to the ADRs specified in the ASEC questionnaire, we also tested the
association between psychological ADRs including “emotional indifference”, “apathy”,
emotionally detached”, “mood swing”, “anxiety”, and “motivation” and cognitive ADRs
including “Difficulty in concentrating” and “memory problem”. Overall 36 unique UMLS
concepts for ADRs that semantically related to the psychological and cognitive ADRs were
grouped and tested for the association with attitude. All the psychological and cognitive ADRs
were strongly associated with patients’ negative attitude toward antidepressants (Table 4-13).
The frequency of ADRs (specified in table 3) for levels of attitude (1-5) depicted in from Figure
4-15 to Figure 4-39.
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Figure 0-15 Frequency of headache for each level of attitude

Figure 0-16 Frequency of insomnia for each level of attitude
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Figure 0-17 Frequency of drowsiness for each level of attitude

Figure 0-18 Frequency of blurred vision for each level of attitude
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Figure 0-19 Frequency of constipation for each level of attitude

Figure 0-20 Frequency of diarrhea for each level of attitude
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Figure 0-21 Frequency of decreased appetite for each level of attitude

Figure 0-22 Frequency of increased appetite for each level of attitude
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Figure 0-23 Frequency of sweating for each level of attitude

Figure 0-24 Frequency of disorientation for each level of attitude
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Figure 0-25 Frequency of yawning for each level of attitude

Figure 0-26 Frequency of weight gain for each level of attitude
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Figure 0-27 Frequency of problem with urination for each level of attitude

Figure 0-28 Frequency of sexual dysfunction for each level of attitude
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Figure 0-29 Frequency of nausea or vomiting for each level of attitude

Figure 0-30 Frequency of nausea or vertigo for each level of attitude
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Figure 0-31 Frequency of emotional indifference for each level of attitude

Figure 0-32 Frequency of apathy for each level of attitude
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Figure 0-33 Frequency of emotionally detached for each level of attitude

Figure 0-34 Frequency of mood swings for each level of attitude
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Figure 0-35 Frequency of restricted emotion (emotional indifference + apathy + emotionally detached +
restricted motivation) for each level of attitude.
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Figure 0-36 Frequency of anxiety for each level of attitude

Figure 0-37 Frequency of motivation for each level of attitude
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Figure 0-38 Frequency of difficulty in concentration for each level of attitude

Figure 0-39 Frequency of memory problem for each level of attitude
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Chapter 5: Discussion
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This study involves both qualitative and quantitative approaches for the purpose of
pharmacovigilance for psychiatric medications and generating and testing hypotheses concerning
patients’ attitudes toward antidepressants. The source of data is a healthcare forum called
“askapatient.com” and the drug source are four psychiatric antidepressant medications including
Sertraline (brand name: Zoloft) and Escitalopram (brand name: Lexapro) from the Selective
Serotonin Reuptake Inhibitor (SSRI) Class and venlafaxine (brand name: Effexor XR) and
duloxetine (brand name: Cymbalta) from the Serotonin Norepinephrine Reuptake Inhibitor
(SNRI) Class.
5.1 Significance of Social Medial for Providing Insight about Attitude and Adherence
Behavior
The data analysis using the framework method showed that drug review posts in social
media provide significant insight for patients’ perception and attitude towards antidepressants
and pharmacological aspects of dugs. However, it does not provide any insight for patients’
adherence to medications, because the key factor in definition of adherence is a patient's
agreement with the healthcare providers’ treatment plan and drug reviews do not contain explicit
information indicating whether a patient’s withdrawal from medication was according to
healthcare providers’ recommendations or not.
5.2 Significance of Social Media in Identifying Underlying Factors Associated with Attitude
1) The analysis of data using analytical framework showed that drug reviews posts can be a
significant source for underlying pharmacological factors affecting patients’ attitudes.
However, it does not provide reliable information to evaluate healthcare system factors,
such as patients’ perceived perceptions from communication with healthcare providers.
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2) In this study, we measured association between patients perceived distresses from ADRs
using patients drug review comments. This variable was measured using explicit
indications including qualifiers representing severity, negative impacts of ADRs on daily
activities and social life, and reporting severe life-threating ADRs (suicidal ideation,
suicidal attempt, and self-harm). The result of the data analysis showed that perceived
distress from ADRs is significantly associated with patients’ attitudes toward
antidepressants. However, currently there is no self-report scale that was specifically
designed to measure patient perceived distress received from ADRs associated with
antidepressants. Although the Antidepressant Compliance Questionnaire (ADCQ) and the
Beliefs about Medications Questionnaire (BMQ), the Drug Attitude Inventory (DAI)
includes items that measure patients concern for antidepressants, such as long term
affects and its impact on patient quality of life, losing autonomy, possibility of addiction,
and control over feelings, they do not measure perceived distress that patients directly
received from ADRs. For example, a patient may experience severe dry mouth, but does
not have concern about long-term effects of antidepressants on life quality or control over
feeling.
In addition, the total ADR score obtained from the Antidepressant Side-Effect Checklist
(ASEC) does not represent perceived distress that a patient received from a set of ADRs.
For example, a patient may obtain total score “four” from four reported mild ADRs,
while another patient may obtain total score “three” from one severe ADR. Apparently,
the second patient received higher perceived distress from the first one, however the
calculated total number does not represent it.
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3) Drug reviews also provide information about patients withdrawal experience as
significant predictive factors for patients attitude toward antidepressants. However, selfreport scale for measuring patients’ attitude for antidepressants do not include any items
related to patients’ withdrawal experience.
5.3 Limitations of Social Media in Identifying Underlying Factors Associated with Attitude
Drug reviews in healthcare forums compared with self-report scales has some limitations:
1) First, they are not a rich source of patients’ perceptions towards healthcare providers.
The ADCQ, a self-report scale that specifically designed for measuring patients attitude
towards antidepressants, includes a component that measure three dimensions of patientphysicians interaction: 1) patient’s perception of physician’s knowledge; 2) patient’s
perception of sufficiency of knowledge provided by physicians; and 3) patient’s
perception of communication effectiveness with providers. We attempted to measure
patients’ satisfaction with healthcare providers using the three dimensions in the drug
reviews. However, majority of the patients did not provide explicit indications showing
their perceptions towards clinicians, which caused low IAA among annotators.
2) Drug reviews posts also do not provide explicit information about patients general
concern and necessity towards medications. However, the BMQ self-report scale includes
components for measuring general concern and necessity towards medications. In
addition, the BMQ includes a component for measuring the perceived necessity of a
prescribed medication, while in the data analysis of this study, patients’ expressions of
perceived necessity for antidepressants was labeled as “drug effectiveness”, because of
difficulty in differentiation of perceived effectiveness and perceived necessity in sentence
classificantion.
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3) Furthermore, while the ADCQ self-report scale can capture patients perceived social
support, few patients expressed their perceived social support in drug reviews.
By comparing items in the final analytical framework and the self-report scales (the
ADCQ, the BMQ, and the DAI), we conclude that drug reviews cannot be used as an alternative
source for measuring patients’ attitudes towards antidepressants compared to self-report scales.
However, they can be used as a supplementary source, due to providing insights for some
underlying factors that are not available in the self-report scales.
5.4 Significance of Social Media in Identifying ADRs and WDs Associated with
Antidepressants
Identifying ADRs and WDs from drug review posts showed that this data source is a
valuable source for identifying ADRs and WDs associated with antidepressants. Although Uher
et al. (2009) demonstrated that adverse effects of antidepressants can be reliably assessed
through self-report scales, the inherent limitations associated with the scales, such as low
coverage of potential adverse effects, particularly the rare ones, may reduce the reliability and
validity of the scales. For example, the ASEC scale does not cover psychological, cognitive and
functional problems associated with antidepressants, which is the major limitation of studies
employing this scale for measuring ADRs associated with antidepressants (Bet, Hugtenburg,
Penninx, & Hoogendijk, 2013; Uher et al., 2009).
The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) and the
WHO Quality of Life Assessment-Brief version (WHOQOL-BREF) are other self-report scales
used for measuring the ADRs associated with antidepressants. The LUNSERS is also associated
with some limitations. First, it is not specifically designed for measuring antidepressants’ adverse
effects. Second, the ADRs indicating emotional problems and cognitive dysfunctions are very
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limited and do not reflect a wide range of emotional and cognitive adverse effects of
antidepressants.
Items in the WHOQOL-BREF assess individual quality of life from a general perspective
that may not be directly related to the impact of antidepressants on quality of life. For example,
items such as “level of satisfaction with living place” or “having enough money to support your
needs” do not measure the impacts of ADRs associated with antidepressants.
These scales may also suffer from patients’ recall bias, because they do not define a
specific time-period during which the adverse effects have been occurred. Hence, patients may
just report severe adverse effects they experienced and disregard the mild ones (Bet et al., 2013).
Patients’ self-reports in healthcare forums are not associated with these limitations. First,
patients can access the forums at their own convenience. Hence, their reports may not suffer
from memory bias. Second, in contrast with structured questionnaires that limit the patients’
reports to a specific set of ADRs, patients in healthcare forums can report any psychological,
physiological, and cognitive ADRs using their own language. So, there is no concern regarding
the patients’ wrong interpretation of ADRs specified in the questionnaires (self-report scales). In
addition, patients voluntarily report their experiences with medications. So, the concern for
hiding information or breaching confidentiality would be minimized.
Regarding this information, we can conclude that drug review posts in social media can
address limitations associated with to self-report scales (questionnaires) and they can be used as
an alternative source for measuring ADRs associated with antidepressants.
5.5 Implications of this Study
5.5.1 Developing tools in the area of text mining algorithms and machine learning
for extraction of health related information from consumer health posts
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The three phases of this study: 1) applying the analytical framework at level of sentences;
2) identifying ADRs, WDs, and DIs; and 3) mapping the identified entities to both UMLS and
SNOMED-CT concepts, provides a corpus that has several implications for developing tools in
the area of text mining and machine learning for extracting health related information form
consumer health posts. First, the generated dataset can be used to improve the recall of
dictionary-based systems designed for automatic identification of pharmacological
aspects of drugs. Second, the dataset has a significant implication in developing and evaluating
text mining and machine learning systems aimed to identify ADRs, WDs, and drug indications
from consumer health posts in social media. Third, the dataset can be used for training machine
learning-based classifiers aiming to distinguish ADRs from other semantic types, such as drugs
indications. Forth, the dataset has important implications for developing and testing automatic
system aimed to measure effectiveness and ineffectiveness associated with psychiatric
medications. Fifth, it can be used for developing systems targeting automatic mapping between
layperson expression of health information to UMLS and SNOMED.
Currently, there is one open source corpus that has been developed using consumer health
posts, which is called CADEC ("Health Information Technology for Economic and Clinical
Health Act," ; Karimi et al., 2015). This corpus consists of 1,231 comments for two categories of
drugs, Diclofenac and Lipitor. The identified entities include ADRs, symptoms, disease, and
mentions of drugs, which were mapped to SNOMED-CT, MEDRA, and AMT.
Our corpus is different from the CDADE from several important aspects, including type
of drugs studied, methodology of development, identified entities, and normalization process.
Because of the nature of the psychiatric medications and the patient population of this study, the
ADRs events, specifically functional problems are not expected to be well-covered by the
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CADEC corpus. Moreover, the corpus created in this study includes the drug
effectiveness/ineffectiveness and qualifiers representing severity and persistency of ADRs and
WDs that are not covered by CADEC. Finally, all the identified entities were mapped to UMLS,
which was not reported by CADEC.
5.5.2 Testing the association between physiological, psychological, cognitive, and
functional problems with attitude
In this study, 698 ADRs and 218 WDs were identified from which the association
between 164 ADRs and attitude were tested. 128 ADRs were grouped using ADRs specified in
the ASEC questionnaire, and 36 ADRs grouped into psychological and physiological ADRs
specified in the literature. Accordingly, we did not measure the association between 534 ADRs
(specified in the dataset) with attitude. The ADRs, such as “detailed recall of dream” and
“suicidal feeling”, “malaise” may have severe negative effect on patients’ attitudes toward
antidepressants and consequently adherence behavior. Future studies can investigate the
association between the ADRs and patients’ attitudes.
5.5.3 Developing self-report scales
The dataset that was produced using the analytical framework and the ADRs/WDs
identification phase can be used for designing patient-driven self-report scale for measuring
patients’ attitudes towards antidepressants.
4.5.4

Implications of the analytical framework

The analytical framework developed in this study has significant implications for data
analysis from other healthcare forums collecting patients’ experiences with pharmacological
treatments and also personal health records that include patients’ experiences with medications.
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5.5.5 Implication of the findings related to the factors associated with attitude
Findings of this study have significant implications for developing clinical interventions
aiming to improve patients’ attitudes and adherence towards medications. In this study, we
showed that lack of knowledge about ADRs and WDs is significantly associated with patients’
negative attitudes towards antidepressants. Therefore, clinicians should design and implement
effective communication mechanisms to inform patients the potential ADRs and WDs that they
may experience during the process of treatment and discontinuation.
In addition, we found that patients’ withdrawal experience is associated with patients’
negative attitudes towards antidepressants. The finding implies that clinicians should consider
interventions to reduce the perceived distress that patients may receive during the discontinuation
process of antidepressants.
We also found that drug effectiveness is the most significant factor associated with
attitude, implying that patients at initial phase of treatment may discontinue antidepressants
abruptly if they do not find it effective in resolving depression symptoms. Regarding the fact that
antidepressants full effects are not seen for typically four to six weeks, clinician should consider
interventions to track antidepressants’ effectiveness and inform patients for treatment mechanism
of the drugs.
5.6 Limitations of this Study
1) Lack of information on drug-drug interactions, drug-herb interaction, and drug overdose:
Identifying ADRs for consumer health posts and evaluating their associations with patients’
attitude toward drugs and antidepressants has some limitations. The focus of patients in the
review posts was mostly on a specific drug. Hence, it is not clear whether the reported adverse
effects are merely caused by the drug or it is the result of interaction of the drug with other
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potential drugs or herbal treatments. Moreover, some of the ADRs for psychiatric medications,
such as suicidal ideation or emergency visits, can happen due to patient’s overdose, which were
not available in these review posts.
2) Uncertainty of data in social media: Although patients’ self-report experience is a reliable
source for evaluating pharmacological effects of medications, the risk of inaccurate and false
information still exists.
3) Concern about dominating dissatisfied patients in drug reviews forum: There is a concern
that patients with negative perception for medication have more willingness to report their
experiences with medications. However, the statistical analysis of the sample size in this study
showed that almost 50% of patients were satisfied with psychiatric medications as they rated
them as 4 and 5. While only 35% of patients rated the drugs as 1 and 2. In addition, the data set
showed that almost half of the reviewers used the antidepressants more than a year, suggesting
that they were not the most dissatisfied patients with antidepressants.
4) Concern about misinterpretation of ADRs and WDs: one problem with data analysis for
consumer health posts for psychiatric medications is the possibility that users misinterpret the
symptoms of their mental disorder with ADRs. Although this study recorded only ADRs that
patients certainly linked them to the psychiatric medications, we cannot exclude patients’
misinterpretation of depression symptoms with ADRs.
5) Concern about representativeness of the sample: As healthcare forum data are self-selected,
there is the risk that the dataset is not representative of patient population. However, the
distribution of sample size in this study for both gender, female and male, is consistent with
those identified in conventional prevalence studies.

146

The review posts in an online healthcare forum may also not be a representative source
for all demographic groups. Some minorities may not have the same access level and skills for
adoption and usage of technology for reporting their experiences in online healthcare forums.
6) Insufficiency of information to estimate prevalence of ADRs/WDs: This study could not
estimate the prevalence of ADRs and WDs, as the healthcare forum contained no prompt for
patients to disclose the particular effects. While some patients seemed to list all ADRs and WDs
they experienced, others mentioned few ADRs. In addition, some patients reported difficulty in
medication discontinuation, while they did not report any specific withdrawal symptoms.
However, the significance of this study compared to the conventional methods for collecting
patients’ experiences with medications is that the drug reviews in healthcare forums are
spontaneous, open-ended, and uncensored format, and they were not collecteded for a specific
project.
7) Sample size: The sample size of this study is limited to 892 posts for four psychiatric
medications. While this sample size is a good representative of posts available in
“askapatient.com” for the four psychiatric medications, it may not be a balanced representative
of other consumer posts in this forum or other healthcare forums. Additionally, it is possible that
a specific group of patients report an unbalanced sample of experiences with drugs in the forum.
8) Limitation for coverage of medications: Our corpus covers sentence classification and
entities identifications for two classes of psychiatric medications, SSRI and SNRI. While
limiting dataset to specific set of drugs enabled us to have a better understanding of the
conceptual models associated with layperson and professional expressions of medical entities, it
may not include the rare ADRs related to other classes of psychiatric medications, such as TCA.
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9) Terminology Mapping challenges
We managed to improve accuracy of inferring the intended meaning of colloquial expression of
ADRs by use of a preliminary mapping table based on clinical trials and qualitative studies,
contextual cues in patients reviews, and discussion meetings. However, we had some challenges
for selecting proper UMLS/SNOMED-CT concepts for ADR expressions. Throughout the
corpus, we could not map 130 expressions (out of 6534) to either UMLS or SNOMED concept.
For example, the ADR of “hardly feel human anymore”, could not be mapped to any concepts
due to uncertainty of the underlying concepts associated with it. Indeed, it is unclear what the
patient meant with this expression: is it about the patient feelings emotionally detached, having
a problem in performing daily activities, or is it about feeling detached from his/her mind or
body (de-realization)?
Another challenge is that layperson expressions of ADRs are fuzzier than the
corresponding UMLS/SNOMED concepts. For synonym concepts, the layperson ADRs
expressions are more likely to be “narrower-than” or “broader-than” their closest UMLS
concept. For example, “not being able to express sadness” or “could not cry in funeral
ceremony” were all mapped to “blunted affects”. This happens particularly for psychological
systems and functional problems.
There were also some cases that, while expression of an ADR is clear and can be
translated to equivalent medical concept, no UMLS concept is available for that expression. For
example, brain shivers (brain zap) (J. Aronson, 2005) is a medical concept that has been reported
in a few medical research as an ADR/WD of psychiatric medication, however, no medical
concept is available for it in UMLS. Eighty-seven (out of 130) expressions without any UMLS
concepts were related to this medical concept.
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Limiting drug reviews to a set of drugs prescribed for a specific disease or mental
disorders, helps to have a better understanding of patients’ colloquial expressions of ADRs by
comparing the expressions with clinical trial studies and qualitative studies addressed the ADRs
for the drugs.
10) Possibility of human errors in data analysis: Although the entire data set is double coded,
there is still the possibility that annotators did not interpret a sentence correctly and therefore
assign it to a wrong label. In addition, the span of the identified entities may include less or more
information than necessary. These issues may affect the performance of machine learning
systems trained based on this corpus to identify drug effectiveness, ADRs, and drug indications
in consumer health posts.
11) Possibility of bias in findings: as the statistics of data source in this study showed, 76% of
the participants in the healthcare forum are female. So, findings of this study may be associated
with gender bias.
Conclusion
In this study, using a mixed method data analysis, we showed that consumer health posts
in social media provide a unique insight into issues such as patients perspective, withdrawal
experience, tolerability for adverse drug reactions, and overall attitudes towards medications.
However, drug review posts is not a rich source for patients’ perceptions of communication with
healthcare providers, affordability of the drugs, or social support for the patients. The most
important use of the drug reviews is providing safety detection signals for ADRs and WDs
associated with medications. The drug reviews in healthcare forums are specifically important
for psychiatric medications because of the limitations of clinical trials in detecting ADRs
associated with this drugs, such as emotional indifference and suicidal ideation.
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Using methods of framework analysis and terminology mapping, we provided structured
data for testing hypotheses concerning patients’ attitude toward antidepressants. The result
showed that drug effectiveness and perceived distress received from ADRs are the most
significant factors affecting patients’ attitude toward antidepressants. In addition, among three
sets of psychological and physiological, and cognitive ADRs associated with antidepressants, we
found that physiological and cognitive ADRs are significantly related to patients’ negative
attitude, while psychological ADRs are partially associated with attitude towards antidepressants.
This work has important implications for generating and testing medical hypotheses
concerning patients experiences with psychiatric medications specified in this study, such as
withdrawal experience and also measuring association between ADRs and attitude. In addition, it
can be used for improving performance of text-mining algorithms aiming to automatically detect
healthcare information from consumer health posts and personal health records.
Future Work
In this study, we developed an analytical framework that can be used for identifying underlying
factors associated with patient attitudes towards antidepressants. The analytical framework was
created and tested using drug reviews in a healthcare forum called “askapatients.com”. Future
work may use the framework in other healthcare forums or personal health records to identify
factors associated with patients’ withdrawal and perceptions towards medications. In addition, in
this study, the phase of sentence classification, entities identification, and entities normalization
created a corpus that can be used for developing automatic systems aimed to identify healthrelated information from healthcare forums and map them to standard medical vocabularies. We
are in the process of developing classifier algorithms to differentiate drug reviews contains
withdrawal experience (both intentional and intentional) form drug reviews without report of
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withdrawal. Finally, we are going to compare the identified ADRs and WDs in this study with
SIDER Side Effect Resource, in order to identify new ADRs/WDs that were not reported by
clinical trials.
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Appendix A:
Self-report questionnaire designed/used for measuring ADRs associated with
antidepressants
The Antidepressant Side-Effect Checklist (ASEC) was constructed as a self-report scale
to measure twenty-one physiological and subjective Antidepressants’ adverse reactions. For each
item, a patient can rate the severity of the specified adverse effect on a four-point scale (0 absent;
1 mild; 2 moderate; 3 severe). The patients can also specify whether a symptom (if present) is
likely to be linked to antidepressants adverse effects (yes or no). The total score can vary
between “0”, if patients marked all symptoms as absent and “63”, if patient marked all symptoms
as severe and specified that they are highly related to antidepressants.
The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) is a fifty-one
items that was primarily constructed to measure adverse effects of antipsychotic drugs. Although
this scale was not specifically designed for antidepressants’ adverse effects, it covers some of the
psychological, emotional, and cognitive adverse reactions of the medications. The adverse
effects in LUNSERS scale are classified in eight classes including extra-pyramidal, psychic,
anticholinergic, autonomic, allergic reactions, hormonal, Miscellaneous (such as weight gain),
and red hearings. The aim of incorporating read hearing category is to detect over-reporting
cases. For each item, a participant can rate the severity of the specified adverse reaction on a
four-point scale (0: not at all; 1: Very Little; 2: A Little; 3: Quite a Lot ; 4: Very Much”). The
total score of LUNSERS can very between “0” if patients market all specified ADR as “0” and
“204” if marked all specified “ADRs” as “4”.
Studies that were also interested in measuring the impact of the antidepressants’ adverse
effects on quality of life employed the WHOQOL-BREF. The WHOQOL-BREF assesses the
physical, psychological, social, and environmental aspects of quality of life. In this
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questionnaire, patients can rate level of satisfaction, frequency, or magnitude of each item on a
five- point scale.
Ng et al. (2012) used the LUNSERS, WHOQOL-BREF, and also BAS and SAS scales to
assess association between attitude toward antidepressants and ADRs among patients with
psychotic and affective disorders such as schizophrenia and depression. Their findings indicated
that there is a negative correlation between LUNSERS and DAI/BEMID scores (scales for
measuring attitude) and attitude toward antidepressants, implying that the increased reported side
effects are associated with poorer attitudes towards antidepressants. But they did not answer the
question of whether there is an association between scores of WHOQOL-BREF, SAS, and BAS
and patients’ attitudes toward antidepressants.
To my knowledge, there have been no studies that applied ASEC to assess the association
between patients’ attitudes and adverse effects of antidepressant. However, De las Cuevas et al.
(2014) used this scale to find out the association between adherence to antidepressants and sideeffects. Their findings indicated that non-adherent patients reported more frequent and more
intense adverse effects than adherent patients. In addition, adherence and non-adherence groups
were significantly different in four reported adverse effects including “dry mouth”, “diarrhea”,
“feeling like the room is spinning”, and “weight gain”.
In contrast to the studies using self-report scales to identify antidepressants adverse
effects, Murata et al. (2012) directly asked patients to report their feelings and their
uncomfortable experiences (subjective experiences) with antidepressants at the point of care. In
addition, the study used tracking of patients’ vital and physical signs to find out potential adverse
effects. Their findings indicated that sleepiness, malaise, dry mouth, constipation, dysuria,
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dizziness, cephalalgia, hidrosis, and anorexia were significant adverse effects that may lead to
negative attitude toward antidepressants.
Although Uher et al. (2009) demonstrated that adverse effects to antidepressants can be
reliably assessed through self-report scales, the inherent limitations associated with the scales
such as not including all potential adverse effects, particularly the rare ones, may reduce the
reliability and validity of the scales. For example, the ASEC scale does not cover adverse effects
indicating emotional problems, cognitive dysfunctions, or quality of life. This is a major
limitation for studies employing this scale as a self-report measure for antidepressants adverse
reactions (Bet et al., 2013; Uher et al., 2009). The LUNSERS is also associated with some
limitations. First, it is not specifically designed for measuring the antidepressants’ adverse
effects. Second, items indicating emotional problems and cognitive dysfunctions are very limited
and do not reflect the wide range of emotional and cognitive reactions linked to all agents and
classes.
Moreover, items in the WHOQOL-BREF assess individual quality of life from a general
perspective that may not be directly related to the impact of antidepressants on quality of life.
For examples, items such as “level of satisfaction with living place or having enough money to
support your needs” do not measure the impacts of antidepressants. Also, other items such as
“satisfaction with interpersonal relationships” or “level of performance in daily activities” do not
provide specific information about patients’ incapacities resulted from antidepressants usage. For
example, patients may report difficulty with driving or exercising because of “brain shivers” that
was not specified in the WHOQOL-BREF. The limitations with WHOQOL-BREF can lead to an
insufficient understanding of the dimensions of antidepressants’ adverse effects on a patient’s
quality of life. These scales may also suffer from patient recall bias, because they do not define a
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specific time period during which the adverse effects have been occurred. Hence, patients may
just report severe adverse effects they experienced and disregard the mild ones(Bet et al., 2013).
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Appendix B:
Self-Report Scales Used in Antidepressants Studies for Measuring Attitude
a) Drug Attitude Inventory (DAI)
The DAI consists of seven components that mainly measure attitude and adherence
behavior towards prescribed psychotic medications mainly in the maintenance phase of
treatment. The DAI assesses patient attitudes based on two major dimensions: Patients’
subjective experience and the perceived necessity of medication and their concern towards
psychotic medications. Hogan et al. (1983) concluded that patients’ attitudes towards psychotic
medications are highly dependent on patient’s subjective experiences during a course of
treatment.
Table Appendix B.1. Drug Attitude Inventory (DAI): summary of components’ items
Subjective
Experience

Necessity and
concern
Locus of
control
Adherence
behavior

Components 1 and 2 include items measuring a patient’s subjective experiences of
medications. These components reflect the balance of a patient’s perceived benefits of
medication and perceived distress from adverse effects. Items in these components are
formulated to assess impact of medication on cognitive functionalities, Interpersonal
relationship, and emotional status.
Components 6 and 7 measure a patient’s perceived necessity of medications in
forestalling relapse and the concern about the potential toxic effects.
Items in Component 4 and 5 express a patient’s perception of locus of control in taking
medication, whether the locus of control is the physician’s authority or a lack of free
choice for pharmacological treatment. Items in this component are generally important to
determine adherence behavior.
Items in component 5 indicate a patient’s understanding of adherence behavior. Patients
with an erroneous view towards adherence behavior may discontinue medication when
they feel better or take more medication when they feel worse.

The ADI has two versions: 30-item and 10-item attitudinal scales that were generally
employed by studies focused on attitudes towards antipsychotic medications. However, it was
also used occasionally for assessing attitudes toward antidepressant medications.
Ng et al. (2012) used the DAI scale to compare outpatient’s attitudes on the maintenance
phase of treatment among patients with psychotic and affective disorders such as schizophrenia
and depression. Their findings indicated that patients with psychotic disorders do not have more
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negative attitudes and beliefs compared to those with affective disorder, implying that the type of
mental illness is not a significant predictive factor for attitude. They also concluded that the
patients reported side effects have significant correlation with medication attitude and belief but
not with education, duration or severity of illness.
Murata et al. (2012) used the DAI tool to investigate different attitudes among both
antidepressant-naïve (patients were not treated by antidepressants) and antidepressant-treated
patients. They found that the mean DAI -10 total score is significantly lower in antidepressanttreated patients compared to antidepressant-naïve patients Their findings also suggested that
patients’ demographic variables, such as age, gender, or education are not significantly
associated with attitude score. However, reported medication side effects and type of depression
(melancholic, nonmelancholic, bipolar) were significantly correlated with negative attitude.
Townsend, Floersch, and Findling (2009) employed DAI to measure adolescents’
attitudes towards psychiatric medications. The adolescents diagnosed with a wide range of
psychiatric disorders including major depression. The findings of this study suggested that
impact of psychotic medications on emotional status, cognitive functioning, and interpersonal
relationship is strongly correlated with adolescents’ attitudes toward these medications.
(De las Cuevas & Sanz, 2007) used DAI and to compare stable psychiatric outpatients
attitude toward psychiatric medications with public opinion on this subject. The result of this
study showed that receiving beneficial aspects of this medications leads to forming positive
attitude in psychiatric patients compared with the attitude of general population without
experience of this medication. This study also implies the stigma in society against psychiatric
medications.
b) Antidepressants Compliance Questionnaire (ADCQ)
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The ADCQ (Demyttenaere et al., 2004) is self-repot scale that is primary designed to
assess attitudes of psychiatric patients towards antidepressant medications. The ADCQ assesses
patients’ attitudes towards antidepressants based on four dimensions: perceived patient-clinician
relationship, concern about the mechanism of antidepressants on personality, subjective
experience of antidepressant usage, and perceived family support. ADCQ has 33 items that were
divided into four components. Table 2 presents a summary of the four components.
Table Appendix B.2. Antidepressant Compliance Questionnaire (ADCQ): Summary of components' items
Perceived patientclinician
relationship

Perceived Concern
(Preserved
autonomy)
Subjective
Experience
(Perceived
Benefits from
Medications)
And Perception of
Adherence
Patients’ Partner
Support

Perceived Patient-Clinician Relationship assesses the patient’s perception of
communication with clinicians. Items in this component mainly indicate three
dimensions of patient-physicians interaction including: 1) patient’s perception of
physician’s knowledge; 2) patient’s perception of sufficiency of knowledge provided
by physicians about the disorder and treatment process; 3) patient’s perception of
communication effectiveness, such as his perception of clinician’s interest in the
patient’s problem and the level of support received from clinicians.
Preserved autonomy includes items indicating a patient’s concern with the
antidepressant mechanism in the pre-treatment phase. Items in this component are
the addictive possibility of antidepressants, control over feelings and thought,
altering personality, and immunity to antidepressants.
Positive Belief about Antidepressants component assesses the patient’s perception
of antidepressants’ helpfulness in improving his coping mechanism, improving
emotional status and removing causes (symptoms) of depression. Some of items in
this component also indicate patient’s understanding of adherence behavior. Patients
with erroneous views about antidepressant behavior may think they can take
additional dosages or they can skip a dose if they feel better.
Items in this component express the perceived support that a patient received from
his/her partner or family. Whether family members agree with the diagnosis or the
pharmacological treatment of depression influences a patient’s perception of
antidepressants.

Several studies administered the ADCQ to patients with depression to analyze patients’
attitude toward antidepressants based on the four dimensions proposed in this scale. The finding
of studies (Chakraborty et al., 2009; Hung et al., 2014; Jacob et al., 2015) applied ADCQ showed
that the majority of patients with depression reported a positive experience in the patientphysician relationship. Hung et al. (2014) found that women had a more negative experience
than men regarding their patient-physician relationship. Regarding the age factor, Chakraborty et
al. (2009) and (Hung et al., 2014) did not agree on the correlation between age and the patient167

physician relationship. While Chakraborty et al. (2009) reported older patients had a more
negative view of patient-physician relationship, Hung et al. (2014) reported younger patients had
lower perception of the patient-physician relationship.
Most of the research administering the ADCQ to patients with depression, they found that
a majority of patients believe antidepressants do not preserve their autonomy. Patients believe
that by being on antidepressants have less control over their thoughts and feelings (Kessing et al.,
2005). They also feel that antidepressants can reduce their alertness (Demyttenaere et al., 2004;
Kessing et al., 2005). Patients also have concern about the impact of antidepressants on their
personality (Chakraborty et al., 2009; Jacob et al., 2015; Kessing et al., 2005). In addition, They
have concern about addictive possibilities (Chakraborty et al., 2009; Jacob et al., 2015; Prins et
al., 2008) and immunity to antidepressants (Kessing et al., 2005). Using the ADCQ, Jacob et al.
(2015) found that patients have misperception about the cause of depression. Patients may
attribute the cause of depression to non-biological factors, such as family issues or a stressful
life. Moreover, Chakraborty et al. (2009) found majority of patients on antidepressants reported
that their partners or families have a positive attitude towards diagnosis and treatment.
c) Beliefs about Medications Questionnaire (BMQ)
The Beliefs about Medications Questionnaire (BMQ) (Horne et al., 1999) is a NecessityConcern Framework that assess patient attitude towards pharmacological treatment in general
and also for a specific prescribed medication. Items representing patients’ necessity and concern
are organized in four components: general necessity, general concern, specific necessity, and
specific concern.

168

Table Appendix B.3. Beliefs about Medications Questionnaire (BMQ): a summary of components' items
General necessity

Items in the general necessity components are formulated to assess patient beliefs
about the necessity of pharmacological treatment in curing illness. Patients with
negative belief may feel that natural remedies are better than medications or that
they should not take medications continuously.

General Concern

Items in this component indicate patients’ general concerns about pharmacological
treatment based on beliefs about harmful aspects such as addiction, harm, and
poison caused by medications and concern about overuse of medication by
physicians.
Items in this component express a medication’s effectiveness and the patient’s
attitude about dependency to the prescribed medication as well as their concern
about their future healthcare status and their quality of life if they continue using
the prescribed medication.
Items in this category mainly indicate three dimensions of specific concern of
patients including: 1) Long-term effects and its impact on quality of life; 2) The
mechanism and addictive possibilities of antidepressants; and 3) losing autonomy
because of the control of the medication.

Specific necessity

Specific Concern

Aikens et al. (2005) used this BMQ scale to develop a categorical perspective that is
more practical to clinicians. The categories are: skeptical (low necessity, high concerns),
ambivalent (high necessity, high concerns), indifferent (low necessity, low concerns), accepting
(high necessity, low concerns). Based on this framework adherence is lowest in the accepting
group, and lowest in the skeptical group (Aikens et al., 2005; Russell & Kazantzis, 2008).
Brown et al. (2005) used the BMQ to find the relationship between beliefs and adherence
to antidepressant medication. The findings of this study suggested that a great number of patients
have concern about the long-term effects and addictive possibilities of antidepressants in
specific, and about the overuse and harmfulness aspects of medications in general (Brown et al.,
2005).
Aikens et al. (2008) employed BMQ to identify factors affecting beliefs about necessity
and concern of antidepressants. This study findings shows that perceived necessity is correlated
with age, severity of symptoms, anticipated duration of symptoms, and source of depression
(attribution of symptoms to chemical imbalance vs. random factors). Perceived concern was
higher in patients using antidepressants for the fist time (who are new to antidepressants), had a
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sufficient knowledge about antidepressants and attribute the source of depression to random
factors rather than biological factors. Patient gender, education, age, and type of depression were
not significantly associated with necessity and concern of antidepressants ” (Aikens et al., 2008).
d) Rating of Medication Influence Scale (ROMI)
ROMI (Weiden et al., 1994) is a self-report scale that was primarily developed for assessment of
attitudinal and behavioral factors affecting outpatient adherence with neuroleptic disorder . This
scale assess patients attitude and adherence in seven major domains that we reorganize them in
six main components: 1) subjective experience, 2) perceived necessity, 3) perceived
psychosocial support, 4) perception about illness, 5) perceived support from healthcare provider,
and 6) features of healthcare services.
Table Appendix B.4. Rating of Medication Influence Scale (ROMI): Summary of Components’ items
Subjective experience
and adverse effects
Perceived necessity
(prevention)
Perception about
illness

Perceived psychosocial
support (Influence of
others)
Perceived physicianpatient relationship
Features of healthcare
services ( adherence
behavior)

Two items in the domain of therapeutic regimen features including treatment
effectiveness and perceived distress of psychotic medications indicate subjective
experience of patients with antidepressants.
Three items in the domain of patients characteristics represents patients belief
about the necessity of the medications, whether patient believes his/her current
and future healthcare status depends on medication. Fear of relapse, fear of
hospitalization, and perceived recovery from illness are the items.
Items in the domain of disease feature and psychological factors indicate patient
perception about illness. The items assess patient perception about existence and
severity of diseases, and whether patient feels stigma/embarrassment against
illness. Item of substance abuse in the category patient characteristic might
reflect patients attitude about illness and medication.
Items in the domain of psychosocial factors domain evaluate patients’ perceived
support received from family and also family attitude toward medication.
Items in the category of patient-physician interaction and also treatment system
features assess patients perceived relationship with physicians and whether they
felt any pressure/force from healthcare providers.
Items in domain of treatment system feature and therapeutic regimens features
evaluate indicate feature of healthcare services, whether healthcare services is
accessible, affordable, it is structured, and physicians believe to medications.

In studies pertain to adherence and attitudes towards antidepressants, ROMI scale
primarily has been applied in research related to adherence (Sajatovic, Velligan, Weiden,
Valenstein, & Ogedegbe, 2010; Sansone & Sansone, 2012).
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There are other scales, such as Brief Evaluation of Medication Influences and Beliefs
(BEMIB), Medication Adherence Rating Scale (MARS) that includes items for assessing patient
attitude, but they are mainly developed for measuring and identifying predictive factors
influencing adherence.
Studies used these scales has yielded two De las Cuevas and Sanz (2007) De las Cuevas
and Sanz (2007) or multi-factor structure Alekhya et al. (2015) as outcome attitude. Two-factor
structure simply classifies individuals’ attitudes as either positive or negative, while multi-factor
structure, such as multi-point Likert scale provides more information about the effect of different
factors on forming patients’ attitudes by classifying patients in more than 2 categories. Some
studies may treat the sclaes outcome as a continuous variables to calculate correlation of other
continues variable, such as correlation of adverse effects with attitude in a study conducted by
Day et al. (2005).
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COURSE TITLE

WHEN

Ethics and Laws for Healthcare Professional Spring 2015
Healthcare Quality Management
Fall 2015
Research Design and Methodology
Fall 2015
Seminar in the Health Professions
Fall 2017

Course Designed
HCA.450
Healthcare Quality Management
HCA 590-SEC210 How to formulate a research question.
HCA 590-SEC206 Accessing data and information
for research
HCA 590-SEC207 How to write a scientific paper?

Fall 2015
Fall 2015
Fall 2015
Fall 2015

SIZE

LOCATION

38
40
8
15

UWM
UWM
UWM
UWM
UWM
UWM
UWM
UWM

Teaching Certificate
Spring 2016

Received UWM certificate for excellence in online and blended teaching

Thesis Mentoring
Pondugala, LR.

(2014) Evaluation of various hospital websites based on Patient
Engagement Framework, Department of Health Informatics, Indiana
University Purdue University Indianapolis (IUPUI), US.

Bayani, M.

(2010- 2011) diagnosing pediatric asthma using type 2 fuzzy clustering,
Department of Industrial Engineering, Amirkabir University Technology,
Tehran, Iran

Darabi, SA.

(2011-2012) Diagnosing adult asthma using case-based reasoning,
Department of Industrial Engineering, Tarbiat Modares University, Tehran,
Iran

Teaching Training
Summer 2015
Training Program for Online and Blended Teaching, University of
Wisconsin-Milwaukee
Course Reviewer
Spring 2017

reviewer of the Online & Blended Teaching Certificates, UWM 2017
177

____________________________________________________________________________

RESEARCH GRANTS AND PATENTS
2011

Research grant awarded by the Immunology, Asthma and Allergy Research Center
(IAARI) for designing a patient-centered decision support system for screening pediatric
asthma, Tehran, Iran

2012

Patent awarded by the Iran Intellectual Property Center for CDS system for screening
asthmatic patients, Tehran, Iran

AWARDS
The Chancellor’s Graduate Student Award (CGSA)- UWM* , Spring 2015, Fall 2015,
Fall 2017
2016

Travel Award, UWM (Fall 2016), American Medical Informatics Association (AMIA)
Conference, Chicago, Illinois.

2015

The Chancellor’s Graduate Student Award (CGSA)- UWM*

2015

Travel Award, American Medical Informatics Association (AMIA) Conference, San
Francisco, California.

2014

Travel Award, HIMSS Conference & Exhibition, HIMSS Conference, Orlando, Florida.

2014

Travel Award, Indiana University, Fall (2014), American Medical Informatics
Association (AMIA) Conference, Washington, D.C.

2013

Travel Award, Indiana University, Summer (2013), Human Computer Interaction
Conference, Las Vegas, Nevada
*CGSA is designed to give UWM a competitive edge in attracting and retaining high quality,
talented graduate students.

SERVICES
Journal Editor
•
•
•
•

Editor of American Medical Informatics Association (AMIA), 2016, 2014
Editor of mental health informatics, American Public health Association (APHA), 2017
Editor of Special issues of Journal of Pulmonary & Respiratory Medicine:
http://www.omicsonline.org/specialissueJPRM.php
Reviewer of Information Technology books in ACECR (Academic Center for Education,
Culture and Research) Student Book Festivals

5)

•

Volunteer Experience
International Graduate Welcome Volunteer (IGWV) Program, Office of International
Affairs, INDIANA UNIVERSITY, 2013-2014
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•
•
•
•
•

Indy Big Data conference, Indianapolis, February 2014. http://www.indybigdata.com
Middle East cultural festival, Eli Lilly Company, August 2014
Program Assistant, HIMSS Conference, Orlando, Florida, February 2014
Project Coordinator, Promoting Programs and Activities of the Department of Health
Informatics administration (HIA) at UWM using Social Media Features, Summer 2015
AMIA 2016, Mentoring high school students
OTHER
Miscellaneous Research Projects

•

Database design: A Web-based System for Organizing Literature Review. This project was
defined as the final project of database design and management course.

•

Contextual Inquiry for Developing a Computerized Patient Education System. This
project was defined for the course of Meaning and Use in HCI.

•

Calculating Diagnosing Value of Risk Factors and Symptoms in Diagnosing Asthma.
This project was defined for the course of statistical analysis.

•

Designing a Feed Forward Neural Network for Prediction of Gold Price. This project
was defined for the course of Neural Network.

•

A Prototype Decision Support System for Recognizing Pesticide Type in Agriculture.
This project was defined for the course of expert system designing and implementation.

•

Predicting the Inflation rate in Iran using Time Serious Analysis. This project was
defined for the course of statistical analysis.

•

An Analysis of Accounting System of Management Department of Tehran University

•

Comparison and Contrast Business Intelligence Style in Product-based Software
Companies and Service- Based Software Companies.

•

Strategic Planning for BaftLoran Company, Lorestan, Iran. This project was defined for
the course of strategic planning.
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APPENDIX A
1. Lister Hill National Center for Biomedical Communications/ National Institute of
Health (May 2016- December 2016), Research Fellow
1.1. Project: Social Media text mining and statistical analysis to identify underlying factors
for attitude to antidepressant treatment (in progress).
1.1.1. Designing research methodology including literature review, data collection
method, data analysis framework, annotation guideline, and statistical analysis plan.
1.1.2. Developing a consumer health vocabulary of medical concepts, such as sideeffects and withdrawal symptoms by systematically mapping these concepts to both
SNOMED-CT and UMLS concepts
1.1.3. Designing a classifier to differentiate symptoms, side-effects, and beneficial
effects of antidepressants
8)
2. Biomedical Data and Language Processing Center of the Department of Health
Sciences at the University of Wisconsin-Milwaukee, Research Fellow (January 2015, May2016)
2.1. Project (1): Representing Depression Drug Side Effect beyond clinical Conditions
2.1.1. Mapped drug adverse effects to limitations in daily activities and social
participations based on data extracted from drug clinical trials and International
Classification of Functioning Disability and Health (ICF) terminology
2.1.2. Analyzed the result and prepared the manuscript for American public health
association (APHA) conference.
2.2. Project (2): Evaluating Acceptability and Efficacy of Antidepressant Medications based
on Patients drug reviews
2.2.1. Compared acceptability (satisfaction) and efficacy (effectiveness) of 13
antidepressant drugs using patients drug reviews in Webmd.com
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2.2.2. Analyzed the results and prepared the manuscript for American Medical
Informatics Association (AMIA)
2.3. Other projects:
2.3.1. Analyzed the Patients Comments in Depression Groups in Facebook
2.3.2. Health data in Social Media and Exploring Text-Mining Methods for Data
Extraction
3. Indiana University, Research Assistant (August 2012- December 2015)
3.1. Project (1): The Extent to which U.S. Hospitals Promote Their Patient Engagement
Activities and Outcomes: Preliminary Results of Quantitative Content Analysis Research
3.1.1. Collaborated with investigators to design research methodology
3.1.2. Conducted literature review to develop framework for content analysis
3.1.3. Worked with PhD students to analyze contents and medical tools provided in
hospitals’ websites
3.1.4. Conducted statistical analysis to test the hypotheses
3.1.5. Prepared manuscript for American Medical Informatics Association (AMIA)
3.2. Project (2): Building a Portal to Health Resources for Cancer Survivors
3.2.1. Collaborated with investigators to develop a framework for the portal
3.2.2. Conducted a research to select proper content for the website
3.2.3. Project (3): Improving Healthcare Systems for Access to Care by Underserved
Patients,
3.2.4. Worked with investigators and team members for conducting patients interviews
and analyzing the collected information
9)
4. Immunology & Asthma & Allergy Research Center (IAARI), Tehran, Iran, Informatics
Specialist, (January 2011- August 2012)
4.1. Project (1): A Clinical Decision Support System (CDSS) for diagnosing pediatric asthma
4.1.1. Prepared a grant proposal for IAARI to finance designing and implementing a
clinical decision support system.
4.1.2. Worked with asthma specialists to generate diagnostic rules
4.1.3. Worked with medical students to provide medical content of the CDSS
4.1.4. Designed the algorithm of diagnosis
4.1.5. Implemented a prototype of the system using Matlab
4.1.6. Worked with programmers and user-interface designers to implement the system
using C#
4.1.7. Tested the system using 138 asthmatic and 138 non-asthmatic patients
4.2. Project (2): Clinical Decision Support System (CDSS) prototype for measuring level of
asthma severity, asthma control, and asthma exacerbation
4.2.1. Worked with asthma specialists to generate rules related to level of severity,
control, and exacerbation
4.2.2. Implemented system prototype using Matlab
4.2.3. Tested the prototype using 85 asthmatic patients
5. Academic Center for Education, Culture, and Research (ACECR) Tehran, Iran,
Research Specialist, (2009-2012)
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5.1. List of projects:
5.1.1. Studied ICT-based SMEs in Iran and providing the government with appropriate
solutions in order to support the enterprises.
5.1.2. Strategic planning: a framework for Internal analysis in high tech SMEs
5.1.3. Designed an efficient engineering and administrative system for exporting
technical services
6. Negah Nou company and Jahan Rayane Company,Tehran, Iran, IT Consultant (20092010)
6.1. Determining information systems requirements
6.2. Designing business plan based on company's clients’ needs
6.3. Designing system analysis framework for system analysis team

7. E-Sabz Company, Tehran, Iran, Director of Analytics Department, (2007-2009)
7.1. For the following projects, I managed a team of system analysts and programmers. I
was also responsible for preparing marketing business plan.
7.1.1. Content Management System
7.1.2. Customer Relationship Management (CRM) system
7.1.3. Archive Management System
7.1.4. Learning Management System
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